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Burkholderia cepacia was first identified in the 1950's as a phytopathogen, in
particular as the causal agent of soft rot disease in onions. In the 1970's, B. cepacia
became recognised as a cause of life-threatening pulmonary infection in human
hosts, in particular patients in intensive care units and individuals with the inherited
disorders chronic granulomatous disease and cystic fibrosis (CF).
Pulmonary colonisation by B. cepacia is a particular problem in CF patients since
20% of those colonised succumb to 'cepacia syndrome', a rapidly fatal necrotising
pneumonia sometimes accompanied by septicaemia. Evidence from national CF
databases also shows that colonisation reduces life expectancy by 50%. Epidemic
strains are readily transmitted between patients both nosocomially and through social
contact. A further problem is that B. cepacia is inherently resistant to most classes of
antibiotics and thus infections are difficult to treat. Several mechanisms of resistance
have been identified in B. cepacia including reduced permeability to most classes of
antibiotics and production of highly inducible P-lactamases.
The aim of this project was to investigate novel antimicrobial strategies against
B. cepacia, based on natural antimicrobial compounds present in plants and human
airways as protection against bacterial disease. The project focused on a panel of 20
strains of the B. cepacia complex. Isolates included strains representing major
epidemic clones of B. cepacia and exhibiting a range of susceptibilities to all classes
of conventional antibiotics. The project is focused on two major themes. First, a
study of antimicrobials from plants and second, examination of the antimicrobial
activities of cationic peptides present in human airway secretions.
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The susceptibility of the B. cepacia strain panel to plant extracts was investigated, in
particular the activity of aqueous garlic extract (AGE) and thyme oil. The MIC of
thyme oil for all 20 strains was found to be 0.01%. MICs ofAGE ranged from
0.25%-3%. Killing curves suggested that AGE produces a slow killing effect over a
twenty hour period, whereas thyme oil kills bacterial cells in less than 20 minutes.
By electron microscopy, no intact bacteria were observed after three minutes
incubation with thyme oil. In contrast, two hours incubation with AGE produced
morphological changes in the cellular structure ofB. cepacia consistent with much
slower damage to the bacterial cell membrane. Attempts were then made to purify
and identify the chemical nature of the antimicrobial agents using reverse phase
HPLC. AGE was shown to contain allicin along with other anti-cepacia compounds.
Thyme oil was shown to comprise the phenols thymol and its isomer, carvacrol.
Eluman (hBD-1) and murine (mBD-1) P-defensins were examined for activity
against B. cepacia. In contrast to the salt-sensitive antimicrobial activity observed
with Pseudomonas aeruginosa, no antimicrobial activity was observed against
strains of B. cepacia. Elafin, a proteinase inhibitor produced in the human lung was
also tested for antibacterial activity against strains ofStaphylococcus aureus,
P. aeruginosa and B. cepacia. Once again, antimicrobial activity was observed
against S. aureus and P. aeruginosa however, no activity was observed against
B. cepacia. These observations indicate that members of the B. cepacia complex are
inherently resistant not only to well-known cationic peptides such as polymyxin, but
also to endogenous cationic peptides which were capable of inhibiting a range of
pathogens.
x
This project showed that natural compounds contained within certain plant extracts
are bactericidal for strains of the B. cepacia complex, whereas most antibiotics and
endogenous human cationic peptides lack such activity. At present, the inherent
resistance of B. cepacia to almost all classic antibiotics including p-lactams,
quinolones and aminoglycosides, denies infected patients of effective therapy. The
project clearly emphasised the inherent resistance of the B. cepacia complex to
antibiotics and produced new evidence that this resistance extends to cationic
peptides. However, the project also showed that extracts from some plants contain
potent antimicrobial activity which includes lethal activity against even the most
resistant of the B. cepacia epidemic clones. Strategically, it would seem worthwhile
to focus further research on the most potent extracts, namely those from thyme oil,




To acknowledge everyone who has helped in the preparation of this thesis is a
difficult task. I am especially grateful to my supervisor, Professor John Govan, for
acquiring the funding which enabled me to carry out my studies and for his guidance,
enthusiasm, patience and constructive advice in the preparation of this manuscript.
Special thanks must also go to my laboratory colleagues for their continued support
and encouragement, particularly Cathy Doherty and Wendy Hannant who have
provided me with excellent technical advice and assistance and without whom I
would have been unable to complete this thesis. I am also indebted to Jayne Hughes
and Mike Hutchison for providing a great deal of advice and assistance and also to
Sazini and Jonny for enduring sharing a bench with me and for cheering me up
especially in the last year. Many other colleagues who have also provided assistance
and advice include Prof. Sebastian Amyes, Robert Brown, Esther Durham, Mike
Kerr, Denise Hutchison, Ian Hodgson and Prof. Ian Poxton.
I am particularly grateful to Dr Donald Davidson with whom experiments involving
defensins were carried out and to Dr John Stewart, Dr Lorna Fyfe and F. D.
Copeland and Sons, Fondon, for advice and provision of the plant oils analysed in
this thesis.
I am also indebted to Elizabeth O'Gara and Dr Farry Fawson who provided a sample
of pure allicin and to Mike Hutchison, Dr Finda Gilmore and Dr Alan Pemberton
who provided a great deal of help with the analysis of plant compounds by HPFC.
xii
Thanks must also go to Dr Jean-Michel Sallenave and Dr John Simpson for making
and providing elafin samples and for initiating interesting collaboration between our
laboratories, and also to Dr Peter Vandamme and Tom Coeyne for providing
genomovar information for my strains
I am also grateful to Derek Notman and Steve Mitchell for assistance with electron
microscopy and to Medical Illustration, University of Edinburgh for printing the
photographs included in this thesis.
Finally, I wish to thank all my laboratory colleges for their friendship and endless
help, especially Wendy, Cathy and Sazini whose generosity has even extended to
putting me up in their homes. I also wish to thank my mother, Joyce for her love,
support, throughout my time at university, and my partner, Andrew for his love,
understanding and patience with an eternal student!
xiii
DECLARATION





Cystic fibrosis (CF) is the most common lethal genetic disease of Caucasians. One in
25 Caucasians of European decent are asymptomatic heterozygous carriers of this
autosomal recessive disorder; the incidence of CF in this population is approximately
one in 2500 live births. Each year approximately 350 children in the UK are born
with CF (Elborn, 1994). CF is less common in other ethnic groups, however cases
have been described particularly within the Ashkenazi Jewish population and
American blacks (Tsui and Buchwald, 1991). Anderson provided the first
comprehensive description of'cystic fibrosis of the pancreas' in 1938 and named it
thus in recognition of the destruction to the pancreatic lesions she observed at
autopsy. Of note, many of the patients studied had died as a result of pulmonary
infections (Anderson, 1938). In 1953, Di Sant'Agnese and co-workers reported that
children with CF had abnormally high levels of sodium and chloride in their sweat
(Di Sant'Agnese et al, 1953). This observation lead to development of a diagnostic
test for CF based on the measurement of raised sweat electrolytes (Gibson and
Cooke, 1959).
CF is a disorder which affects a number of organs including the lungs,
gastrointestinal tract, pancreas, liver, vas deferens and sweat glands. It was not until
the 1980's that the basic physiological defect in salt transport which affects these
organs was described. Poor chloride transport across CF epithelia leads to the
production of viscid secretions which cause the major clinical problems associated
1
with this disease (Quinton, 1983). Viscid bronchial secretions within the lung are
thought to lead to poor mucociliary clearance, whereas in the gastrointestinal tract
the abnormal secretions can cause blockages termed 'meconium ileus'.
Approximately 90% ofCF patients have poor pancreatic function as the viscid
secretions block the pancreatic ducts preventing release of pancreatic enzymes
(Kubesch et al, 1993). Pancreatic damage can also lead to the development of
diabetes in some patients. Other complications of CF include chronic damage to the
liver leading to the development of cirrhosis and male infertility due to blocked or
absent vas deferens (FitzSimmons, 1993).
1.1.1 Genetic basis of CF
In 1989, the basic genetic defect responsible for reduced ion transport in CF was
discovered and the location, sequence and function of the gene responsible were
described (Rommens et al, 1989; Riordan et al, 1989; Kerem et al, 1989).
Chromosome walking and jumping techniques along with DNA hybridisation were
used to isolate gene sequences from the previously identified CF region on the long
arm of chromosome 7 (Tsui et al, 1985), one of these sequences was found to encode
the cystic fibrosis gene. This gene sequence was found to encode a protein of 1480
amino acids which has sequence homology with other membrane associated proteins.
The gene product was named the cystic fibrosis transmembrane conductance
regulator (CFTR) (Riordan et al, 1989). The structure ofCFTR was then determined
and found to contain two hydrophobic helices which spanned the membrane to form
three loops. Each of these membrane spanning domains is linked to a hydrophilic
region which contains nucleotide binding folds. In the centre ofCFTR there is a
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cytoplasmic regulatory domain named the R domain. This region contains sites
which can become phosphorylated by protein kinases.
The difference in the sequence of the CFTR gene between CF and unaffected
individuals was identified as a three base pair deletion which results in the loss of
phenylalanine at position 508 (AF508). The position of this crucial amino acid is
within the first nucleotide binding fold (Riordan et al, 1989). Subsequent studies
indicated that the AF508 mutation accounts for approximately 70% of all CF cases
(Karem et al, 1989), and is associated with the most severe CF form, including
pancreatic insufficiency and meconium ileus. The remaining 30% of cases are made
up of over 700 much rarer mutations (Davis et al, 1996).
To confirm that CFTR functions as a chloride ion channel or a regulator for such an
ion channel, cDNA for normal CFTR was transfected into a CF pancreatic cell line
(Drumm et al, 1990) and into cultured CF airway epithelial cells (Rich et al, 1990).
In both studies, the chloride ion channel defect was corrected. Confirmation that
CFTR was indeed a chloride ion channel came when highly purified CFTR protein
was inserted into artificial cell membranes (planer lipid biolayers) containing no
other channel like proteins. When CFTR was incorporated into the biolayer, normal
regulated chloride channel activity was observed (Bear et al, 1992).
On present evidence it appears that CFTR functions as a chloride ion channel, which
is opened by the hydrolysis ofATP by the nucleotide binding domains (Anderson et
al, 1991) and regulated by the phosphorylation of the R domain by protein kinase A
(Cheng et al, 1991).
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1.1.2 How does defective CFTR cause lung disease?
Two main hypotheses have arisen to provide an explanation of how CFTR
dysfunction causes lung disease in CF. Both the low volume hypothesis (Matsui et
al, 1998) and the high salt hypothesis (Smith et al 1996; Zabner et al, 1998) focus on
disrupted absorption of ions from the airway surface fluid (ASF) of patients with CF.
Low volume hypothesis
In addition to its function as an ion channel, CFTR has now been recognised to
function as a regulator of membrane proteins, including other ion channels. Of
particular interest is CFTR's function as a regulator of an epithelial sodium channel,
ENaC (Stutts et al, 1997). CFTR decreases the amount of time this channel is open,
thus, when CFTR function is lost, Na+ conductance across the airways is increased.
In the low volume theory of Boucher and co-workers, both normal and CF airways
are thought to have levels ofNaCl similar to those found in plasma. In CF, the
mutation ofCFTR eliminates the inhibition of ENaC leading to increased sodium
absorption. Chloride ions are drawn out of the ASF due to this sodium
hyperabsorption, but they travel through the epithelial cells via shunt pathways, as
CFTR is not functioning. Water follows the ions back through the cells by osmosis,
causing the ASF to become dehydrated. As the volume ofASF is critical to ensure
that cilia beat correctly and mucociliary clearance is effective, the low volume of
thick mucus left behind in CF airways prevents effective mucociliary clearance. This
defective mucociliary clearance leads to an increased incidence of respiratory
infections.
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Fig 1.1 Low volume hypothesis
Na+ cr h2o cr cr Na+ cr h2o cr cr
Non CF epithelial cell CF epithelial cell
The ENaC channel is shown in black, CFTR in red and alternative pathways for chloride ion transport
in green. Na+ hyperabsorption draws CI- and H20 across epithelial surface which leads to dehydrated
ASF.
High salt hypothesis
In this second model, non-CF ASF is considered to have a low, hypotonic salt
concentration, which allows salt-sensitive antimicrobial peptides to keep the airways
free of bacterial pathogens. In this hypothesis, it is thought that normal airways
reabsorb salt, without the consequential flow ofwater. Sodium is pumped back into
the epithelium and chloride follows passively through the CFTR. As Na+ and Cl-
transport is linked, when CFTR is defective, chloride cannot flow back into the
epithelium and only a small quantity of sodium ions can be pumped out of the ASF
as a negative charge is produced which prevents further Na+ movement. High levels
of salt accumulate in the ASF which inactivate endogenous antimicrobial peptides
(Smith et al, 1996; Zabner et al, 1998).
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Non -CF epithelial cell
The ENaC channel is shown in black and CFTR in red.
Na+ CF H20
CF epithelial cell
Each of these models provides a plausible theory as to why the CF lung is susceptible
to infection. At present, it is technically difficult to measure the salt concentration of
ASF accurately as it forms only a very thin film of approximately 30pm over the
airway surfaces. One study using microanalytical techniques, found that normal ASF
had a lower NaCl concentration than CF ASF (Joris et al, 1993). At present, there is
not enough evidence to support or disprove either theory. However, there is no
doubt that in some way defective CFTR is the cause of an increased susceptibility to
lung infections.
1.1.3 Microbial colonisation of the CF lung
Infections of the respiratory tract have long been recognised as a major symptom of
CF. In the earliest reports ofCF, cultures from bronchial secretions were found to
contain Staphylococcus aureus in almost every case (Anderson, 1938; 1949). A
study of bacterial pathogens isolated from the respiratory tracts of CF patients carried
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out between 1950 and 1971 noted that a decline in the number of patients with
S. aureus infections coincided with an increase in culture of
Pseudomonas aeruginosa. The introduction of antibiotic therapy had apparently
reduced the incidence of staphylococcal infections resulting in an increased
incidence of the more antibiotic resistant organism, P. aeruginosa. The role of
Haemophilus influenzae in CF lung disease was also recognised at this time (Mearns
et al, 1972).
Advances in treatment of CF, the consequent increase in the life span of patients and
improved microbiological procedures has lead to recognition of an increasing range
of bacterial and fungal pathogens from CF bronchial secretions. By 1990, it was not
unusual to culture P. aeruginosa from approximately 60% of CF patients, with an
incidence of approximately 20% in children of under one year of age rising to 80% in
adult patients. Other Pseudomonas species were isolated from around 5% of patients.
At this time the S. aureus isolation rate was around 28% and the rate ofH. influenzae
isolation 9%. Candida and Aspergillus species were isolated from approximately 4%
and 3% of patients respectively (FitzSimmons, 1993).
Even today a surprisingly restricted spectrum ofmicro-organisms is responsible for
the lung infections ofCF patients. S. aureus is still the most common pathogen in
infancy, often followed by infection with H. influenzae. Infections with these
organisms can be effectively treated with antibiotics. P. aeruginosa is the most
common pathogen affecting approximately 60% -90% of adult CF patients in most
centres and is the major pathogen responsible for chronic bronchopulmonary
infection and progressive lung disease.
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P. aeruginosa in CF
By early adulthood, most CF patients have become chronically colonised with
P. aeruginosa. Within the CF lung, non-mucoid P. aeruginosa characteristically
converts to a mucoid, non-motile phenotype which is seldom, if ever eradicated
(Doggett et al, 1964; Govan and Deretic, 1996). In vivo, mucoid P. aeruginosa
grows within in complex biofilms made up of alginate, a highly charged bacterial
exopolysaccaride released by P. aeruginosa, host cellular DNA, and host pulmonary
mucins. Within these biofilms, P. aeruginosa is less susceptible to antibiotics
(Anwar et al, 1992) and to phagocytosis (Govan and Harris, 1986; Simpson et al,
1988).
Several explanations for the increased P. aeruginosa colonisation of the CF lung
have been proposed. Infection with P. aeruginosa is not recognised as a major
problem in patients with other mucociliary defects such as ciliary dyskinesia,
therefore there may be factors other than poor mucociliary clearance which
contribute to the susceptibility of the CF lung to P. aeruginosa colonisation. CF
respiratory epithelial cells have been shown to bind twice as many P. aeruginosa as
non-CF cells (Saimen et al, 1990), suggesting that there may be an increase of
receptors for P. aeruginosa in the CF lung. It has been suggested that abnormalities
in CFTR cause alterations in glycosolation which lead to an increased presence of
incompletely sialyated glycolipids, such as asialoGMl, a receptor for the major
P. aeruginosa pilin adhesin (Saiman and Prince, 1993). Rather controversially, it has
also been suggested that the first extracellular domain of CFTR also functions as a
receptor for P. aeruginosa (Pier et al, 1996). In this case, it is postulated that in non-
CF lungs, P. aeruginosa attaches to CFTR and is removed through normal cellular
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desquamation; thus, when CFTR is not present, greater numbers of P. aeruginosa
can accumulate in the bronchial lumen.
Other factors may also contribute to the susceptibility of CF patients to
P. aeruginosa colonisation. P. aeruginosa lipopolysaccharide (LPS), and cytokines
released by inflammatory cells responding to P. aeruginosa infection, have been
shown to upregulate human mucin genes causing further accumulation of viscid
mucin which increases impairment ofmucociliary clearance (Dohrman et al, 1998).
Inflammatory cytokines and bacterial LPS would normally initiate production of
nitric oxide (NO), however levels ofNO are reduced in the exhaled air of CF
patients, indicating that CF airways are somehow made further susceptible to
bacterial infection (Balfour-Lynn et al, 1996).
Accumulated evidence indicates that it is the immunopathological consequences of
chronic lung infection with P. aeruginosa which ultimately destroy the airways,
impair gas exchange and leads to the death of the CF patient. There is evidence to
suggest that even CF infants with very mild lung disease have a considerable
inflammatory response in their airways with high levels of neutrophils present in
their airway secretions (Konstan et al, 1994). It has also been suggested that
adherence of P. aeruginosa and the subsequent production of the quorum sensing
agent, N-acyl homoserine, may induce the production of IL-8 by respiratory
epithelial cells which would attract neutrophils into the airways (Moss, 1995). Large
numbers of neutrophils in the airways release neutrophil elastase and reactive
species, which damages the lung epithelium, causing more neutrophils to be attracted
and more cytokines to be released (Doring, 1994).
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Ineffective phagocytosis of P. aeruginosa growing within protective biofilms would
cause an increased release of reactive oxygen intermediates and free radicals from
degranulating neutrophils resulting in greater inflammatory damage to the lung. It is
this amplification of a frustrated immune response within the lung, caused mainly by
chronic P. aeruginosa infection which is ultimately the major cause ofmorbidity and
mortality in CF patients (Hutchison and Govan, 1999).
Emerging CFpathogens
Over the last 20 years, there has been an increased recovery of inherently resistant
Gram-negative bacteria, including Stenotrophomonas maltophilia and Burkholderia
cepacia, from CF sputum. Early and more intensive antimicrobial treatment of
P. aeruginosa infections (Denton et al, 1996), coupled with improvements in
selective culture media and identification techniques may explain the increased
culture rate of S. maltophilia. Isolation of S. maltophilia from the sputum of a CF
patient was first reported in the 1970's (Frederiksen et al, 1995). Information
regarding the number ofCF patients colonised with S. maltophilia has been limited,
however a prevalence of as high as 30% has been reported in one clinic (reviewed in
Denton, 1997). Transmission of S. maltophilia between siblings has been reported,




During the 1980's, another bacterial pathogen emerged as a major cause of lung
infections in CF patients. The first report of B. cepacia colonisation in a CF patient
appeared in the 1970's (Ederer and Matsen, 1972), however it was not until the
1980's that the importance of B. cepacia as an inherently multi-resistant pathogen of
CF patients was confirmed. By 1996, the average culture rate of B. cepacia amongst
US CF patients was 3.6% (LiPuma, 1998). However, considerable clinic to clinic
variation was noted with prevalence rising to 30-40% in clinics where spread
between patients has occurred, and reaching as high as 70% in some large clinics
(Anonymous 1992; Govan et al, 1996). Although colonisation rate of B. cepacia is
generally lower than that of P. aeruginosa, B. cepacia is considered a more
dangerous and troublesome problem and causes much anxiety in the CF population.
1.2.1 B. cepacia the plant pathogen
B. cepacia was originally described in 1950, as a soil born phytopathogen, capable of
causing slimy yellow necrosis of the bulb's outer scales, in the 'yellow globe' variety
of onions (Burkholder, 1950). B. cepacia could be described as an opportunistic plant
pathogen as mechanical damage to the bulb is required before soft rot is initiated.
Burkholder suggested that B. cepacia did not cause disease of any other plant
species. He proposed that this organism should be placed in the Pseudomonas genus
as it stood at that time, with the species name, Pseudomonas cepacia (cepa = onion).
However, Burkholder also stated that the strains of B. cepacia he analysed possessed
certain characteristics that did not fit well with the majority of the plant pathogens
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then present in genus Pseudomonas (Burkholder, 1950). In 1966, Stanier and
co-workers described a group of bacteria recovered from soil, water and clinical
environments which they named Pseudomonas multivorans (Stanier et al, 1966).
Later work established that P. multivorans was synonymous with P. cepacia (Ballard
et al, 1970; Sands et al, 1970). A group of strains isolated from clinical environments
originally described as 'eugonic oxidisers group 1' (King, 1964) and subsequently
named Pseudomonas kingii (Jonsson, 1970), were also synonomized with P. cepacia
in 1972 (Snell et al, 1972).
1.2.2 The evolving taxonomy of the B. cepacia complex
Until 1993 (Anonymous, 1993), B. cepacia was officially classified as part of
Pseudomonas RNA homology group II, one of five subdivisions of this genus
proposed by Palleroni and co-workers based on the results of rRNA-DNA
hybridisation (Palleroni et al, 1973). A new genus, Burkholderia, was subsequently
proposed to include seven species belonging to homology group II and with
B. cepacia as the type species (Yabuuchi et al, 1992). These seven species were able
to utilise a greater range of sugars and alcohols than P. aeruginosa, the type species
of the Pseudomonas genus. Subsequent studies have led to the removal of two
species to a further new genus Ralstonia (Yabuuchi et al, 1995) whilst other
'pseudomonal' species have been added to the Burkholderia genus (Urakami et al,
1995; Zhao et al, 1995). The genetic complexity of isolates presumptively identified
as B. cepacia has led to further taxonomic clarification. B. cepacia strains isolated
from both clinical and environmental settings, were subdivided into five distinct
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genomic species named 'genomovars' on the basis ofDNA-DNA and DNA-rRNA
hybridisations together with analysis of fatty acid content and whole cell protein
profiles (Vandamme et al, 1997). One genomic group, genomovar V, was
recognised as the previously described species Burkholderia vietnamiensis (Gillis et
al, 1995). Another group, genomovar II, was named as a new species, Burkholderia
multivorans due to distinct biochemical characteristics (Vandamme et al, 1997).
Genomovar IV has also recently been described as a new species named
Burkholderia stabilis in recognition of the limited genomic variability of this species
when compared to the diversity of B. cepacia strains in general. B. stabilis is distinct
from other strains of the B. cepacia complex by the absence of beta-galacatosidase
activity and the inability to oxidase sucrose (Vandamme et al, in press) The
remaining genomic species are termed 'genomovars' I and III pending identification
of distinguishing phenotypic characteristics. Genomovar I contains the type species
B. cepacia ATCC 25416 and by convention must retain the name B. cepacia.
The identification of'atypical' protein profiles amongst a group of strains isolated
from the sputum of CF patients lead to further investigation of their phenotypic and
genotypic characteristics. These strains were collectively recognised as a new
member of the B. cepacia complex and were termed genomovar VI (Coenye et al, b
in press). Other strains that were originally tentatively described as B. cepacia or
Ralstonia pickettii like organisms have been included in a new genus Pandoraea
(Coenye et al, a, in press). At present Pandoraea comprises five new species
however considering the rapidly evolving taxonomy of the B. cepacia complex it
would not be surprising if further taxonomic clarification of'B. cepacia like' strains
is required. At present, the term B. cepacia complex is used to refer collectively to
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all strains previously classified as B. cepacia (Vandamme et al, 1997). For
simplicity, unless otherwise stated, the term B. cepacia will be used to incorporate all
members of the B. cepacia complex.
1.2.3 Characteristics of B. cepacia
B. cepacia is a Gram-negative, non-spore forming, aerobic bacillus. The species is
motile with polar flagella and is typically catalase and oxidase positive. Members
have the capacity to produce various non-fluorescent pigments and
poly-P-hydroalkanoates can be accumulated as reserve materials. The optimal
temperature for growth is 30-35°C (Palleroni, 1984). B. cepacia has considerable
nutritional diversity, some strains can even utilise penicillin G as a sole carbon and
energy source (Beckman and Lessie, 1979). Considerable genetic diversity exists
amongst individual strains of B. cepacia, even between isolates from a single
environmental source. Recombination rates among strains isolated from a single
stream were higher than would be expected for binary fission alone (Wise et al,
1995).
Most strains of B. cepacia have been reported to possess between two and four
chromosomes and can also possess a number of plasmids (Gonzalez and Vidaver,
1979; Lennon and DeCicco, 1991; Cheng and Lessie, 1994; Lessie et al, 1996).
Strains of B. cepacia have a relatively large genome with a mass ranging from 5 to
9Mb and contains multiple insertion sequences. These numerous insertion sequences
can facilitate genomic rearrangements and increase the expression of neighbouring
genes (Lessie et al, 1996). B. cepacia may also be able to assimilate DNA from
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other bacterial species by horizontal transfer which may account for this species'
impressive versatility and diversity (Lessie et al, 1996).
Early studies describe B. cepacia as ubiquitous in natural environments (Isles et al,
1984; Tablan et al, 1985; Goldman and Klinger, 1986), however this claim has been
challenged. Extensive surveillance studies have shown that although B. cepacia can
be cultured from a number of environmental sources, including water, soil and
plants, in particular the plant rhizophere, isolation rates are relatively low. Rates of
isolation from the environment varied from as low as 4% (Fisher et al, 1993;
Mortensen et al, 1995) up to 22% (Butler et al, 1995). Surprisingly, even in the
homes of CF patients the isolation rates of B. cepacia are low (Mortensen et al,
1995).
1.2.4 Bioremediation and biological control
Due to its enormous metabolic versatility, B. cepacia has the potential to break down
herbicides, pesticides and industrial wastes. Some strains have been shown to
degrade highly stable toxic compounds which can contaminate water supplies and
soil including trichloroethylene (Krumme et al, 1993) and
2,4,5-trichlorophenoxyacetic acid, the principle herbicide present in agent orange
(Kilbane et al, 1983).
B. cepacia also has the ability to repress the growth ofmany soilborn plant pathogens
due to the production of antimicrobial compounds which include pyrrolnitrin
(Elander et al, 1968), altericidins (Kirinuki et al, 1977), cepacidine (Lee et al, 1994)
and cepacins A and B (Parker et al, 1984). Because of the potential beneficial effects
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of this antimicrobial activity, strains of B. cepacia are being developed for use as
biological control agents to suppress fungal damage in a wide range of commercial
crops. B. cepacia has been shown to inhibit bacterial wilt disease of tobacco (Aoki et
al, 1993) and fungal pathogens ofwheat (DeFreitas and Germida, 1991). As seed
dressings, B. cepacia can control black rot of carrots by Alternaria radicina (Chen
and Wu, 1999), 'damping off caused by Pythium and Aphanomyces root rot of peas
(Parke et al, 1991). B. cepacia can also colonise the rhizosphere ofmaize to protect
this important crop against soil-borne diseases (Hebber et al, 1992) and suppress
fungal spoilage of stored fruit (Janisiewicz and Roitman, 1988).
The economical and ecological benefits to the agricultural industry from the
development ofB. cepacia as a biological control and bioremediation agent are
tempered by evidence from medical microbiologists that B. cepacia causes life-
threatening infections in immunocompromised patients and that most
environmentally isolated strains are phenotypically indistinguishable from clinical
isolates (Vandamme et al, 1997).
1.2.5 Emergence of B. cepacia as human pathogen
Contamination of hospital water supplies, equipment and disinfectant solutions by
B. cepacia has long been recognised as a cause of opportunistic infections in
immunocompromised hosts. Nine cases of B. cepacia wound infection were
suspected to have arisen from a contaminated 'Savlon' solution (Bassett, 1970). A
contaminated chlorhexidine solution was also implicated as the source of an outbreak
of B. cepacia infections which included wound infections, urinary tract infections
and bacteraemias. The chlorhexidine solution had been used to clean infected
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wounds, catheters and catheter insertion sites of the patients who became infected
(Speller et al, 1971). Contaminated distilled water, used in nebulisers, oxygen
humidifier bottles, respirators and croup tents, was also associated with an outbreak
of B. cepacia infections which occurred among patients undergoing treatment in a
hospital intensive care unit (Rapkin et al, 1976). Van Laer et al, (1988) reported
eight cases of septicaemia due to B cepacia affecting patients on a cardiology ward
over a three-day period. The infections were thought to have arisen from heparin
injections, where the heparin had been diluted with a dextrose solution contaminated
with B. cepacia. In another study, a batch of contaminated human serum albumin
was traced as the source of an outbreak ofB. cepacia infections which affected 15
patients in five hospitals (Steere et al, 1977). Other sporadic nosocomial B. cepacia
infections have been reported including cases of endocarditis observed in heroin
addicts. (Noriega et al, 1975).
B. cepacia infection of immunocompetent hosts has also been documented.
B. cepacia was shown to be the cause ofmacerated, hyperkeratotic foot lesions in
healthy Marines training in swampy conditions (Taplin, 1971). In addition,
B. cepacia was found to be the cause of community acquired pneumonia in an
immunocompetent host (Pujol et al, 1992). Most recently, ear drops contaminated
with B. cepacia were implicated as the cause ofmultiple brain abscesses secondary
to otitis media, in an otherwise healthy offshore oil worker (Hobson et al, 1995).
Certain inherited genetic disorders may also increase susceptibility to B. cepacia
colonisation and infection. In particular, patients with chronic granulomatous
disease (CGD) appear particularly vulnerable to serious lower respiratory tract
infections with B. cepacia (O'Neil et al, 1986). CGD is a neutrophil disorder in
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which cells do not produce oxidative reactive intermediates such as hydrogen
peroxide. The association of B. cepacia with life-threatening infections in patients
with CGD is thought to be due to resistance of this organism to nonoxidative killing
by neutrophils (Speert et al, 1994).
1.3 B. cepacia in CF
Although the first report of B. cepacia colonisation of a CF patient appeared in 1972
(Ederer and Matsen, 1972), it was not until the late 1970s that B. cepacia was
recovered with increasing frequency from individuals with CF. In 1980, a case of
B. cepacia pneumonia and septicaemia in a 17-year-old CF patient was described
(Rosenstein and Flail, 1980). Subsequently, the seminal report by Isles and
co-workers (Isles et al, 1984) highlighted the increased incidence of B. cepacia
colonisation in Western Canada during the previous decade and described the
variable clinical outcomes observed amongst B. cepacia colonised patients. Once a
patient is colonised with B. cepacia one of three clinical sequelae can occur.
B. cepacia can be carried chronically and asymptomatically either alone or in
combination with P. aeruginosa. Alternatively, the patient's lung function may
progressively deteriorate over many months accompanied by fever and weight loss,
in much the same pattern as infection by P. aeruginosa. The third and most severe
outcome of B. cepacia colonisation is 'cepacia syndrome' a rapidly fatal and
necrotising pneumonia which can be accompanied by septicaemia. Of particular
concern, it was noted that cepacia syndrome could occur unexpectedly in patients
who have relatively 'mild' CF disease.
18
B. cepacia colonisation ofCF patients continues to provoke major concern within the
CF community for a number of reasons. Colonisation is associated with poorer
clinical outcome, not only for the 20-30% of colonised patients who experience the
rapid decline associated with cepacia syndrome, but for most patients who become
colonised with this organism. Furthermore, evidence from national CF databases
shows that colonisation reduces life expectancy by 50% (Corey, 1999). B. cepacia is
also difficult to treat because of its innate resistance to antibiotics. In addition,
evidence strongly suggests that direct patient-to-patient transmission of B. cepacia
can occur which may account for the high colonisation rates recorded in some
treatment centres.
1.3.1 Transmission of B. cepacia
Escalation in the incidence of B. cepacia colonisation during the 1980's among CF
patients may have partly been due to the development of selective media for the
isolation and growth of this organism and improved identification techniques
(Gilligan et al, 1985; Tablan et al, 1987). However, it is likely that other factors
were also responsible. Early studies highlighted apparent risk factors for B. cepacia
colonisation which included having a colonised sibling or having spent periods in
hospital (Tablan et al, 1985; 1987). Clustering of cases was also observed in some
CF centres leading to speculation that specific hospital practices or person-to person
spread may be responsible for increased prevalence (Goldman and Klinger, 1986).
Implementation of stringent infection control procedures, including physical
separation of B. cepacia colonised patients from those who were not colonised,
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dramatically reduced the incidence of colonisation at one centre (Thomassen et al,
1986).
Accumulating evidence in the late 1980's continued to suggest a role for person to
person transmission in new cases of B. cepacia colonisation. However, it was not
until 1988 that use of a genomic fingerprinting technique known as ribotyping
confirmed that the majority of B. cepacia colonised patients at each of three CF
treatment centres were colonised with the same strain although the epidemic strain in
each of the three treatment centres was different (LiPuma et al, 1988). Moreover,
ribotyping was also used to provide further scientific evidence for person to person
transmission between two CF patients who were attending a summer camp. One CF
patient became colonised with the same strain of B cepacia as another CF camper
after only six days of social contact. However, the possibility of that transmission
occurred via contaminated environmental sources was not examined (LiPuma et al,
1990). B. cepacia colonised patients can contaminate the environment thus the
potential for transmission via contaminated environmental sources does exist (Nelson
et al, 1991).
Subsequently, several other studies provided further evidence of transmission of
B. cepacia between CF patients. Pegues and co-workers sequentially examined the
sputum or throat cultures of patients attending one of three CF summer camps for
B. cepacia, upon arrival, each week during the camp, at the end of camp and 14 and
30 days after the camp. Ribotypes of the B. cepacia isolates from patients with
sputum conversion were compared with isolates from other campers and those from
environmental sources. All 11 campers who became colonised with B. cepacia
during the study period had become colonised with strains possessing identical or
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very similar ribotypes to each other and to those isolated from previously colonised
campers. Examination of environmental sources yielded only one isolate of
B. cepacia which had a ribotype unique from the patients attending the camp where it
was isolated. (Pegues et al, 1994).
1.3.2 Epidemic B. cepacia strains
By the early 1990s, it was recognised that certain strains of B. cepacia appear to be
highly transmissible. One such 'epidemic' strain was recognised as the cause of 33
of the 60 cases of B. cepacia colonisation among patients attending Edinburgh and
Manchester CF clinics between 1986 and 1992 (Govan et al, 1993). Genotyping and
phenotyping techniques along with a detailed study of contacts between cases
provided compelling evidence that this epidemic strain had been spread between
patients through social contact, both within and between each of the centres by
attendance of patients from both these clinics at a weekend camp for CF patients.
Details of both social and hospital contacts between patients provided insight into the
level of contact required for transmission of this epidemic strain. Regular social
contact at fitness classes and social kissing appeared to be all that was necessary for
transmission of this strain. Within the Edinburgh clinic, 50% of B. cepacia
colonised CF patients who died during this study period were colonised with this
epidemic strain. However, clinical outcome following colonisation cannot be
predicted and there was no deterioration in the health of some individuals. Poor lung
condition before colonisation tended to be associated with poor survival, however
this did not appear to be associated with an increased risk of colonisation. The
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'Edinburgh epidemic strain' was later recognised as the same strain that was
responsible for an ongoing epidemic in the Toronto region of Canada. This strain
later to be known as the notorious Edinburgh / Toronto ET12 lineage (Govan et al,
1996), may have been spread between patients from these two continents while they
were attending a summer camp (Johnson et al, 1994).
1.3.3 Segregation of B. cepacia colonised patients
The risk to the CF community of transmission of B. cepacia led to UK guidelines
recommending that individuals colonised with B. cepacia should avoid sleeping,
exercising and performing physiotherapy in the same room as non-colonised
individuals and that kissing and the sharing of physiotherapy equipment and eating
utensils should be avoided. The risks involved in attending conferences and CF
summer camps where B. cepacia colonised individuals may be present were also
highlighted (Govan et al, 1992). Similar guidelines were also produced in Europe,
Canada and in the USA. It is not an exaggeration to say that the implication of these
strict infection control policies has lead to considerable distress and debate in the CF
community. Many of the social activities including summer camps which built
friendships and community spirit amongst CF patients have been discontinued and
B. cepacia colonised individuals are left feeling like outcasts (Anonymous, 1992).
In a further twist, recent case studies including a report of a previously healthy
mother who acquired B. cepacia from her CF children and developed severe
bronchiectasis (Ledson et al, 1998a) and a report of fatal cross infections with the
epidemic strain between patients already colonised with other B. cepacia strains
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(Ledson et al, 1998b) suggests that even more draconian infection control procedures
may be necessary.
Accumulating evidence suggests that not all strains of B. cepacia are equally
transmissible nor are all members of the B. cepacia complex associated with
virulence (Vandamme et al, 1997; LiPuma, 1999; Hutchison and Govan, 1999).
With greater understanding of the pathogenicity of B. cepacia and the host factors
that may be involved in the development of the more severe outcomes of B. cepacia
colonisation, it may be that in the future, segregation could be relaxed for patients
colonised with non-transmissible strains. However, although unpopular, reliable
surveillance and segregation of new cases is essential to reduce spread of B. cepacia
colonisation (Govan, 2000).
1.4. Virulence determinants ofB cepacia
In contrast to an increased understanding of B. cepacia epidemiology, the
pathogenicity of B. cepacia is relatively unclear. Several putative virulence factors
of B. cepacia have been identified, however their relevance to colonisation and
damage of the CF lung has not yet been fully described. A greater understanding of
the mechanisms involved in colonisation of the CF lung and the more severe
pulmonary deterioration which occurs in some patients could potentially lead to
effective treatment for B. cepacia infections.
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1.4.1 Adherence
Adherence of bacterial fimbriae or pili to host epithelial and mucosal surfaces is
often the first step in the establishment of infection by bacterial pathogens. An
adhesin, which facilitates attachment of B. cepacia to mucin and buccal epithelial
cells, has been described (Sajjan and Forstner, 1992; 1993). The 22kDa protein
shown to be located on pili is present in only certain B. cepacia strains.
Subsequently, a 17kDa pilin subunit was purified from one the isolates previously
shown to express the 22kDa adhesin. Pilin subunits are though to interact with other
gene products to permit the assembly of fimbriae. This 17kDa pilin subunit
assembles into large peritrichous fimbriae, with which the 22kDa mucin binding
adhesin is associated (Sajjan et al, 1995). These pili, named cable or cbl type II pili,
constitute one of five different classes of fimbriae expressed on the surface of
clonally diverse strains of B. cepacia (Goldstein et al, 1995). The cable pilus was
first identified in the highly transmissible ET12 strain of B. cepacia, which lead to
speculation that the cable pilus phenotype may identify other highly transmissible
B. cepacia strains (Sun et al, 1995). However, the cable pilus has not been identified
in other epidemic strains (Mahenthiralingam et al, 1997). Four other
morphologically distinct classes ofperitrichous fimbriae in B. cepacia have been
identified by electron microscopy. Type III filamentous (Fil) pili are expressed
mainly by CF isolates of B. cepacia where as type IV spine (Spn) pili are mainly
expressed by non CF clinical isolates and type V spike (Spk) by environmental
isolates. Cable, filamentous and spike pili are expressed on the cell surface in
association with the final pilin class, type I mesh (Msh) pili (Goldstein et al, 1995).
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A novel genomic marker termed 'B. cepacia epidemic strain marker' (BCESM) has
been identified in seven epidemic strains of B. cepacia. However, this marker was
found to be absent from non-epidemic strains isolated from CF patients and rare
among strains from the natural environment. The absence of BCESM for
non-transmissible strains suggests that it may provide a useful marker for
transmissibility. The role of the protein encoded by the 1.4 kb BCESM DNA has not
yet been identified (Mahenthiralingam et al, 1997).
1.4.2 Extracellular virulence factors
Strains of B. cepacia have been shown to produce a number of extracellular products
which may play a role in the pathogenicity of this species. A number of factors such
as proteases, lipases, haemolysins and siderophores have been closely examined,
whilst other characteristics have merely been identified as more common in clinical
than in environmental strains. Isolates from CF patients more frequently produce
catalase, ornithine decarboxylase, valine aminopeptidase, C14 lipase, alginase and
trypsin; reduce nitrate to nitrite; hydrolyse urea and xanthine and hydrolyse bovine
red blood cells (Gessner and Mortensen, 1990). However, the function these
characteristics may have in the pathogenesis of B. cepacia infections is unknown.
Protease
B. cepacia has been shown to secrete at least two proteases. A 32kDa protease with
antigenic similarity to P. aeruginosa elastase has been shown to cleave gelatin, hide
powder and collagen but not the human immunoglobulins IgG, IgM, IgA or secretory
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IgA. Purified protease caused bronchopneumonia, characterised by
polymorphonuclear cell infiltration and proteinaceous exudation, within rat lungs.
Immunisation of rats with this protease elicited an immune response, however, it was
not protective against subsequent lung infection with B. cepacia (McKevitt et al,
1989). A second, 40kDa protease with much lower activity is also produced by some
strains ofB. cepacia (Kooi et al, 1996).
Lipase
Several reports have described lipolytic activity in B. cepacia (Carson et al, 1973)
(McKevitt and Woods, 1984; Lonon et al, 1988; Straus et al, 1992). The majority of
strains tested had some lipolytic activity, however, activity appeared to be strain
dependent. The toxin purified by Lonon and co-workers was not cytotoxic to HeLa
cells or when injected intravenously into mice. However, this lipase was
subsequently shown to significantly reduce phagocytosis by rat pulmonary alveolar
macrophages both when macrophages were preincubated with lipase and when
phagocytosis occurred in the presence of lipase. Morphological changes were
observed in macrophages incubated with this lipase (Straus et al, 1992).
Phospholipase C has been associated with lung cytopathology due to its ability to
cleave phosphotidylcholine, a major lung surfactant. Reports have shown that
phospholipase C (PLC) activity amongst strains of B. cepacia can vary from 40%
(Vasil et al, 1990) to as high as 70% (Nakazawa et al, 1987) and is associated with
haemolytic activity in some strains of B. cepacia. However, unlike P. aeruginosa the




Several haemolysins have been isolated from strains of B. cepacia. The haemolytic
activity observed by Vasil and co-workers (1990) was always associated with some
level ofPLC activity, and appeared to require the expression of two closely linked
genes. Another study characterised a heat sensitive haemolysin from B. cepacia
(Nakazawa et al, 1987). In this study, all haemolytic strains were found to possess
PLC activity, however only 4% of strains in this study were heamolytic. Cepalysin, a
compound displaying haemolytic and antifungal activity, isolated from a Japanese
clinical isolate of B. cepacia and has been shown to form pores of between 20 and
30nm in red blood cells (Abe and Nakazawa, 1994). More recently, another
haemolysin has been isolated, on this occasion from the highly transmissible ET12
strain of B. cepacia (Hutchison et al, 1998a). This lipopeptide toxin produced pores
in human red blood cells of less than 20nm. When neutrophils were exposed to low
levels of this toxin, DNA degradation typical of apoptotic programmed cell death
was observed. High levels of haemolysin resulted in the release of both cathepsin G
and elastase from human neutrophils. It is tempting to hypothesise that this toxin
may contribute to the severe inflammatory response often observed in patients
colonised with this bacterium.
Siderophores
Bacteria that produce siderophores can compete with host iron binding proteins
which improves the ability of potential pathogens to establish and maintain infection.
To date, B. cepacia strains have been shown to produce three siderophores,
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pyochelin, cepabactin and azurechelin. 51% of the clinical isolates studied by Sokol
(1986) were pyochelin negative, thus this siderophore may not be important for the
establishment of infection in CF patients. However, increased morbidity and
mortality was reported in CF patients colonised with pyochelin producing strains
(Sokol, 1986). Cepabactin and pyochelin are both produced by the type strain of
B. cepacia (ATCC 25416), an environmental isolate (Meyer et al, 1989). Cepabactin
is reported to strongly chelate iron and to facilitate iron translocation. Azurechelin
was found to be produced by 88% ofCF respiratory isolates of B. cepacia and thus
may have a stronger association with virulence than pyochelin (Sokol et al, 1992).
The association of siderophores with virulence of B. cepacia however, requires
further investigation.
Exopolysaccaride production
Unlike P. aeruginosa, the majority of B. cepacia strains do not appear capable of
producing alginate-like exopoloysaccarides. A non-alginate heteropolysaccaride has
been reported in some strains of B. cepacia, however production is not thought to
correlate with colonisation or virulence of B. cepacia (Nelson et al, 1994). In
contrast to P. aeruginosa, isolation of mucoid forms of B. cepacia from CF patients
is rare (Govan and Deretic, 1996).
1.4.3 Inflammatory damage
B. cepacia colonisation has been shown to produce a pronounced humoral response.
Serum IgG and sputum IgA antibodies directed towards the core of B. cepacia LPS
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have been identified in the sera of B. cepacia-colonised CF patients. The presence of
these antibodies did not appear to prevent bacterial colonisation and no cross
reactivity was observed with P. aeruginosa LPS (Nelson et al, 1993). However, IgG
antibodies to outer membrane proteins of P. aeruginosa have been reported to
crossreact with surface antigens ofB. cepacia (Arnoff et al, 1991). As P. aeruginosa
often colonises the CF lung before B. cepacia it was concluded that antibodies to
outer membrane proteins did not inhibit B. cepacia colonisation.
Interestingly, the LPS of B. cepacia appears to be capable of causing considerably
more immunological damage to lung tissue than P. aeruginosa LPS. On a weight-
for-weight basis LPS preparations from both clinical and environmental isolates of
B. cepacia have been shown to induce the production of approximately nine times as
much TNF-a as P. aeruginosa LPS (Shaw et al,1995). Neutrophil activation by
B. cepacia LPS has also been described. Increased expression of complement
receptor 3, important for neutrophil transmigration into alveolar spaces, and priming
of neutrophil respiratory burst activity, was observed for both clinical and
environmental isolates of B. cepacia (Hughes et al, 1997). LPS from the ET12
strain of B. cepacia has also been shown to upregulate the production of inducible
nitric oxide synthase and inflammatory cytokine mRNA in CF and non-CF
leukocytes (Hutchison et al, 1998b).
An extracellular factor distinct from LPS has also been shown to induce a cytokine
response. Cell free supematants from clinical and environmental isolates of
B. cepacia were found to stimulate the release of IL-8 from epithelial cells and
human monocytes (Palfreyman et al, 1997). Studies have also shown that levels of
neutrophil elastase and C-reactive protein are raised during exacerbations with
29
B. cepacia (Elborn et al, 1994), and that B. cepacia stimulates a pronounced
inflammatory response in CF mouse model (Davidson et al, 1995). The
susceptibility of patients with CGD to infections with B. cepacia is thought to be due
to resistance of this organism to nonoxidative killing by human neutrophils (Speert et
al, 1994). It is not yet known if this feature contributes to survival of B. cepacia in
the CF lung.
In conclusion, although no definite role has been described for many of the other
virulence factors described to date, increasing evidence suggests that endotoxin
activation and subsequent acute inflammatory response are important factors in the
acute pulmonary deterioration often associated with B. cepacia infection.
1.4.4 Antimicrobial resistance
Most B. cepacia possess intrinsic resistance to many antibiotics and antibacterial
agents (Lewin et al, 1993), exemplified by an ability to use penicillin G as a carbon
source (Beckman and Lessie, 1979). Even when sensitivity to antibiotics is
demonstrated in vitro, antibiotic treatment is often ineffective thus depriving
colonised patients from effective antibiotic therapy. Several mechanisms have been
described to account for the resistance of B. cepacia to a variety of antimicrobial
agents.
^ -lactam resistance
Resistance of B. cepacia to p-lactam antibiotics is thought to be partly due to low
permeability of the outer membrane and partly due to inducible p-lactamases. The
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outer permeability of B. cepacia to the p-lactam nitrocefin was reported to be ten
times less than that of E. coli and similar to P. aeruginosa (Parr et al, 1987).
Unusually small porins with low single channel conductance, are present in the
B. cepacia outer membrane which may account for the low permeability of the
membrane.
Decreased expression of a 36kDa outer membrane protein and loss of a 27kDa
protein has also been associated with decreased permeability and P-lactam resistance
in isolates of B. cepacia (Arnoff, 1988). The 27kDa outer membrane protein may be
a major porin or major component of a porin complex of B. cepacia (Arnoff, 1988).
Beckman and Lessie first identified a highly inducible p-lactamase activity in
B. cepacia. Strains which had this enzyme could also utilise penicillin G their sole
source of carbon and energy (Beckman and Lessie, 1979). Two separate
P-lactamases have been identified in B. cepacia ATCC 17616. The penicillinase
originally described by Beckman and Lessie is responsible for about 80% of the
P-lactamase activity of this strain. A second P-lactamase with mainly
cephalosporinase activity accounts for the rest of the activity (Hirai et al, 1980;
Prince et al, 1988).
The penicillinase described by Beckman and Lessie (1979) was subsequently
sequenced and recognised to belong to the molecular class A P-lactamases. This
chromosomal P-lactamase, penA, is regulated by the penR gene and has high basal
and hyperinducible activity (Trepanier et al, 1997). The P-lactamases produced by
B. cepacia strains also exhibit carbapenamase activity (Simpson et al, 1993; Iaconis
et al, 1993; Trepanier et al, 1997). Resistance to imipenem is thought to be due to
reduced permeability brought about be loss or decreased expression of a 36kDa outer
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membrane protein and to the production of carbapenemases. Meropenem was found
to be more stable to (3-lactamases than imipenem (Iaconis et al, 1994). The penA
encoded penicillinase isolated from ATCC17616 also has activity against imipenem
(Trepainer et al, 1997).
Aminoglycoside resistance
B. cepacia strains are invariably resistant to aminoglycoside antibiotics. This
resistance has been attributed to low outer membrane permeability (Parr et al, 1987).
However, resistance is not considered to be due to small porin size or to decreased
porin expression, but rather to properties of bacterial LPS. Aminoglycosides and
polypeptide antibiotics such as colistin and polymyxin B interact with the outer
membrane ofGram-negative bacteria as the first step of their antimicrobial activity.
The antibiotics displace divalent cations that crossbridge and provide stability
between LPS molecules. Cracks are then formed in the outer membrane allowing for
greater uptake of these antibiotics. Polycationic antibiotics can thus reach their final
target, the negatively charged cytoplasmic membrane in which they form channels,
destroying membrane integrity and causing death of the bacterial cell (Moore and
Handcock, 1986).
It has been suggested that in this 'self promoted uptake' system, aminoglycoside
antibiotics cannot breach the outer membrane of B. cepacia as divalent cations are
not responsible for crosslinking between LPS molecules. High levels of
4-amino-4-deoxyarabinose, present in the LPS of B. cepacia, may confer polymyxin
resistance as its presence makes the binding of divalent cations unnecessary for outer
membrane stability. To provide stability, positively charged arabanose forms ion
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pairs with negatively charged phosphate molecules present in adjacent LPS
molecules (Cox and Wilkinson, 1991; Vaara,1992). The overall negative charge of
B. cepacia LPS is explained by low levels of KDO and phosphate compared to other
Gram-negative bacteria. In conclusion, the capacity of the outer membrane of
B. cepacia to bind cations is low (Cox and Wilkinson, 1991).
Resistance ofB. cepacia to other antibiotics
Plasmid encoded tetracycline and ampicillin resistance has been reported in a single
strain of B. cepacia (Williams et al, 1979). However, surprisingly few antimicrobial
resistance genes have been detected on B. cepacia plasmids.
Resistance of B. cepacia to several antibiotics has been attributed to low outer
membrane permeability. Impermeability has been reported to account for the high
level of resistance of B. cepacia to chloramphenicol, trimethoprim and ciprofloxacin,
although no difference in LPS or outer membrane proteins was detected (Bums,
1989). However, resistance of B. cepacia to trimethoprim, ciprofloxacin and
chloramphenicol has recently been associated with the expression of an antibiotic
efflux pump. Subcloning of a 3.4kb fragment of B. cepacia DNA revealed one
complete and one partial open reading frame which are homologous with two of the
three components of an efflux operon ofP. aeruginosa (mexA-mexB-oprM) (Bums et
al, 1996b). Thus, resistance to several antibiotics by B. cepacia may not solely be
due to reduced permeability; active efflux may be an important factor.
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Resistance in the CF lung
B. cepacia is able to invade respiratory epithelial cells. Intracellularity would enable
strains that appear sensitive to antibiotics in vitro, to survive within the CF lung
despite antibiotic therapy. This invasive potential would also explain to some extent
why this CF pathogen and not P. aeruginosa can cause bacteraemic infections (Burns
etal, 1996a).
Conditions which exist in the CF lung may also affect the susceptibility of B. cepacia
to antibiotics in vivo. Susceptibility of B. cepacia strains to (3-lactam antibiotics is
reduced when incubated in an atmosphere of 5% carbon dioxide. This factor may be
relevant in vivo since patients with advanced CF may have high alveolar carbon
dioxide concentrations (Corkill et al, 1994). Growth of B. cepacia in nutrient
depleted conditions has also been shown to increase resistance to antimicrobial
agents. Thus, nutrient depletion in vivo may cause strains to become more resistant
to antibiotics (Cozens and Brown, 1983). Differences in oxygen availability in the
CF lung due to accumulation ofmucin and bacterial exopolysaccaride may also have
an effect on the susceptibility of strains of B. cepacia to antibiotics in vivo.
Susceptibility of B. cepacia to ciprofloxacin and tobramycin increased in conditions
of oxygen depletion (McKenney and Allison, 1997). Bacteria may experience
oxygen depletion when trapped within layers of alginate, mucin and other host debris
present in the CF lung. However, antibiotic activity in the lung may also be reduced,
if penetration into the glycocalyx-like biofilm surrounding B. cepacia is impaired.
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1.5 Plant extracts as therapeutic agents
For centuries, plant extracts have been used to treat a wide range ofmedical
conditions. The World Health Organisation estimates that 80% of the world's
population use herbal medicines for some aspect of primary health care. By 1980,
the United Nations had identified 400 plant derived medicines in commercial use
(Jones, 1996). It has been calculated that approximately, one in four prescription
drugs dispensed by local chemists in the USA contain at least one ingredient derived
from plants. Medicines derived from plants include analgesics, anasthetics, oral
contraceptives, heart drugs and anti-cancer treatments (Lewington, 1990).
Salicylic acid, a compound isolated from meadowsweet (Filipendula ulmaria) and
related to salicin, a well-known painkilling compound from willow trees (Salix alba),
was modified by German chemists to produce aspirin (acetyl salicylic acid) (Jones,
1996). Two other more potent pain relieving compounds, morphine and codeine are
derived from the opium poppy (Papaver somniferum). Morphine was chemically
modified to produce the even more effective painkiller, heroin.
Digitalis extracted from the foxglove {Digitalis spp.) comprises a mixture of
glycosides which include digitoxin, digoxin and lanatoside c. These chemicals have
beneficial effects on the cardiovascular system including regulating heartbeat,
stimulating more forceful contractions and increasing the muscular activity of the
heart (Lewington, 1990).
The muscle relaxant, tubocurarine, often used in abdominal surgery, comes from the
stem of Chondrodendron tomentosum, which is used by South American Indians as a
source of arrow poison. Another well known relaxant, atropine from deadly
nightshade (Atropa belladonna) is used to dilate the pupil of the eye for diagnostic
35
purposes and as a treatment for stomach and duodenal ulcers. Diosgenin, a steroidal
sapogenin that occurs naturally in yam species, is utilised for the large scale
production of male and female hormones required for the manufacture of oral
contraceptives (Lewington, 1990). Taxol, a drug extracted from the pacific yew tree
(Taxus baccata) has been developed as an anti-cancer treatment.
A number of studies have reported the antimicrobial activity of plant extracts. Since
even the most potent antipseudomonal antibiotics are not effective in eradicating
B. cepacia from the CF lung, one of the major aims of this thesis was to focus on
plants, in particular garlic {Allium sativum), thyme {Thymus vulgaris), as potential
sources of novel antimicrobial agents against this untreatable opportunistic pathogen.
1.5.1 History of the medicinal use of garlic
Extracts of garlic {Allium sativum), a member of the Liliaceae family, have been used
therapeutically for several thousand years. The Sumarians produced some of the first
written accounts of the medicinal properties of garlic extracts around 2600 - 2100
BC. The Egyptians also recorded their use of garlic extracts as medicines in the
Codex Ebers (1550 BC), discovered by the German Egyptologist Georg Ebers in
1872. This document contains 800 therapeutic formulations, 22 of which mention
garlic (Block, 1985).
Dioscorides, a Greek who accompanied the Roman troops in Asia as an official
physician in the first century AD, wrote the first detailed description of the
therapeutic uses of garlic (Stoll and Seebeck, 1951). Included in these records were
descriptions of the use of garlic as a treatment for skin rashes, parasitic infections of
36
the skin, leprosy and as a remedy for snake bites and the bites ofmad dogs was
recorded. Textbooks of Sanskrit medicine, known as 'Ayurveda' (Science of Life)
written around 500AD contain information about the three legendary Indian
physicians Charaka, Susruta and Vagbhata who used garlic, which they called
'mahushuea', as a remedy for skin and abdominal diseases.
In the early 18th century, four condemned criminals, recruited to bury victims of
plague in Marseilles supposedly drank a concoction of garlic juice and wine to
'protect' them against the disease. This mixture is known as 'vinaigre des quatre
voleures' and can still be purchased in France.
Louis Pasteur reported the antibacterial properties of garlic in 1858. Later, Albert
Schweitzer (1875-1965), is stated to have treated amoebic dysentery with garlic.
Garlic was also used during both world wars as an antiseptic to prevent gangrene
(Block, 1985).
1.5.2 Discovery of allicin
The scientific basis for the medicinal use of garlic was not established until 1930,
when it was shown that garlic could inhibit the growth of E. coli (Lehmann, 1930).
In 1944, Cavallito and Bailey demonstrated that a relatively unstable, colourless oil
obtained from the steam distillation of ethanolic extracts of garlic retained
antimicrobial activity at concentrations as low as 1:125000. They named the active
agent they had discovered 'allicin' (allyl 2 propene thiosulphinate). This sulphur
containing compound was also shown to have considerable activity against both
Gram-positive and Gram-negative bacteria. Stoll and Seebeck later elucidated the
pathway by which allicin is formed in garlic (Stoll and Seebeck, 1951). Briefly,
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allicin is not present within intact garlic bulbs. However, the garlic bulbs contain the
precursor compound, 'alliin' ((+)-S-allyl-L-cysteine sulphoxide). This compound is
hydrolysed to allicin by the plant enzyme, alliinase, which comes into contact with
alliin when a bulb is cut or crushed. In 1956, Willis reported, that allicin is an
inhibitor of sulphydryl enzymes suggesting that the antibacterial properties of allicin
may be due to interference with SH-groups (Willis, 1956).
1.5.3 The sulphur chemistry of garlic
Garlic has a particularly high content of sulphur compounds with 1.1 to 3.5% of the
fresh weight of garlic comprising such compounds (Lawson, 1995). Wertheim
(1844), was first to demonstrate that the compounds that give garlic its distinctive
smell are organosulphur compounds but he incorrectly proposed that these
compounds have the same basic formula CeHioS. It was almost 50 years later, that
Semmler correctly determined the basic formula as C3H5S and identified the specific
compounds. The oil obtained from steam distillation of garlic bulbs was found to
consist mainly of diallyl disulphide (60%), diallyl trisulphide (20%) and diallyl
tetrasulphide (10%) (Semmler, 1892). It was not until 1944, that Cavallito and
Bailey discovered the major antibacterial component of crushed garlic, allyl-2-
propene thiosulphinate, which they named allicin. They observed that the
antimicrobial activity of allicin was reasonably stable at 4°C but rapidly lost activity
on heating. Furthermore, activity was immediately lost upon addition of alkali
whereas dilute acids had no effect (Cavallito and Bailey, 1944a; b; 1945).
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Allicin can be synthesised by the mild oxidation of diallyl disulphide (Stoll and
Seebeck, 1951). Experiments carried out with a dried, low temperature, acetone
extract of garlic showed that no diallyl sulphides are present in intact garlic bulbs and
that allicin is not formed when organic solvents are present or in the absence ofwater
(Cavallito et al, 1945). It was concluded that allicin must be formed from a parent
compound by the action of an enzyme which is inactivated by ethanol and that the
diallyl sulphides present in the oil of steam distilled garlic are derived from allicin.
The precursor of allicin was found to be an oxygenated sulphur amino acid named
alliin and the enzyme that converts this substrate to allicin was identified and named
alliinase (Stoll and Seebeck, 1951). Alliin is also formed from a parent compound,
y-glutamyl-S-allylcysteine, the second most abundant of nine different y- glutamyl
peptides present in garlic (Lawson et al, 1991b).
Alliin and alliinase are located in different cell types within garlic bulbs a fact that
might be expected from the absence of thiosulphinate production until cloves are cut
or crushed. Alliinase is located in the bundle sheath cells located around the phloem
(Ellmore and Feldberg, 1994) whereas alliin is found in the more abundant storage
mesophyll cells of the plant (Lawson, 1995). Interestingly, this is a different
situation from that which exists in onion bulbs where alliinase and the cysteine
sulfoxides are located in different compartments of the same cell (Lancaster and
Collin, 1981).
Allicin is the principle thiosulphinate compound produced when a garlic bulb is cut
or crushed. The enzyme, alliinase, is also responsible for catabolising reactions of
other cysteine sulfoxides including methiin and isoalliin and for production of other
thiosulphinates including two allyl methyl thiosulphinates, two allyl trans-1 propenyl
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thiosulphinates, two methyl trans- 1-propenyl thiosulphinates and methyl
methanethiosulphinate (Lawson et al, 1991c).
Not surprisingly, garlic's well known and long established medicinal properties have
led to a 'garlic industry' producing numerous commercial preparations. These
products include garlic powders, steam distilled garlic oils, oils of macerated garlic
and minced garlic aged in ethanol. It should be noted that high performance liquid
chromotography (HPLC) analysis has shown that only aqueous garlic extracts and
dried garlic powders contain thiosulphinates (Lawson et al, 1991a).
HPLC is the most reliable method to identify organosulphur compounds present in
garlic preparations. The apparatus can be operated at ambient room temperatures,
and thus can measure allicin and other thiosulphinates at temperatures which avoid
the destabilising injection port and column temperatures of gas chromatography.
Studies have shown that Cis HPLC and Si HPLC used in association with external
standards produce reliable qualitative and semiquantative measure of the compounds
present in garlic preparations (Jansen et al, 1987; Lawson et al, 1991a; Lawson et al,
1991c). Si HPLC with 2-propanol / hexane gradients produces the best resolution of
isomers present in thiosulphinate mixtures, however poorer separation of these
isomers is also achievable with Cis HPLC (Block et al, 1992). A spectophotometric
method for the quantification of allicin and other thiosulphinates, developed by Han
and co-workers, is based on a reaction reported in 1944 by Cavallito and co-workers.
One molecule of allicin reacts with two molecules of cysteine to form
S-allylmercaptocysteine. The decrease in the amount of cysteine present can be
measured spectophotometrically using 5,5'dithio-bis(2-nitrobenzoic acid) (DTNB)
(Han et al, 1995).
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Allicin is formed at an optimum pH of 4.5-5.0. Below pH 3.6 no thiosulphinates are
formed as alliinase is completely and irreversibly inhibited. As stomach acid has a
low pH, a stomach acid resistant coating to protect alliinase would be required for
ingested garlic powder preparations (Lawson and Hughes, 1992).
Although allicin is a relatively unstable compound, it is reasonably stable with a
half-life of about 4 days at room temperature when stored in water. Allicin is less
stable within garlic homogenate than in water. Stability of allicin within garlic
homogenates increases with dilution. Allicin is an unstable compound mainly
because it reacts easily with itself to form vinyldithiin, ajoene and about 40
unidentified compounds (Lawson, 1995). Thus dilution, especially in water,
increases stability. Stability is thought to be further increased in water due to
hydrogen bonding between water molecules and the oxygen atom present in allicin.
Allicin is also most stable at low temperatures (Lawson, 1993). At room
temperature, aqueous allicin is transformed to mainly diallyl trisulphide, diallyl
disulphide and allyl methyl trisulphide (Iberl et al, 1990). However, within garlic
homogenate the trisulphides are formed first followed by a slower transformation to
more stable disulphides and tetrasulphides. In solvents such at methanol and
chloroform, the half life of allicin is reduced to 48 hours, and to 24 hours in ethanol
or acetonitrile (Lawson, 1993).
1.5.4 Antibacterial mode of action of allicin
It has been known from the early work of Cavallito and co-workers that allicin reacts
rapidly with sulphydryl compounds. Since allicin reacts readily with cysteine to
produce S-allylmercaptocysteine an early hypothesis was that allicin inhibits
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bacterial growth by reacting with essential bacterial -SH groups either by reacting
with the thiol groups of enzymes or with cysteine residues on elongating polypeptide
chains during protein synthesis (Cavallito, 1946). Confirmation that the
thiosulphinate link (-SO-S) of allicin was essential for bactericidal action was
provided by Small, Bailey and Cavallito (1947). Furthermore, addition of thiol
compounds such as cysteine was shown to react with allicin and reverse
bacteriostasis (Bailey and Cavallito, 1948). The explanation was that allicin reacts
with cysteine allowing bacterial enzymes normally inhibited by allicin to remain
active.
Enzymes containing sulphydryl (-SH) groups have been tested for sensitivity to
allicin (Rao et al, 1946). Wills (1956) examined a variety of different enzymes and
found that 11 out of 15 enzymes inhibited by allicin contained -SH groups whereas
of the 15 enzymes tested that were resistant to allicin, only three were sulphydryl
enzymes. Wills also confirmed that addition of cysteine protected bacterial cells
from the inhibitory action of allicin.
Inhibitory activity of allicin against yeast has also been reported. Barone and Tansey
(1977) hypothesised that even subinhibitory concentrations of allicin would affect
cell division of C. albicans by inhibiting disulphydryl reductase, an NADPH -
dependant fiavoprotein, which reduces yeast cell wall disulphides to the thiols
necessary for budding. Interactions between allicin and -SH groups may also induce
the formation ofmycelia. Ghannoum (1988), investigated that activity of an aqueous
garlic extracts (AGE) against C. albicans. Scanning electron microscopy and cell
leakage studies revealed that AGE affects the structure and integrity of the outer
surface of yeast cells. Studies of the affect ofAGE on yeast lipids showed that in the
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presence ofAGE the total lipid content of C. albicans was decreased with higher
levels of phosphatidylserines and lower levels of phosphatidylcholines. Changes in
fatty acid concentrations such as increased concentrations of palmitic and oleic acids,
but lower concentrations of linoleic and linolenic acids, were also observed. There
were also increases in the accumulation of esterified steryl glycosides. Ghannoum's
study confirmed the earlier work of Adetumbi and co-workers who had shown that
garlic blocks lipid synthesis of C. albicans (Adetumbi et al, 1986). Thus, the
evidence suggests that AGE affects the total lipid and fatty acid content of
C. albicans. Finally, allicin has also been shown to inhibit the growth of the
protozoan parasite Entamoeba histolytica by inhibiting the activity of the
trophozoites cysteine proteinase (Ankri et al, 1997).
It has also been proposed that the antimicrobial activity of allicin is not solely based
on activity as a sulphydryl reagent. Changes in the DNA, RNA and protein synthesis
of Salmonella typhimurium have been reported in the presence of allicin. Protein
synthesis was reduced to 40% of the control value ten minutes after addition of
allicin, but recovered to reach normal levels after 50 minutes. DNA synthesis was
also only transiently and partially inhibited by allicin and restored to 100% after only
35 minutes contact. RNA synthesis was, however, much more profoundly inhibited
by exposure to allicin. Only five minutes after allicin addition, RNA expression was
merely 1% of the control value. However, expression began to recover after 40
minutes, and after 50 minutes reached 73% of the control value accompanied by
bacterial growth. Three phases of inhibition of S. typhimurium by allicin were
evident; a lag phase, an inhibition phase and then reduced resumption of growth.
The lag period corresponds to the time between chromosome replication and cell
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division, thus cells that have completed DNA synthesis before allicin addition are
able to proceed through cell division. The inhibition of cells undergoing chromosome
replication can be attributed to the almost total inhibition ofRNA synthesis, as DNA
synthesis requires RNA polymerase. S. typhimurium resumed growth 50 minutes
after addition of allicin, however growth was at only 55% of the uninhibited control.
Allicin was shown to be stable in the LB broth used in this experiment for more than
four hours therefore, as these cells do not totally recover from allicin inhibition it can
be speculated that allicin causes irreparable damage to the cell. Furthermore, as
resumption of growth was most closely associated with resumption ofRNA
synthesis, it was assumed that this was the primary target of inhibition (Feldberg et
al, 1988).
1.5.5 Antimicrobial spectrum of garlic
Garlic extracts have been tested for inhibitory activity against a wide array of
micro-organisms. Studies have ranged from investigation of inhibition of single
species to evidence of broad-spectrum anti-microbial activity against a range of
Gram-positive and Gram-negative bacteria. Dehydrated garlic extracts have been
shown to possess inhibitory activity against S. typhimurium and Eschericheria coli
(Johnson and Vaughn, 1969). Production of enterotoxins and growth of S. aureus is
inhibited in the presence of dehydrated garlic (Gonzalez-Fandos et al, 1994). AGE
has also been demonstrated to have bactericidal activity against Helicobacter pylori
(Cellini et al, 1996) and Mycobacterium avium complex (Deshpande et al, 1993).
Other studies, including those carried out by Cavallito and Bailey (1944), Rees and
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co-workers (1993) and Didry and co-workers (1987) have emphasised the wide
ranging antibacterial activity of garlic extracts. Garlic extracts have also been shown
to inhibit many pathogenic species of fungi including Aspergillus (Pai and Piatt,
1995) and Candida (Barone and Tansey, 1997; Ghannoum, 1988) species. In vitro
studies have shown that intra-venous administration of commercial garlic
preparations increase the anti-Cryptococcus neoformans activity of human plasma
(Davis et al, 1990). Allicin preparations have also been shown to have considerable
germicidal activity against protozoan species such as Entamoeba histolytica, the
causative agent of amoebic dysentery (Ankri et al, 1997).
1.5.6 Metabolism and pharmacokinetics of constituents of garlic
Allicin is not found in the blood of individuals who have ingested garlic. No
detectable serum or urine levels of allicin, or its metabolites ajoene, vinyldithiins or
diallyl sulphides were found in volunteers who ingested up to 25g of raw garlic
(Lawson, 1993). Experiments have also been described in which allicin was added to
blood plasma and then immediately extracted with chloroform. The results showed
that allicin was not recovered unless the plasma was first deproteinated suggesting
that allicin reacts with protein in the bloodstream. The half-life of allicin in fresh
whole blood at 37°C is less than one minute (Lawson, 1993). It seems likely that
allicin reacts in vivo with protein bound cysteine to produce the temporary
metabolite S-allylmercaptocysteine. This compound then quickly reacts with blood
cells to form allyl mercaptan. To account for the activity of garlic preparations as
antimicrobial agents and the in vivo instability of allicin in the bloodstream, it has
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been suggested that allyl mercaptan or a further metabolite of this compound is
responsible for the therapeutic activity of garlic preparations (Shashikanth et al,
1985; Davis et al, 1990).
1.6 Oil extracts of plants
An essential oil is a mixture of organic compounds obtained from a singe botanical
source. Such oils can be extracted by either distillation or cold pressing. Use of
distilled oils dates back only 1000 years to when the process of distillation was
invented. However, the plants from which essential oils are derived have been used
as medicines for much longer. Essential oils are not obtained readily from all plants.
Typically, fresh plant material yields 1% to 2% of its weight as essential oil. The
oils, however, can be obtained from a variety of plant materials including flowers,
leaves, seeds, grasses, roots, rhizomes, woods, barks, gums, tree blossoms, bulbs and
dried flower buds.
Oils from the same plant variety can contain different quantities of chemical
compounds. This variation can be due to many factors including, the age of the
plant, the time of year or even day upon which it is harvested. Environmental and
other cultural conditions which affect plant growth, such as geographical location,
elevation, weather conditions and soil type may also effect the quality of oil
produced (Cruz et al, 1993). Differences in extraction techniques and the equipment
used can also affect the composition of oil obtained. Oxidation and subsequent loss
of activity of compounds present within essential oils can occur over time. This
process occurs more rapidly in incorrectly stored oils. To preserve activity, oils
should be stored away from heat and light (Tisserand and Balacs, 1995).
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1.6.1 Antimicrobial activity of plant essential oils
Although spices and essential oils have been used since antiquity it was not until the
1880's that the first scientific studies of plant essential oils were published. In 1887,
Chamberland reported the antimicrobial activity of oils in their gaseous and liquid
states against anthrax bacteria. Cinnamon, marjoram, sandalwood, clove and juniper
were found to be the most active of the oils tested. Cadeac and Meunier in 1889
published their findings, that cinnamon and clove were the most inhibitory of various
essential oils tested against Salmonella typhi and Burkholderia mallei. The potential
use of essential oils as food preservatives was recognised in 1911 by Hoffman and
Evans, who observed that cinnamon, cloves and mustard prevented bacterial growth
(Bartels, 1947). By 1925, the antimicrobial potential of individual compounds
present within essential oils was recognised. Myers and Thienes, discovered that
thymol, a compound present in thyme and oregano essential oils, could kill a
yeast-like organism which caused dermatitis after only one minute of exposure; in
contrast, 60 minutes exposure of 1% phenol was required to produce the same effect
(Myers and Thienes, 1925). Myers, later showed that carvacrol, a compound also
present in thyme essential oil, was capable of the same rapid killing of the same
'yeast-like organism'. Nine other yeast-like organisms were also studied. All were
killed within one minute's exposure to thymol; however, cinnamon and clove oils
required at least 25 minutes exposure (Myers, 1927). Kingery and Adkisson (1928)
also reported the fungicidal activity of thymol and the oils of cinnamon and cloves.
Recently, there has been renewed interest in the antimicrobial properties of essential
oils and spice extracts. Due to the increasing prevalence ofmicro-organisms
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exhibiting resistance to conventional antibiotics, several studies have been carried
out to investigate the susceptibility of a number of bacteria, yeasts and fungi to
essential oils. Some studies have demonstrated susceptibility against challenging
pathogens such as methicillin resistant Staphylococcus aureus (MRSA) and
vancomycin resistant enterococci to tea tree, lavender, mint and thyme oils (Nelson,
1997). More extensive studies have involved screening of over fifty plant essential
oils for antibacterial activity against twenty five genera of bacteria (Deans and
Ritchie, 1987) or against various bacterial, fungal and yeast species (Hammer et al,
1999; Farag et al, 1989; Yousef and Tawil, 1980). Oils of bay, cinnamon, clove,
oregano and thyme were the most consistently active of the oils tested in these
studies. Numerous other studies have concentrated on the potential use of essential
oils as food additives to prevent bacterial spoilage. This strategy is by no means
novel. Mustard which the Romans used to preserve grape juice from the growth of
fermenting organisms is believed to have derived its name from must, newly
fermented grape juice. Renewed interest in the addition of plant extracts to foodstuffs
has been generated since synthetic food additives are no longer perceived as safe by
the consumer (Shelef, 1983). Several investigators have reported the antimicrobial
activity of essential oils against foodborne pathogens such as Campylobacteur jejuni,
Salmonella enterididis, Listeria monocytogenes, S. aureus, E. coli (Smith-Palmer et
al, 1998; Aureli et al, 1992; Pasteur et al, 1990; Farbood, 1976) and
Vibrio parahaemolyticus (Beauchat, 1976). The most inhibitory oils were revealed as
those from oregano, thyme, cinnamon, clove, rosemary and garlic. Gram-positive
bacteria appeared more susceptible than Gram-negative bacteria to the oils (Smith-
Palmer, 1998; Shelef, 1983; Farbood, 1976). The susceptibility of food spoilage
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yeasts to the antimicrobial activity of essential oils has also been noted (Conner and
Beauchat, 1984). For practical purposes it is important to note that higher
concentrations of essential oil are required in foods than in laboratory media to
inhibit growth of micro-organisms (Farbood, 1976).
Investigators have also highlighted the potential use of essential oils in cosmetics
and soaps (Nadal et al, 1973; Maruzzella and Henry, 1958). However, when oils
active against S. aureus, E. coli and C. albicans in laboratory media were added to
soap, antimicrobial activity was not observed (Morris et al, 1979). The activity of
antimicrobial compounds present within the oils maybe inhibited by soap, thus
rendering them ineffective in these conditions.
1.6.2 Use of essential oils in dentistry
Essential oils, particularly oils of cloves and thyme have been used in dentistry since
the late 19th century. Oil of cloves contains high concentrations of the phenol,
eugenol whilst thyme oil comprises mainly the phenols thymol and carvacrol.
Thymol and carvacrol can also be extracted from caraway, marjoram, oregano,
rosemary and savory plants. The first reported use of eugenol in dentistry was in
1837, when Bonastre used a mixture of eugenol and magnesium oxide as a filling
material. Dentists have also used thymol and carvacrol since the 19th century. In
1885, Gorgas reported the use of thymol and carvacrol as a treatment for suppurating
pulps, alveolar abscesses, stomatitis and odontalgia. The use of thymol for cavity
sterilisation was discontinued in the first half of the 20th century, however its use is
still evident in dentistry today as one of the main ingredients of Listerine® (Meeker,
49
1988). A more recent, scientific examination of the effectiveness of various essential
oils and their component compounds against some of the important pathogenic
micro-organisms found in the mouth including, Streptococcus mutans, S. aureus,
Klebsiella pneumoniae, and Actinomyces viscosus, found thyme oil to be the most
active. The most active essential oil ingredients were found to be thymol followed
by carvacrol and eugenol (Meeker, 1988). In a separate study, fifteen oral bacteria
were challenged with essential oils and oil components. Thymol was the only
substance to be active against all the bacteria surveyed and once again was found to
be more active than eugenol (Shapiro et al, 1994).
1.6.3 Essential oil composition
Each essential oil typically comprises a number of organic compounds many of
which may be present in the essential oils ofmore than one plant. Thyme oil can be
extracted from Thymus zygis or Thymus vulgaris. Different chemotypes of thyme oil
are obtained from this genus. Each chemotype of thyme oil has a different chemical
composition, the most common of which is the thymol chemotype, composed of
between 32% and 63% thymol and l%-5% carvacrol. Others chemotypes include
the carvacrol and wild thyme chemotypes which both contain more carvacrol than
thymol, and the thymol / carvacrol chemotype made up of equal amounts of these
compounds (Tisserand and Balacs, 1995).
Other essential oils tend to vary less dramatically in composition; in as much as one
compound consistently dominates the oil. Bay oil, most commonly produced from
Pimenta racemosa contains 38% to 75% eugenol. Cinnamon leaf oil from
Cinnamonum verum also contains eugenol at a concentration of between 70 % and
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90%. Clove oil from Syzygium aromaticum contains large amounts of eugenol and
some iso-eugenol at concentrations of 70%-95% and 0.14%-0.23% respectively.
Sweet fennel oil from Foeniculum vulgare contains mainly trans- anethole (75%-
92%), but also contains small quantities of estragole and cis-anethole. Melaleuca
alternifolia produces tea tree essential oil which contains between 27%-58%
terpinen-4-ol, a terpene alcohol. Other major components of tea tree oil are the
monoterpenes a-terpinene and y-terpinene. Garlic produces mainly diallyl disulphide
along with a large number of other sulphur containing compounds.
Phenols
Most essential oils contain many different compounds but it is the one or two major
components that largely shape the pharmacology of the oil. Many of the most
commonly used oils are composed of phenols such as eugenol and the isomers
thymol and carvacrol. The chemical structure of phenol contains a benzene ring with
a highly reactive -OH group attached directly to the ring. Other chemical groupings,
commonly found in essential oils include ethers, such as anethole and estragole, or
terpenes and terpene alcohols that are built on the isoprene unit commonly found in
plant biochemistry.
Phenol was first described by Runge in 1834, but it was not until 1860 that
Kuchenmeister advocated the use of phenol as an antimicrobial agent (Bennet, 1959).
In 1875, Lister introduced a phenol spray as the first general disinfectant in medical
history (Meeker, 1988). Phenols are more active at elevated temperatures and acid
pH. They partitioned from aqueous phase to lipoidal phase; thus, soaps can interfere
with the activity of phenols by creating an additional lipoidal phase, reducing the
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concentration available to inhibit bacteria. The presence of blood, serum, alcohol
and salivary mucus all reduce the activity of phenols. Dead bacterial cells absorb
phenol and thus reduce the amount available to inhibit live cells (Bennet, 1959).
Phenols and other cyclic hydrocarbons exert their bactericidal effect by disrupting
the bacterial cell membrane (Judis, 1963). Hydrophobic reactions of phenols with the
cell membrane affect membrane embedded proteins and membrane function. In the
presence of cells, these lipophilic compounds partition into the membrane where
their accumulation leads to swelling of the lipid biolayer and subsequent increased
membrane permeability (Sikkema et al, 1994). Ultimately cell contents are lost
through the damaged cell membrane (Judis, 1963). The biological activity of
membrane proteins may be altered by hydrogen bonding of the highly reactive OH
group of phenols with the active site ofmembrane bound enzymes (Farag, 1989;
Sikkema, 1994). As thymol, carvacrol and eugenol are all phenols, the major
antimicrobial mechanism by which essential oils containing these compounds act is
most likely to be by destruction of the bacterial cell membrane. Finally, it is
important to consider that a number of chemical constituents, each of which may
exert antimicrobial activity by different mechanisms, acting against different targets
within the bacterial cell, may work together within essential oils in 'natural synergy'
to kill bacterial cells.
1.7 Endogenous antimicrobial peptides
A variety of antimicrobial substances which act as endogenous antibiotics are
produced by humans, animals, insects and plants. Thus, it would appear that
antimicrobial peptides of less that 100 amino acids form an intrinsic part of innate
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host defences. Most of these peptides are cationic, i.e. they have a net positive
charge and amphipathic, i.e. they are composed of hydrophilic and hydrophobic
regions. For the purpose of this thesis, discussion will be limited to the major groups
of antimicrobial peptides expressed in humans.
1.7.1 Defensins
Defensins are a family of antimicrobial peptides which have been identified in plants,
animal and humans. A well as their antimicrobial properties, some of these peptides
also have a role in inflammation. Defensins share structural similarities. They
contain six cysteine residues which form three intramolecular disulphide bridges.
Human defensins are divided into a-defensins and P-defensins based on how the
cysteine residues are paired into disulphide bridges, a-defensins are linked 1 -6, 2-4
and 3-5 (Hill et al, 1991) whereas P-defensins are linked 1-5, 2-4 and 3-6
(Zimmerman et al, 1995). Human a and p-defensins are encoded by a cluster of
genes on chromosome 8p23 and are thought to have a common genetic ancestry
(Sparkes et al, 1989; Bevins et al, 1996; Liu et al, 1997; Harder et al, 1997).
a-defensins
a-defensins were first described in 1985 (Ganz et al, 1985) and six have been
identified to date in humans. Four such peptides are found within the azurophilic
granules of the neutrophil (HNP 1-4) (Lehrer et al, 1993). The two other
a-defensins identified to date, HD-5 and HD-6, are found in the secretory granules of
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the intestinal Paneth cells (Jones and Bevins, 1992; 1993). HD-5 is also found in the
epithelial cells of the female reproductive tract (Quale et al, 1998).
Defensins HNP 1, 2 and 3 make up 30-50% of the protein present in azurophilic
granules, constitutes 5-7% of total neutrophil protein. HNP-4, however, constitutes
only 1% of the total defensin content. When phagosomes containing engulfed
microbes fuse with these granules, the defensins bind to the membrane and associate
into multimers to form channels, which disrupt the integrity of the microbial cell
membrane, and through which more defensin can pass into the cell (Lehrer et al,
1993).
a-defensins can also perform other activities as part of the immune response. For
example, defensins have been shown to stimulate the release of cytokines from
airway epithelial cells (Van Wettering et al, 1997) and T cells (Lillard et al, 1999)
and to play a role in the attraction ofmonocytes, (Territo et al, 1989) macrophages,
granulocytes and lymphocytes (Welling et al, 1998) into inflammatory sites.
(3-defensins
The first (3-defensin to be identified was tracheal antimicrobial peptide (TAP)
isolated from bovine trachea (Diamond et al, 1991). Shortly after the discovery of
TAP, Selsted and co-workers identified 13 other antimicrobial peptides from bovine
neutrophils that shared high sequence similarity with TAP, but differed from
a-defensins (Selsted et al, 1993). These peptides were named p-defensins. It was
not until 1995 that the first human p-defensin was identified in human plasma
(Bensch et al, 1995). Subsequently, this defensin was also shown to be present in the
epithelial cells of various human organs including the lung (McCray and Bentley,
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1997; Goldman et al, 1997) and urinary and female reproductive tracts (Valore et al,
1998). The second human fl-defensin, hBD-2, was identified two years later from
psoriatic scales of human skin. Expression of this defensin was also identified in the
lung (Harder et al, 1997; Bals et al, 1998).
The activity of hBD-1 and hBD-2 was reported to be salt sensitive (Goldman et al,
1997; Bals et al, 1998). However, hBD-1 isolated from human urine was found to
maintain its antimicrobial activity against E. coli in both dilute and normal urine
suggesting that not all forms of hBD-1 are salt sensitive (Valore et al, 1998). ASF
isolated from primary cultures of airway epithelial cells of non-CF individuals has
been shown to have antimicrobial activity which was absent in similar secretions
from CF airway epithelial cells (Smith et al, 1996). Investigators had previously
reported that concentrations ofNa+ and CF were raised in CF compared to non-CF
airways (Joris et al, 1993). This led to the possibility that inactivation of P-defensins
by the high salt levels in CF ASF might in some part explain the susceptibility ofCF
patients to chronic bacterial infections. As P-defensins are structurally similar to
a-defensins, it is likely that P-defensins also kill microorganisms by disrupting the
cell membrane. Homologues of hBD-1 and hBD-2 which have salt sensitive activity
against E. coli, S. aureus and P. aeruginosa have been described in mice (Morrison
et al, 1998; Bals et al, 1998b; Morrison et al, 1999). Interestingly, the inhibitory
activity of hBD-1 against P. aeruginosa is considerably greater than the activity of
the murine homologue mBD-1.
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1.7.2 Cathelicidins
Cathelin is an acronym for cathepsin L inhibitor and peptide antibiotics which when
synthesised are preceded by a cathelin-containing domain, are called cathelicidins.
To date, humans are known to express only one cathelicidin, LL-37. The cathelin
containing prepropeptide hCAP-18 is cleaved by neutrophil elastase to release the
a-helical antimicrobial peptide LL-37. Expression of this peptide has been identified
in the human lung (Bals et al 1998c). Synthetic LL-37 is active against
Gram-positive and Gram-negative organisms and exhibits some salt sensitivity at
NaCl concentrations of lOOmM (Turner et al, 1998). When LL-37 activity against
E. coli was examined by Bals and co-workers, salt sensitivity was noted through the
20 and 300mM range ofNaCl examined (Bals et al, 1998c).
1.7.3 Granulysin
Granulysin, a protein present in the granules of human T cells and natural killer cells
is a member of the saposin-like protein family. Recombinant human granulysin, has
been shown to have inhibitory activity against a broad spectrum ofmicro-organisms
(Stenger et al, 1998).
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1.7.4 Histatins
Histatins are histidine rich proteins, present in human saliva, which have some
activity against C. albicans (Tsai et al, 1998). The mechanism of action of these
peptides appears to differ from that of other antimicrobial peptides as loss of
membrane integrity was shown to occur after cell death and not as a result of
histatins disrupting the yeast cell membrane. Activity of histatins may be linked to
the binding of a 67kDA protein of C. albicans (Edgerton et al, 1998).
1.7.5 Antileukoproteases (ALP)
The antimicrobial activity of two proteinase inhibitors of the ALP family has
recently been described. Both secretory leucocyte proteinase inhibitor (SLPI) and
elafin (also known as elastase specific inhibitor or skin derived antileukoprotease)
were originally described as inhibitors of serine proteases secreted by neutrophils
such as human neutrophil elastase (HNE) and cathepsin G. Serine protease inhibitors
neutralise proteolytic enzymes such as HNE when the protease is released from
neutrophils during phagocytic destruction ofmicro-organisms, thus preventing
damage to the host. Both inhibitors are produced locally in human airways
(Sallenave et al, 1999).
SLPI
SLPI is a 107 amino-acid long protein that contains sixteen cysteines which form
eight disulphide bridges (Seemuller et al, 1986; Grutter et al, 1988). SLPI has two
domains. The COOH-terminal domain contains the antiproteinase site (Kramps et al,
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1990; Mickelein et al, 1990; Eisenberg et al, 1990) and the NH2-terminal domain is
responsible for the antimicrobial activity and for stabilising complexes between SLPI
and elastase (Hiemstra et al, 1996; Ying et al, 1994). Whole recombinant ALP and
the isolated NH-terminal domain have been reported to have salt-sensitive
antibacterial activity against strains of E. coli or S. aureus (Hiemstra et al, 1996).
Elafin
Elafin is 95 amino acids long and is also composed of two domains, the
COOH-terminal proteinase domain and the NH2-terminal domain. Elafin has less
than 40% sequence homology with the COOH-terminal domain of SLPI but, like
SLPI, contains eight cysteines arranged into four disulphide bonds (Wiedow et al,
1990; Tsunemi et al, 1992). Elafin has greater specificity in proteinase inhibition
than SLPI, inhibiting only human neutrophil elastase, porcine pancreatic elastase and
proteinase-3 (Sallenave and Ryle, 1991; Wiedow et al, 1991). Recently, synthetic
elafin has been reported to have antibacterial activity against P. aeruginosa and
S. aureus (Simpson et al, 1999).
The aim of this project was to investigate novel antimicrobial strategies against
B. cepacia. The project focused on two major themes. First, a study of antimicrobial
compounds present in plants, in particular compounds from garlic (Allium sativum)
and thyme (Thymus vulgaris). Second, antimicrobial activity of cationic peptides
present in human airway secretions such as human (3-defensin-l and elafin was
examined.
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CHAPTER 2 MATERIALS AND METHODS
2.1 MATERIALS
2.1.1 Bacterial isolates
Twenty isolates of Burkholderia cepacia from the collection of Prof. John Govan and
listed in Table 2.1, were used throughout this thesis. All of these isolates were from
different patients or environments except strains CI963 and CI964, which were
isolated from the sputum of the same patient. Additional bacterial strains also used
are listed in Table 2.2.
2.1.2 Media
Unless otherwise stated media were provided by Oxoid Ltd., Basingstoke,
Hampshire, England. All media were prepared in distilled water and sterilised by
autoclaving at 121 °C at 15 psi for 15 minutes.
Nutrient agar: Columbia agar base, 39g/L
Cepacia isolation agar (CIA): 32.5g/L (MAST Diagnostics, Bootle, Merseyside)
plus one selectab (MAST) per 100ml of agar added after autoclaving and once the
agar has cooled to 50°C. This gives a final antibiotic concentration of lOOpg/ml
ticarcillin and 300 units/ml ofpolymyxin B.
Pseudomonas isolation agar (PIA): 45g/L (Difco Laboratories, Detroit, Michigan,
U.S.A.) plus 2% (v/v) glycerol (Sigma) added prior to autoclaving.
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Blood agar: Columbia agar base plus 5% defibrinated horse blood added after
autoclaving and once agar has cooled to 50°C.
Iso-sensitest agar (ISA): 31.4g/L.
Nutrient broth (NYB): Nutrient broth no.2 plus 0.5% yeast extract (Difco)
Iso-sensitest broth (ISB): 23.4g/L
Skimmed milk: Skimmed milk powder 10% (w/v) sterilised for 5 minutes.
Saline: 0.85% sodium chloride (w/v) (Sigma-Aldrich Coy. Ltd., Poole, Dorset, UK)
Phosphate buffered saline (PBS): One PBS tablet per 100ml distilled water.
60
Table 2.1. Isolates of B. cepacia used in this thesis.
Isolate Description Genomovar
Isolated from CF patients
C1052 Sputum, Edinburgh, non epidemic II
C1511 Sputum, Manchester epidemic strain III
C1576 Sputum, Glasgow epidemic strain II
C1632 Sputum, Newcastle epidemic strain III
CI 963 Sputum, Edinburgh, non epidemic, non mucoid I
CI 964 Sputum, Edinburgh, non epidemic, mucoid I
J415 Sputum, Edinburgh, non epidemic III
J419 Sputum, Edinburgh, non epidemic I-III
J2315 Sputum, Edinburgh epidemic index case, III
ET12 lineage
A507 Sputum, Edinburgh, non epidemic III
Non-CF clinical isolates
CI 773 Blood culture, Papworth III
CI 962 Cerebral abscess, Aberdeen II
J2503 Wound infection, ATCC 25608 III
J2524 Urinary tract infection, ATCC 17765 III
Environmental isolates
J673 Onion, type strain, ATCC 25416 I
J2502 ATCC 10856 I-III-IV
J2421 Soil, Canada, ATCC 17616 II
J2537 Soil, RBGE I-III-IV
J2552 Soil, RBGE I
J2742 Biological control isolate from pea rhizosphere V
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Non muciod CF strain
Non CF clinical strain, classic lab strain
Susceptibility testing control strain
Burkholderia cepacia
C3055 K61-3, opcM PCR control
All chemicals were provided by Sigma-Aldrich Coy. Ltd., Poole, Dorset, UK unless
otherwise stated.
2.1.3 Buffers for pulsed field gel electrophoresis
SE Buffer: 4.38g NaCl plus 9.3g EDTA Na2 dissolved in 900ml distilled water.
The pH was adjusted to 7.5 and the solution made up to 1 litre. The buffer was then
filter sterilised and stored at 4°C.
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Lysis Buffer: lg N-lauroylsarcosine plus 18.6g EDTA Na2 was added to 80ml of
distilled water. 10ml NaOH was added to dissolve the EDTA Na2. The pH was
adjusted to 9.5 and the solution made up to 1 litre. The buffer was then filter
sterilised and stored at room temperature.
TE Buffer: 1.2lg Tris (hydroxymethl)-aminomethane (Bio-Rad, Hercules,
California, U.S.A.) plus 3.72g EDTA Na2 was dissolved in 900ml of distilled water.
The pH was adjusted to 7.5 and the solution made up to one litre. The buffer was
then filter sterilised and stored at 4°C.
2.2 METHODS
2.2.1 Storage and recovery of isolates
Bacteria were stored at -70°C in 1ml of 10% w/v skim milk. After thawing,
B. cepacia were inoculated onto nutrient agar, incubated overnight at 30°C and
subcultured on CIA at approximately four day intervals. Strains of P. aeruginosa
were inoculated onto nutrient agar and subcultured on PIA at approximately weekly
intervals. The S. aureus and E. coli strains were recovered and subcultured weekly
on nutrient agar.
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2.2.1 Pulsed Field Gel Electrophoresis
Preparation ofunsbeared DNA in agarose plugs
Isolates of B. cepacia were inoculated into 10ml volumes of nutrient broth and
incubated overnight at 37°C in an orbital incubator. These cultures were then
centrifuged at 4000 x g for 10 minutes, the supernate discarded and the remaining
bacterial pellet re-suspended in SE buffer until standardised to an optical density of
1.5 at 590nm by spectrophotometry (Camspec, Sawston, Cambridge, England.).
1% low melting point agarose (Bio-Rad) was prepared in SE buffer. 500pl of this
agarose was then added to 500pl of bacterial suspension in a sterile microcentrifuge
tube. The mixtures were then dispensed into the slots of a plug mould to create one
plug for each of the bacterial isolates. Once the agarose had set the plugs were
transferred to sterile bijou bottles.
Lysis ofbacteria within plugs
2ml of lysis buffer containing 0.5% triton-X 100 was dispensed into each bijou. The
plugs were then incubated overnight at 56°C in a waterbath. The lysis buffer was
then removed and replaced with 2ml of TE buffer and the plugs left for 30 minutes at
4°C. This step was repeated twice before the plugs were left overnight at 4°C.
Restriction ofbacterial DNA within plugs
A 2.5mm by 9mm portion of each plug was cut and placed in a sterile
microcentrifuge tube. 90pl of sterile distilled water and lOpl of lOx reaction buffer 2
(Gibco BRL, Life Technologies Ltd., Paisley, Renfrewshire, Scotland) was then
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added to the tubes and the plugs left at 4°C for 30 minutes. The buffer was then
removed and replaced with 90pl of sterile distilled water, lOpl of lOx reaction buffer
2, 2pl of lOmg/ml bovine serum albumin (Promega, Madison WI, U.S.A.), 2pl
dithiothreitol and 2pl of the restriction enzyme Xbal (Gibco BRL). The contents of
the microcentrifuge tubes were mixed gently and incubated in a 37°C overnight.
The next day the enzyme mixture was removed and replaced with TE buffer, while
100ml of pulsed field gel agarose (Bio-Rad) was prepared in 0.5 x TBE buffer
(Gibco BRL). Once the agar had cooled to 60°C, most was poured into a gel mould
and allowed to set. The plugs were then loaded into the gel and sealed in with the
remaining agarose. The gel was then placed into the tank of the CHEF - DR II
electrophoresis system (Bio-Rad) and covered with 2 litres of TBE buffer. The gel
was then run with an initial pulse time of 2.9 seconds and a final pulse time of 35.4
seconds for 20 hours at 200 volts and at a temperature of 14°C.
Following electrophoresis, the gel was stained in lpg/ml ethidium bromide (Bio-
Rad) for 15 minutes and destained twice in distilled water to enable the DNA bands
to be viewed within the gel by UV translumination and recorded photographically.
2.2.3 Antibiotic susceptibility testing
Broth macrodilution method
Twenty isolates of B. cepacia and the control strain of P. aeruginosa (NCTC 10662)
were inoculated into 10ml volumes of ISB and incubated for 18 hours at 37°C with
shaking. After this time, each culture contained approximately lxlO9 cfu/ml, as
verified by viable counts performed on five selected strains. The cultures were then
• • 7
diluted in ISB to a concentration of approximately 1x10 cfu/ml.
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Stock solutions of the antibiotic to be tested were made up at concentrations of
lmg/ml, lOOpg/ml, lOpg/ml and lpg/ml. These stock solutions were then added to
10ml aliquots of ISB to give final concentrations of doubling dilutions between
32pg/ml and 0.03pg/ml.
100pi of bacterial culture was then added to the broth aliquots containing antibiotics,
to give a final concentration of approximately lxl 05 cfu/ml.
Controls containing no antibiotics were also prepared for each strain.
The tubes were incubated for between 16 and 18 hours at 37°C with shaking before
the MIC was determined. The MIC was taken to be the lowest concentration of
antibiotic at which there was no visible growth. Individual experiments were
considered valid if the MIC for the control strain of P. aeruginosa was within one
twofold dilution of the expected result as set out in Phillips et al (1991).
Agar dilution method
Stock solutions of antibiotics and cultures to be tested were prepared as in the 'broth
macrodilution method' previously described. Plates were prepared containing
antibiotics at concentrations of between 32pg/ml and 0.03pg/ml in doubling dilution
steps. The correct volume of antibiotic was added to 20 ml of ISA (cooled to 60°C)
in a Petri dish. A control plate containing no antibiotics was also prepared. The
plates were swirled gently to mix and the agar left to set.
Once the plates had been dried they were inoculated with 1 pi of a diluted broth
culture of each isolate delivered by a multipoint inoculator (Denly, Billingshurst,
Sussex) and providing a final inoculum of approximately 104 cfu. The plates were
then incubated for 16-18 hours at 37°C before the MIC was determined. The MIC
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was once more defined as the lowest concentration at which there is no visible
growth; in this assay system one or two colonies or hazes of growth were
disregarded.
2.2.4 Determination ofminimum inhibitory concentration and minimum
bactericidal concentration of plant extracts
Broth cultures of 20 B. cepacia isolates and control strains of S. aureus (J2407),
E. coli (J2408) and P. aeruginosa (NCTC 10662) were prepared at a concentration of
approximately lxlO7 cfu/ml as set out in the broth macrodilution method. Plant
extracts were added to 10ml aliquots of ISB to give final concentrations of between
6% and 0.05% for aqueous garlic extract and between 0.25% and 0.01% for the plant
oils. lOOpl of bacterial culture was then added to the broth aliquots to give a final
bacterial concentration of approximately 1x10s cfu/ml. Controls containing no plant
extract were also prepared for each bacterial strain. The contents of each tube were
mixed for 30 seconds to ensure the plant extract had been evenly dispersed through
the broth. The tubes were then incubated at 37°C with shaking for 16-18 hours.
lOOpl was then sampled from each tube and spread over a plate of nutrient agar.
Tenfold dilutions were also made of the tube containing the lowest concentration of
plant extract that did not appear turbid. One hundred fold dilutions were made of the
control tube. lOOpl of each of these dilutions was spread over plates of nutrient agar
and were incubated for 48 hours at 37°C to obtain a count of the number of viable
organisms remaining. Due to the limitations of the serial dilution technique it was not
possible to detect less than 10 cfu/ml.
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2.2.5 Synthesis of aqueous garlic extract
AGE was prepared by a modification of the extraction procedure outlined by Pai and
Piatt (1994). A known weight of peeled, chopped garlic cloves was added to a equal
volume of distilled water in a Waring blender (Waring, New Hartford, Connecticut,
U.S.A.) and blended for approximately 3 minutes at high speed. The homogenised
garlic was then strained through two layers of muslin to remove any large debris.
The liquid obtained was then centrifuged at 20,000g for 40 minutes at 4°C in a
Sorvall centrifuge.
The supernatant was then sterilised by Seitz filtration under a pressure of 10 psi. Pai
and Piatt recommended storage for no more than one week at -70°C before use,
however the extract was found to be active for up to one month when stored at -
70°C.
2.2.6 Synergy testing by the checkerboard technique
The 'checkerboard' technique described by Garrod and Waterworth (1962) is
commonly used to test synergy between conventional antibiotics. The technique was
modified to test for synergy between AGE and four antibiotics commonly used to
treat microbial lung infections ofCF patients, ceftazidime, ciprofloxacin,
chloramphenicol and meropenem. As the MICs for both AGE and the selected
antibiotics had previously been determined, checkerboards were set up as shown in
Figure 2.1.
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Each square on the diagram represents a WR tube, in which the final volume
4
equalled 1ml. Each tube contained 0.5ml of approximately 2x10 cfu/ml. of
B. cepacia, 0.25ml of one concentration ofAGE and 0.25ml of one antibiotic
concentration. Each of the antimicrobials to be tested was initially prepared at a
concentration 8 x the MIC, to achieve a concentration of 2 x MIC in 1.0ml, when
only 0.25ml was added. The antibiotic suspensions were then diluted to give final
concentrations of 1 x MIC, 0.5 x MIC, 0.25 x MIC and 0.12 x MIC and the
checkerboard arranged accordingly. All dilutions of antibiotics and bacterial cultures
were made in ISB to support the growth of the organisms. The 'checkerboards' were
incubated at 37°C overnight.








0.0 0.12 0.25 0.5 1.0 2.0
Garlic Concentration x MIC (G)
The checkerboards were used to determine the amounts of garlic and antibiotic that
alone or in various combinations produce a minimum inhibitory combination of
antimicrobials. To visualise this, the amounts of garlic and antibiotic were plotted on
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an arithmetic scale, as proportions of the MIC that, alone or in combination inhibit
the growth of a particular strain of B. cepacia. If the line joining these points, known
as an isobol, is straight this indicated an additive effect. If the isobol bowed upwards
this indicated an antagonistic effect of the drugs in combination whereas if the isobol
bowed downwards, synergy was indicated.
2.2.7 Killing curves
Preparation ofstatic cultures
10ml aliquots of iso-sensitest broth were inoculated with the strain under
investigation and incubated for 16-18 hours at 37°C with shaking. At this time, the
number of organisms present in the culture was approximately lxl 09 cfu/ml. This
• • • • 7
overnight culture was diluted in ISB until it contained approximately 1x10 cfu/ml.
Preparation oflogphase cultures
10ml aliquots of iso-sensitest broth were inoculated with the strain under
investigation. These suspensions were then incubated for 16-18 hours at 37°C with
shaking and the bacteria then centrifuged at 4000 x g for 10 minutes and the pellet
washed in 10ml of fresh prewarmed ISB. 100p.l of this suspension was then used to
inoculate a fresh prewarmed 10ml aliquot of ISB, and the culture incubated at 37°C
with shaking until the bacteria reached the log phase of growth. Growth curves were
produced for B. cepacia strains J2315 and J2421 to establish at what time after
inoculation log phase growth occurs.
lOOql of a lxl 07 cfu/ml suspension of either static or log phase bacteria was added to
10ml of ISB to which the minimum bactericidal concentration of the plant extract to
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be analysed had already been added. A control containing no plant extract was also
prepared. The tubes were then incubated at 37°C with shaking. Killing curves with
AGE were achieved by sampling at 0 hours and then hourly between eight and 20
hours, for both test and control tubes. Killing curves with thyme oil and thymol
involved sampling at zero hours, 10 minutes, 20 minutes, 30 minutes, 45 minutes and
one hour. Sampling was carried out in triplicate. At each time point 100p.l of
undiluted sample was spread directly onto a nutrient agar plate. Tenfold dilutions
1 9 T # # #
(10 ,10 ,10 ) were made and 100pl of each dilution was spread onto nutrient agar
and the plates incubated for 48 hours 37°C to determine the number of surviving
organisms.
2.2.8 Dose Response Curves
Cultures of the bacterial strains to be analysed were grown to log phase as set out
above. 200pl of this bacterial suspension was added to 5mls of double strength broth
to which 4.8mls of antibiotic solution, in sterile distilled water had been added.
Antibiotics were added to give final concentration in lOmls of 0, 0.001, 0.01, 0.1, 1,
10 and 100 where 1 equals lmg/ml for thymol, 1ml/ml for AGE and 1 pl/ml for
thyme oil. An initial count of viable bacteria was obtained from an average of three
counts from the tube containing no antibiotics at time zero. The tubes were then
incubated at 37°C for the same time the bacteria were initially incubated to reach
their log phase of growth. Viable counts were then made from each tube and the
number of surviving bacteria calculated as a percentage of the initial count.
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2.2.9 DNA extraction
An aliquot of 500pl of an overnight broth culture was placed in a sterile
microcentrifuge tube and spun in a microcentrifuge (Sanyo, Itasca, IL, USA) for 2
minutes at 15,000g. The supernatant was removed and the remaining pellet washed
in 1 ml of 50mM Tris HC1 (Bio-Rad), 20mM EDTA. The pellet was then
resuspended in 500pl of 50mM of Tris HCL, 2mM EDTA with 100p,g/ml of
lysosyme and incubated for 15 minutes at 4°C. Five mg/ml SDS (BDH, Poole,
Dorset, England) and lOOpg/ml proteinase K was added to the suspension before
incubation for a further 2 hours at 37°C.
The bacterial lysate was sequentially extracted with equal volumes of Tris saturated
phenol, phenol:chloroform (1:1) and chloroform. In each extraction 0.5ml of solvent
was added, the suspension mixed thoroughly and then spun down at 15,000g for 5
minutes. The aqueous layer was then removed into a fresh tube to which the next
solvent was added.
50pi of 3M sodium acetate and two volumes of 95% ethanol (Mackay and Lynn,
Edinburgh, Scotland) were then added and the suspension held overnight at -20°C.
The suspension was centrifuged at 15,000g for 30 minutes, and the pellet washed in
70% ethanol. The pellets were then dried at room temperature to insure all the
remaining ethanol was removed and resuspended in 200pl of lOmM Tris, ImM
EDTA.
To measure the purity ofDNA present in the sample, optical densities at 260nm and
280 nm were compared. The ratio between the readings provides an estimate of the
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purity of the nucleic acid; a pure preparation ofDNA has a value of between 1.8 and
2.0. All the DNA preparations used for PCR had ratios of approximately 1.8.
2.2.10 Amplification ofDNA by the Polymerase Chain Reaction (PCR)
DNA was extracted from 21 isolates of B. cepacia and from a control strain of
P. aeruginosa (NCTC 10662), as described previously. Primers were selected to
detect and amplify a 493bp piece of the pen A gene or a 564bp piece of the opcM
gene of B. cepacia. The sequence of the primers used is shown below. A reaction
mix was prepared for each isolate containing 34.5pl sterile distilled water, 5pi PCR
buffer (Promega), 2pi of dNTP (Promega), 2pl of each of the primers (Cruachem,
Glasgow, Scotland), 2pl of dimethyl sulfoxide (DMSO), 0.5pl ofTaq polymerase
(Promega) and 2pi of the DNA to be analysed. The reaction mix was then cycled
automatically in a thermal cycler (Techne, Cambridge, UK) Thirty five cycles of
denaturation at 94°C, annealing at 60°C and extension at 72°C were performed.
Each step lasted one minute. The PCR products were then removed from the thermal
cycler and stored at 4°C.
The PCR products were analysed on a 1.5% agarose gel (Bio-Rad) run in 0.5% TBE
buffer. 2pl of gel loading buffer, containing 0.05% bromophenol blue, 0.05% xylene
cyanol and 25% glycerol was added to lOpl ofPCR product and this mixture loaded
into the well of the agarose gel. A 100 base pair marker (New England Biolabs,
Beverly, MA, USA) was used to estimate the size of the PCR products, lpl of
marker was added to 11 pi of sterile distilled water and 2pl of gel loading buffer and
these markers run along side the PCR products on the gel. The gel was run at 50
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volts for approximately 4 hours, then stained in 1 pg/ml ethidium bromide (Bio-Rad)







2.2.11 Analysis of plant extracts by High Performance Liquid Chromotography
Aqueous garlic extract, allicin, thyme oil and its major component thymol were
analysed by reverse-phase high performance liquid chromotography (RP-HPLC)
with Gilson 712 series chromatographic equipment (Gilson Pic, Middleton, WI,
USA). Detection was at 240nm for AGE and allicin, and 275nm for thyme oil and
thymol using a column with Ci8 as the active group (Beckman, Fullerton, CA, USA;
5pm pore size Ultrasphere ODS; internal dimensions - 150 by 10 mm). Separation
was performed using a gradient of acetonitrile containing 0.1% (vol/vol)
trifluoroacetic acid and HPLC grade water. Thyme oil and thymol were separated
using a continuous linear gradient (0 to 100%) of acetonitrile. AGE was analysed
using a different gradient of acetonitrile and water designed to give a clear separation
of the components of this extract. The flow rate in both cases was 1.3 ml min"1. Plant
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extracts were filtered through a 0.2pm filter before injection to remove any particles
that might damage the column. lOOpl of plant extract was then added to 900pl of a
12% solution of acetonitrile and this 1ml sample injected into the column. The
fractions corresponding to peaks shown on the detector were collected and the
acetonitrile removed by evaporation.
These compounds were then tested for antimicrobial activity against B. cepacia
strain J2315. Each fraction was added to 10ml of ISB containing 1 x 105 cfu/ml
J2315 and incubated overnight at 37°C with shaking. lOOpl dilutions were spread




Bacterial cells were fixed in 0.4% formaldehyde and the preparations centrifuged at
100 OOOg for 1 hour to deposit cells or cell debris. After centrifugation, the pellet
was then gently resuspended in 1% w/v ammonium acetate buffer. The samples were
then negative stained with 2% phosphotungstic acid and viewed using a CM12
Transmission Electron Microscope.
Scanning Electron Microscopy
Samples for scanning electron microscopy were prepared using the following
method. Samples were fixed for three hours in 3% glutaraldehyde in 0.1M sodium
cacodylate buffer at pH 7.4, then washed three times in 0.1M sodium cacodylate
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buffer for 20 minutes. The samples were then left in 0.1M sodium cacodylate buffer
with 1% osmium tetroxide in for 2 hours, before washing in distilled water for 30
minutes. The samples were then dehydrated in increasing concentrations of acetone.
First, at a concentration of 50% acetone for approximately 1 hour then at 70%, 90%
and finally 100%, again for one hour. The 100% acetone step was then repeated
twice before critical point drying with carbon dioxide was carried out in a Poleron
E3000 SII CPD. The samples were then sputter coated with 20nm gold/palladium
(60/40) in an EMscope SC500 sputter coater, and viewed in a Phillips 505 scanning
electron microscope.
2.2.13 Activity of human and mouse p-defensin 1 against multiresistant B. cepacia
Experiments involving hBD-1 and mBD-1 were carried out in collaboration with
Dr DJ Davidson, MRC Human Genetics Unit, Western General Hospital.
The antimicrobial activity of human and mouse salt-sensitive P-defensins was
investigated in the presence of various concentrations ofNaCl. Experiments were
carried out in 0.01M phosphate buffer which contained 8.02ml of 1M K^HPO^
1.98ml of 1M KH2PO4 and 1 gram of D-Glucose in 1000ml distilled H2O. 10 x stock
solutions of sodium chloride were prepared as shown in Table 2.3. A 5 x stock
solution of the peptide to be tested was then prepared by dissolving approximately
300pg of peptide in 600pi phosphate buffer. For each concentration of salt, two
peptide containing reaction mixes and two controls were generated. The reaction
mix contained 50pl of 5x P-defensin 1, 47.5pl of the appropriate 10 x salt solution,
25pl of a 5 xlO7 cfu/ml suspension of bacteria and 377.5pl of 0.01M phosphate
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buffer. Controls contained the same components as the reaction mix except the 50pl
ofpeptide was replaced with the same volume of phosphate buffer.
The bacterial inoculum was prepared from an overnight culture B. cepacia (J2315)
containing approximately lxlO9 cfu/ml. Bacteria were centrifuged at 4000 x g for 10
minutes and the supernate discarded and the bacterial pellet re-suspended in PBS. A
lml aliquot of this bacterial suspension was then prepared for each salt
concentration. The lml aliquots of bacteria were spun down at 4000 x g in Sorvall
centrifuge (Stevenage, Herts, UK) at room temperature for 10 minutes, and the
bacteria resuspended in 10 ml of 1 x salt buffer.
This suspension was then diluted to a concentration of 5 xlO7 cfu/ml and 25pi of this
added to the peptide reaction mixes and blank controls.
Each tube was mixed thoroughly and incubated at 37°C for 25 minutes. After this
time 10 and 10 dilutions were made of each sample and spread onto plates ofCIA.
Plate cultures were then incubated at 37°C for 48 hours and the number of cfus
assessed.














2.2.14 Investigation of the antimicrobial activity of elafin
Samples of elafin, a proteinase inhibitor produced in the human lung, were provided
by Dr J-M. Sallenave, Rayne Laboratory, University of Edinburgh Medical School.
They were prepared by transfecting the human cell line A549 with adenovirus
containing the elafin gene causing the cells to over express this protein (Sallenave et
al, 1998). Elafin samples were dialysed extensively with water and freeze dried
before being tested.
Cultures of strains of S. aureus (CI 705), P. aeruginosa (PAOl) and B. cepacia
(J2315) were grown up in 10ml of nutrient broth plus 5% yeast extract, overnight at
37°C in an orbital incubator (Gallenkamp). lOOpl of the overnight cultures was
inoculated in fresh bottles of nutrient broth and incubated at 37°C for three hours,
until the bacteria were in log growth phase as concluded from predetermined growth
curves.
The log phase bacterial cultures were spun down at 4000 x g for 20 minutes and the
supernatant removed and replaced with 10ml of 0.01M phosphate buffer. This step
was then repeated to insure all the nutrient broth had been removed. Bacterial
suspensions were then diluted in phosphate buffer to a concentration of
approximately 5x104 colony-forming units permillilitre (cfu/ml).
50pl of this concentration of bacteria were then placed into the microcentrifuge tubes
containing adeno-elafin, mixed thoroughly and incubated for 2 hours at 37°C.
After this incubation, a neat sample and a 1 in 10 dilution from each tube were
spread onto plates of suitable agar and incubated for 24-48 hours until colonies were
visible and viable counts carried out.
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CHAPTER 3 RESISTANCE OF B. CEPACIA
3.1 Description of strains included in the B. cepacia strain panel
The panel of 20 'Burkholderia cepacia'' isolates used throughout this thesis was
selected to include clinical and environmental strains (Table 2.1). As this thesis
progressed, the important taxonomic data from Peter VanDamme was published,
(University ofGent) clearly showing that isolates tentatively identified as B. cepacia,
belonged to several individual subpopulations showing close phenotypic and
genomic relationships. The term B. cepacia complex is sometimes used to describe
all the members of this rapidly expanding genus. The strain panel was constituted to
include the range of B. cepacia 'genomovars' known at the time and for the purpose
of this thesis the term B. cepacia will be used throughout.
Fourteen clinical isolates collected from CF and non-CF patients included epidemic
strains responsible for large outbreaks in CF centres in Edinburgh, Glasgow,
Newcastle and Manchester. Non-CF isolates consisted of two from the American
Type Culture Collection (ATCC 17765 and ATCC 25608), another from a cerebral
abscess which occurred in an otherwise healthy individual following treatment of an
ear infection with antibiotic drops contaminated with B. cepacia, and finally one
non-CF isolate was from a patient with septicaemia. The five environmental isolates
selected included two strains cultured from soil collected in the Royal Botanical
Gardens, Edinburgh, three ATCC strains (ATCC 10856, ATCC 17516 and
ATCC 25416) and AMMD, a strain developed for use as a biological control agent.
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As a first step, pulsed field gel electrophoresis following digestion of chromosomal
DNA with the restriction enzyme Xbal was used to confirm that the collection of
isolates represented individual strains of B. cepacia and to confirm the clonality of
B. cepacia CI963 (non-mucoid) and CI964 (mucoid). It can be observed from
Figures 3.1 and 3.2 that 17 of the isolates analysed possessed unique banding
patterns and thus can be described as individual strains ofB. cepacia. Despite
repeated attempts, no banding pattern could be obtained for isolate J2552. This
phenomenon has been observed previously in B. cepacia and attributed to high levels
of endogenous DNAse (C. Doherty, personal communication). For the purpose of
this thesis, J2552 was assumed to be clonally unrelated to other isolates. As
expected, the non-mucoid (CI963) and mucoid (CI964) colonial morphotypes
isolated from the same patient produced an identical PFGE profile. Two isolates,
C1632 and CI773, for which no epidemiological connection could be determined,
produced PFGE profiles differing by only four bands. Since this is on the borderline
of what is acceptable to differentiate isolates by PFGE, these isolates were retained
in the study as distinct strains.
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Fig. 3.1 PFGE patterns of isolates of B. cepacia. Lanes 1-10; C1052, C1511,
C1576, C1632, C1773, C1962, C1963, C1964, J415 and J419 respectively.
Fig. 3.2 PFGE patterns of isolates of B. cepacia. Lanes 1-10; J673, J2315, J2421,




The sensitivity of the panel of B. cepacia isolates to conventional antibiotics was
determined by both the broth macrodilution method employing ISB and by the agar
dilution method employing ISA according to standard guidelines (Phillips et al,
1991). Breakpoint information is also provided within these standard guidelines.
MIC values are outlined in Tables 3.1 and 3.2.
Despite its reputation as a pan resistant species, with the exception of colomycin,
polymyxin and vancomycin, a wide range of inhibitory activity was observed against
the B. cepacia panel. Indeed, for several antibiotics including chloramphenicol,
trimethoprim and rifampicin some members of the B. cepacia panel were found to be
more susceptible than the P. aeruginosa control strain NCTC 10662. In terms of
antibacterial activity ciprofloxacin, grepafloxacin and meropenem appeared to be the
most active, and polymyxin the least active.
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Table 3.1 MICs of conventional antibiotics against the B. cepacia panel measured by
broth macrodilution method.
Strain Ceftaz Mero Chlor Cipro Grepa Trimeth Rifamp Tobra Colo Poly Vanco
C1052 4 4 8 1 0.25 1 8 32 >256 >512 >256
C1511 4 2 >32 8 1 32 >32 >32 >256 >512 >256
C1576 >32 8 >32 16 8 4 >32 >32 >256 >512 >256
C1632 >32 8 >32 16 1 8 >32 >32 >256 >512 >256
C1773 32 0.5 8 >32 32 1 16 32 >256 512 256
C1962 1 0.5 8 8 2 4 8 32 >256 >512 >256
C1963 1 0.5 32 2 0.5 4 16 >32 >256 >512 >256
C1964 1 0.25 32 2 0.5 1 16 4 >256 >512 >256
J415 2 0.5 >32 8 2 32 >32 >32 >256 >512 >256
J419 1 1 >32 >32 >32 >32 >32 32 >256 >512 >256
J673 2 1 16 0.5 0.25 1 32 2 >256 >512 >256
J2315 16 16 32 8 2 32 >32 >32 >256 >512 >256
J2421 4 4 16 4 1 2 32 16 >256 256 >256
J2502 0.25 1 16 0.5 0.25 1 8 2 >256 >512 >256
J2503 2 1 32 4 4 1 16 >256 >512 >256
J2524 4 2 >32 2 0.25 4 >32 32 >256 >512 >256
J2537 2 2 16 4 2 2 32 >32 >256 >512 >256
J2552 1 1 8 1 0.5 1 8 8 >256 512 >256
J2742 0.25 0.5 8 0.5 1 8 4 >256 >512 >256
A507 1 0.5 >32 1 32 >32 32 >256 >512 32
MIC50 2 1 32 4 1 2 32 32 >256 >512 >256
MIC90 32 8 >32 16 8 32 >32 >32 >256 >512 >256
Break¬ 2 4 8 1 1 0.5 1 1 4 4 4
point
NCTC 2 1 >32 0.5 0.25 32 32 0.12 8 0.5 >256
10662*
* P. aeruginosa control
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Table 3.2 MICs of conventional antibiotics against the B. cepacia panel measured by
agar dilution method.
Strain Ceftaz Mero Chlor Cipro Grepa Trimeth Rifamp Tobra Colo Poly Vanco
C1052 2 4 4 0.5 0.12 0.5 8 16 >256 512 >256
C1511 4 1 32 2 1 16 >32 >32 >256 >512 >256
C1576 >32 2 32 4 4 4 >32 >32 >256 >512 >256
C1632 >32 4 32 4 0.5 4 >32 >32 >256 >512 >256
C1773 16 1 8 32 32 1 8 >32 >256 512 >256
C1962 0.5 0.12 2 2 1 2 4 32 >256 >512 >256
C1963 1 1 16 1 0.5 32 16 32 >256 >512 >256
C1964 0.5 0.5 32 1 0.5 1 32 1 >256 >512 >256
J415 1 0.5 32 4 2 16 >32 >32 >256 >512 >256
J419 1 0.5 32 >32 32 32 >32 32 >256 >512 >256
J673 1 0.5 16 0.5 0.25 0.5 16 16 >256 >512 >256
J2315 4 4 32 4 2 32 >32 >32 >256 >512 >256
J2421 4 2 16 1 0.5 1 32 8 >256 256 >256
J2502 0.12 0.12 8 0.5 0.12 0.5 4 16 >256 >512 128
J2503 2 0.5 16 4 2 0.5 16 >256 >512 >256
J2524 1 1 16 1 0.25 2 16 >32 >256 >512 >256
J2537 1 0.5 16 2 2 1 16 32 >256 >512 >256
J2552 1 0.5 8 1 1 0.25 16 4 >256 >512 >256
J2742 0.5 0.25 8 0.25 0.5 4 8 >256 >512 >256
A507 1 0.25 >32 1 32 >32 32 >256 >512 64
MIC50 1 0.5 16 2 1 1 16 32 >256 >512 >256
MIC90 16 2 32 32 32 32 >32 >32 >256 >512 >256
Break¬ 2 4 8 1 1 0.5 1 1 4 4 4
point
NCTC 1 0.25 >32 0.25 0.12 32 32 0.25 8 0.5 >256
10662*
* P. aeruginosa control
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3.3 Analysis of resistance genes
To investigate the presence of known resistance mechanisms in the strain panel,
primers were used to identify a) the penicillinase gene penA, first identified in the
strain J2421 (249) (Trepanier et al, 1997), b) opcMwhich codes for an efflux pump
originally identified in strain C3055 (K61-3) (Burns et al, 1996b). Preparations of
DNA were made for all 20 B. cepacia isolates. Amplification of small sequences of
this DNA containing sections of the antibiotic resistance genes was carried out by
PCR and the amplified fragments visualised by agarose gel electrophoresis.
Interestingly, although the presence ofpenA was confirmed in the B. cepacia control
strain J2421, the gene sequence was not detected in any of the other 19 isolates of
B. cepacia analysed (Fig 3.3). In contrast figure 3.4 confirms the presence of opcM
in the control strain C3055 and in almost all the other 20 B. cepacia isolates
analysed. An identical sequence was also amplified from a P. aeruginosa control.
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Fig 3.3 PCR amplification of sequence of the penA gene. Lanes 1 and 22 contain a
lOObp marker. Lanes 2-21 contain C1052, C1511, C1576, C1632, C1773, C1962,
C1963, CI964, J415, J419, J673, J2315, J2421, J2502, J2503, J2524, J2537, J2552,
J2742 and A507 respectively. Lane 23 is the negative control.
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Fig 3.4 PCR amplification of sequence of the opcM gene. Lanes 1-22 contain
C1052, C1511, C1576, C1632, C1773, C1962, C1963, C1964, J415, J419, J673,
J2315, J2421, J2502, J2503, J2524, J2537, J2552, J2742, A507, C3055 and NCTC
10662. Lane 23 contains a negative control. Lane 24 contains a lOObp marker.
1 2 3 4 5 6 7 8 9 10 11 12 13141516 17181920 21 22 23 24
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3.4 Discussion: Resistance of B. cepacia.
3.4.1 Susceptibilities to conventional antibiotics
The chemotheraputic agents used in this study were selected to represent the major
classes of antibiotics including conventional antipseudomonal agents representing
standard care for B. cepacia infections. These agents inhibit bacterial growth by
disrupting different stages of the cell cycle unique to bacteria. The p-lactams,
ceftazidime and meropenem inhibit bacterial cell wall synthesis. Ceftazidime, a third
generation cephalosporin and meropenem, a carbapenem are also amongst the most
active agents against P. aeruginosa and have been reported to have useful activity
against B. cepacia strains in vitro (Lewin et al, 1993; Pitt et al, 1996). Vancomycin,
a glycopeptide, is also an inhibitor of cell wall synthesis but has a narrow spectrum
of activity which principally involves Gram-positive organisms. Vancomycin was
included in this study for interest due to the unpredictability ofB. cepacia and the
inherent activity of the agent. Tobramycin, an aminoglycoside antibiotic is
selectively active against prokaryote 70s ribosomes and thus disrupts bacterial
protein synthesis. Nebulised tobramycin is presently undergoing major clinical trials
in the treatment ofP. aeruginosa lung infections in CF patients and results are
encouraging (Ramsey et al, 1999). Ciprofloxacin and grepafloxacin are
fluoroquinolones whose bactericidal activity is principally mediated by interference
with DNA gyrase and thus inhibition of bacterial DNA synthesis. Both agents have a
broad spectrum activity. Grepafloxicin, the most recently developed quinolone, is
considered to have enhanced activity against Gram-positive organisms whilst
retaining good activity against Gram-negative and atypical organisms (Imada et al,
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1992). Previous reports have found most strains of B. cepacia, particularly those
isolated from clinical environments, to be resistant to ciprofloxacin (Lewin et al,
1993; Pitt et al, 1996;Visalli et al, 1997).
Historically, trimethoprim, an inhibitor of folate synthesis, and chloramphenicol, an
inhibitor of bacterial protein synthesis, were reported to be the most effective
antibiotics for treatment of B. cepacia infections in CF patients (Isles et al, 1984)
(Lewin et al, 1993). However, these agents were rarely capable of eradicating
B. cepacia from the respiratory tract of patients (Isles et al, 1984). More recently
developed agents such as ceftazidime and meropenem appear to have superseded
trimethoprim and chloramphenicol as the agents of choice against B. cepacia. The
antimicrobial peptides, colomycin and polymyxin, were included in this study as
increased use of these drugs during thel980's provides an attractive hypothesis to
explain the selection of B. cepacia in the CF lung and the striking increase in
prevalence of B. cepacia infections during the last two decades (Littlewood et al,
1985). Previous studies have shown all isolates of B. cepacia to be resistant to
colomycin and polymyxin (Ferreira et al, 1985; Moore and Hancock, 1986).
Rifampicin was included in this study since it is the only clinically important
antibiotic to inhibit bacterial RNA synthesis.
To assess the effect of different methods of susceptibility testing for B. cepacia,
MICs of each of the antimicrobial agents were assayed against the panel by both the
broth macrodilution method and the agar dilution method. Results indicated that the
outcomes are generally concordant, or one dilution lower by the agar dilution
method. For the purpose of this thesis, the broth method was chosen for further
studies as it provides a more consistent inoculum and more even distribution of the
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antibacterial agent through the culture media. This factor was particularly relevant in
the investigation of the antimicrobial activity of plant oils which are more difficult to
disperse (Hammer et al, 1999).
Although the panel comprised a relatively small number of B. cepacia isolates, it was
interesting to note differences in susceptibility between environmental and clinical
isolates and, taxonomically, differences between members of the B. cepacia
complex. In general, the environmental isolates proved to be more sensitive to
antibiotics than clinical isolates. For example, five of the six environmental isolates
were sensitive to ceftazidime, in contrast only half of the clinical isolates were
sensitive to this agent. All three meropenem resistant strains were clinical isolates
whereas all of the environmental isolates were sensitive. Only one environmental
strain was resistant to grepafloxacin whereas half of the clinical strains were
resistant. Also two thirds of the environmental isolates were sensitive to
ciprofloxacin, but only one clinical isolate was sensitive. Interestingly, most strains
were resistant to chloramphenicol and all of the strains tested were resistant to
polymyxin, rifampicin, trimethoprim, tobramycin and vancomycin.
Genomovar III strains were found to be particularly resistant to the antibiotics
investigated. Recently, isolates ofB. cepacia classified as genomovar III have been
identified in the environment (Govan et al, 2000). Isolates studied in this thesis were
selected before environmental genomovar III isolates were discovered, thus, the nine
genomovar III strains investigated in this thesis were all clinical isolates. Two of the
three strains resistant to meropenem were genomovar III strains. More than half of
these strains were resistant to ceftazidime or grepafloxacin, which is a higher
proportion than observed for clinical strains as a whole. Only one genomovar III
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strain was sensitive to chloramphenicol and none sensitive to ciprofloxacin.
Genomovar II isolates were also observed to have a broader resistance spectrum than
genomovar I isolates. Of particular interest was the observation that the only
environmental genomovar II strain was resistant to all the antibiotics tested except
meropenem and grepafloxacin.
Only two of the twenty isolates tested were completely resistant to all of the
antibiotics. These were CI576, representing the Glasgow epidemic strain
(genomovar II) and J2315, representing the Edinburgh epidemic strain and ET12
lineage (genomovar III). The other epidemic strains included in this study were also
highly resistant to most antibiotics. CI632, the Newcastle epidemic strain was
sensitive only to grepafloxacin and the Manchester epidemic strain, C1511, was
sensitive only to grepafloxacin and meropenem.
Thus, with the caveat that the panel represents a relatively small number of
B. cepacia isolates, it appears that, in this study, clinical isolates are relatively more
resistant to antibiotics than environmental isolates. From a taxonomic viewpoint, the
genomovars II and III isolates were the most resistant. It should be noted, however
that not all genomovars were represented in this study. The four epidemic strains
were observed to be particularly resistant to the antibiotics tested.
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3.4.2 Analysis of resistance genes of B. cepacia
The pen A gene of B. cepacia 249 (J2421) encodes an inducible class A (3-lactamase
(Trepanier et al, 1997). Amplification of a small sequence (493bp) of this resistance
gene by PCR and subsequent visualisation of this fragment by agarose gel
electrophoresis confirmed that this gene sequence was present in the control strain
J2421. Rather surprisingly, this sequence was not amplified in any of the other
B. cepacia isolates tested. Thus it appears that none of the other 19 B. cepacia
isolates contain an identical DNA sequence. As ceftazidime resistance is widespread
among B. cepacia isolates, it is surprising that Pen A appears to be a rare enzyme in
strains of B. cepacia other than J2421. It is possible that a gene similar to pen A is
present in other strains of B. cepacia but that the primers chosen match a sequence
which is not conserved. However, particularly in view of the genetic diversity
displayed by members of the B. cepacia complex, it seems more likely that a range
of very different (3-lactamases are encoded by different B. cepacia strains.
OpcM, a gene subcloned from B. cepacia strain K61-3 (C3055) codes for an outer
membrane lipoprotein which is homologous to the oprM gene of P. aeruginosa
(Burns et al 1996b). OprM codes for the outer membrane channel of a three part
efflux pump present in P. aeruginosa known as MexA-MexB-OprM (Poole et al,
1993). Antimicrobial substrates eliminated from the cell by this pump include
tetracycline, chloramphenicol, fluoroquinalones, (3-lactams excluding carbapenems,
novobiocin, erythromycin, fusidic acid and rifampicin (Li et al, 1995). The oprM
efflux pump is one of three efflux pump systems also found in P. aeruginosa.
Following the recently completed sequencing of P. aeruginosa PAOl it has been
proposed that PAOl contains a further 17 efflux pumps (Rick Gerber, personal
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communication). In this thesis, amplification of a 564bp sequence of opcM by PCR
and subsequent visualisation of this fragment by agarose gel electrophoresis
confirmed that the sequence, detected by the primers, was present in the control
strain of B. cepacia C3055 (K61-3), and demonstrated the presence of this pump in
19 B. cepacia isolates tested, and even in a P. aeruginosa control. On this evidence,
it seems reasonable to speculate that opcM is highly conserved and present in most
strains ofB. cepacia. An important point for consideration is that although almost all
the strains tested have the gene for this efflux pump, each has a different
antibiogram. One explanation is that opcM is regulated by an as yet unknown
resistance mechanism and that the protein OpcM is not produced in all isolates or
that the number of channels produced varies from strain to strain. Furthermore,
B. cepacia may utilise a number of other as yet undiscovered resistance mechanisms,
capable of eliminating a variety of other substrates. As the primers also detected a
564bp sequence in the P. aeruginosa control, it seems likely that efflux systems of
B. cepacia and P. aeruginosa are shared in some instances and have a conserved
evolution. At present there are plans to sequence the entire B. cepacia genome. As
this organism is 1.5 times the size ofP. aeruginosa there is the potential that many
unique gene sequences may be discovered which may encode additional resistance
mechanisms.
94
CHAPTER 4 AQUEOUS GARLIC EXTRACT
4.1 Susceptibility testing with AGE
The panel of 20 B. cepacia strains was tested for susceptibility to AGE. The
minimum inhibitory concentration (MIC) and minimum bactericidal concentration
(MBC) ofAGE for each isolate was determined using an inoculum of approximately
lxlO5 cfu/ml. A control for each isolate was prepared containing no AGE. In the
controls, all inocula grew to concentrations of approximately lxlO9 cfu/ml in the 18
hour incubation period; exceptions were the slower growing strains CI773 and J2513
o
which grew to concentrations of approximately 1x10 cfu/ml. Results are shown in
Table 4.1. Overall the antibacterial activity ofAGE against the B. cepacia panel
showed a range ofMIC's between 0.25% and 3%, with a MIC 90 of 2% and a range
ofMBC's between 3% and >6%, with an average of 5% recorded.
Table 4.1 MICs ofAqueous garlic extract
MIC% MBC% MIC% MBC%
A507 2 6 J673 3 >6
C1052 2 6 J2315 2 3
C1511 2 >6 J2421 1 >6
C1576 2 5 J2502 2 6
C1632 2 6 J2503 2 6
C1773 1 2 J2524 3 6
C1962 0.25 4 J2537 2 6
C1963 2 5 J2552 2 5
C1964 2 >6 J2742 2 3
J415 2 >6
J419 2 5 NCTC10662 4 >6
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The susceptibility of strains J2315 and J2421 to pure allicin preparation provided by
L.D. Lawson was also tested. MICs were recorded of 0.024mg/ml and 0.08mg/ml
respectively and MBCs of 0.08mg/ml and 0.12mg/ml respectively.
4.2 Killing curves
Logphase killing curves
The decline of logarithmic and stationary phase populations of clinical and
environmental isolates of B. cepacia when challenged with 1 x MBC ofAGE was
studied. Kill curves for AGE against log phase cultures of a clinical isolate (J2315)
and an environmental isolate (J2421) are shown in figures 4.1 and 4.2. Each
experiment was carried out three times and on each occasion sampling was carried
out in triplicate. Standard error of the mean error bars are shown.
The kill curve experiments showed that AGE takes nineteen hours to kill logarithmic
phase cultures of J2315; in contrast, only nine hours was required to reduce the
population of the environmental strain J2421 to almost zero. A small and transient
recovery of growth of strain J2421 was observed at 10 hours.
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Figure 4.1 The bactericidal action of AGE at 1 x MBC (3%) against a log phase









Figure 4.2 Bactericidal activity of AGE at 1 x MBC (6%) against a log phase
culture of B. cepacia J2421.
time(h)
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Stationary phase killing curves
In further experiments, the bactericidal activity ofAGE at 1 x MBC against
stationary phase cultures of B. cepacia J2315, J2537, C1052 and A507, was
measured at one hour intervals over a 20 hour period, and the results shown in
figures 4.3, 4.4, 4.5 and 4.6.
The results showed that cfus present within of stationary phase cultures of the
clinical strains, B. cepacia J2315, A507 and CI052 were considerably reduced by the
MBC ofAGE within 16 to 20 hours. A small recovery of growth was observed with
strain J2315 after 17 hours. Initially, a similar pattern of inhibition was observed
against the environmental strain J2537. After 12 hours, however, bactericidal activity
against J2537 ceased and subsequently only bacteriostatic activity for the AGE was
observed.
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Figure 4.3 Bactericidal activity ofAGE at 1 x MBC (6%) against a stationary phase













Figure 4.4 Bactericidal activity ofAGE at 1 x MBC (6%) against a stationary phase
















Figure 4.5 Bactericidal activity ofAGE at 1 x MBC (3%) against a stationary phase













Figure 4.6 Activity of AGE at 1 x MBC (6%) against a stationary phase culture

















4.3 Dose response curves
The bactericidal activity ofAGE against log phase cultures of B. cepacia J2315 and
J2421 at a range of concentrations between 0.01% (v/v) to 50% (v/v) is shown in
figure 4.7. Bacterial cfus were shown to decrease steadily with increasing
concentrations of AGE.
Fig. 4.7 Survival of B. cepacia J2315 (initial concentration 3.36 x 105 cfu/ml)
and J2421 (initial concentration 9.4 x 106 cfu/ml) after exposure to AGE for 5h and
4h respectively in iso-sensitest broth at 37°C.
1 o-4 1 o-3 10-2 1 o-1
AGE ml/ml
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4.4 Synergy testing by the checkerboard technique
To investigate the effects of AGE in the presence of conventional antibiotics six
strains of B. cepacia (CI052, CI511, J419, J2315, J2524 and A507) from Table 2.1
were exposed to combinations ofAGE and one of four antibiotics commonly used to
treat CF lung infections. Isobolograms were produced for each strain with each
combination of antimicrobials. Interestingly, with all of the six strains tested, most
combinations ofAGE and an antibiotic produced an antagonistic effect. However,
synergy was observed with combinations of ceftazidime and AGE against strains
J2315 and CI 052 and the combination ofAGE and ciprofloxacin produced
synergistic activity against strains C1511 and A507. Combinations of
chloramphenicol and AGE and meropenem and AGE produced only antagonistic
effects against the six B. cepacia strains.
4.5 HPLC analysis ofAGE
As spectrophotometry had revealed that allicin, the antibacterial agent within AGE
absorbs light at a wavelength of 240nm; this wavelength was chosen to detect
components ofAGE separated by HPLC. AGE moieties were separated at 240nm on
a gradient of acetonitrile in 0.1% (vol/vol) trifluoroacetic acid designed to give a
clear separation of the constituents. Seven different compounds were detected in the
sample. When this trace was compared with that of a sample of pure allicin, peak 7
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was found to correspond to the peak produced when allicin was analysed under
identical conditions. This suggested that peak 7 is the allicin fraction ofAGE.
The fractions corresponding to these peaks were collected and spectrophotometry
used to check that each sample only absorbed light at 240nm and thus contained no
contaminants. Once the acetonitrile was removed by evaporation, these seven
concentrated samples were reconstituted in 1ml ISB and tested for antimicrobial
activity against B. cepacia strain J2315. Samples 3, 4, 6 and 7 each had considerable
antimicrobial activity eradicating all bacteria present in the samples. Samples 1, 2
and 5 showed no notable antimicrobial activity. However, sample 5 may appear to
have less antimicrobial activity as it is present at a considerably lower concentration
than the other compounds.
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The concentration of acetonitrile (solvent B) is shown by the broken line on the right
hand axis.
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Scanning and transmission electron microscopy revealed significant changes in the
cellular structure of B. cepacia J2315 following two hours incubation in AGE. Apart
from a reduction in the bacterial population compared to the control, the surviving
bacteria were smaller than the control and their shape distorted.
Transmission electron microscopy






Figure 4.11 B. cepacia J2315 after two hours incubation with the 1 X MBC ofAGE.
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Scanning electron microscopy
Figure 4.12 Control B. cepacia J2315
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4.7 Discussion: Aqueous Garlic Extract
Although garlic preparations in various forms are widely available in pharmacies and
health food stores, many do not contain biologically active compounds because of
the way they are prepared and stored. Freshly prepared aqueous extracts and certain
dry powder preparations often contain detectable quantities of allicin and other
thiosulphinates. However, only when partially chopped garlic cloves are dried at or
below 60°C before grinding to garlic powder (Lawson and Hughes, 1992) or frozen
in liquid nitrogen, pulverised and vacuum dried will extracts retain thiosulphinates
and their precursor compounds. During storage humidity must be kept low to
prevent mould formation and the destructive activation of alliinase (Lawson et al,
1991a). The amount of allicin and other thiosulphinates contained in commercial
garlic powder has also been found to vary greatly between brands (Lawson et al,
1991a). As the quantity of thiosulphinates and storage history of these powders
could not be guaranteed, it was decided to use freshly prepared aqueous extracts of
garlic throughout this thesis. Aqueous garlic extracts contain similar amounts of
allicin and other thiosulphinates to the best commercial garlic powder tablets
(Lawson et al, 1991a). Foodstore-purchased garlic has been shown to contain more
allicin and other thiosulphinates per gram than freshly picked garlic (Lawson et al,
1991a), therefore foodstore-purchased garlic was used to prepare AGE throughout
this thesis. The antimicrobial activity ofAGE was found to be stable at -70°C for one
month.
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4.7.1 Susceptibilities to AGE
Susceptibility of micro-organisms to garlic extracts has been the subject of
considerable research. Important studies include those by Cavallito and Bailey
(1944), which show that a 1 in 125 000 dilution of an allicin preparation was
sufficient to inhibit the growth of a range ofGram positive and Gram negative
bacteria.
Subsequent studies of aqueous and dried powder extracts of garlic include a study of
20 isolates ofMycobacterium avium complex, mainly from AIDS patients, that were
inhibited by an AGE which contained 1 mg/ml of thiosulphinates (Deshpande et al,
1993). Cellini and co-workers (1996) observed that AGE at a concentration of
between 2-5mg/ml was required to inhibit clinical isolates ofHelicobacter pylori.
Growth of S. aureus was shown to be completely inhibited after 24 hours incubation
with 5% garlic powder extract (Gonzales-Fandos et al, 1994).
Other studies have shown that many bacterial species, including Mycobacterium
tuberculosis and Bacillus subtilis, (Rao et al, 1946) Bacillus cereus, Eshericheria
coli, Serratia marcescens and Pseudomonas aeruginosa, (Elnima et al, 1983)
Shigella dysenteriae (Al-Delaimy and Ali, 1970) and Salmonella typhimurium,
(Johnson and Vaughn, 1969; Rees et al, 1993) are also inhibited by garlic extract
concentrations of between 1 and 10%.
In this thesis, initial attention was directed towards the potential activity ofAGE
against a carefully selected panel of 20 B. cepacia isolates. Each of the isolates was
also assessed for susceptibility to conventional antibiotics. The MIC 90 ofAGE
against the panel was 2% and the range ofMBCs between 3% and >6%, with an
average of 5%. These results correlate well with previous studies in which other
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bacterial species were inhibited by similar concentrations ofAGE. This concordance
was surprising since B. cepacia is notorious for its inherent resistance to many
conventional antibiotics.
When inhibitory activity of AGE against B. cepacia was compared with inhibition by
conventional antibiotics, it became apparent that strains resistant to conventional
antibiotics did not necessarily require the highest concentrations ofAGE for
inhibition and vice versa. For example, three highly resistant B. cepacia strains
(CI 962, CI773 and J2421) have MICs of less than 2% AGE.
Strains which exhibited the greatest resistance to AGE, i.e. MIC of 3% or MBC of
more than 6% included the environmental isolates J673 and J2421 and the clinical
isolates CI511, CI964, J415 and J2524. These strains do not show any pattern of
resistance to conventional antibiotics. Also no particular genomovar is predominant
amongst these strains.
In conclusion, because of the MIC data, it would appear that the mechanism of
inhibition ofAGE is unlikely to be shared with any the conventional antibiotics
tested. The antibiotics included in this thesis were selected to represent each of the
major classes of antibiotics which inhibit bacterial growth by disrupting unique
points of the bacterial cell cycle. As the resistance profile of the strain panel to AGE
is not comparable with that of any of the conventional antibiotics, we must conclude




Dose response curves show a constant decline in bacterial numbers with increasing
concentrations ofAGE. Thus, the MBC ofAGE was used for all time / kill
experiments.
The bactericidal activity ofAGE is exemplified in the killing curves of log phase
cultures of two B. cepacia strains. The multi-resistant ET12 isolate (J2315) is much
slower growing than the environmental isolate J2421. J2315 did not reach a
stationary phase of growth within the 20 hour period analysed whereas J2421
reached stationary phase after 11 hours. In the presence ofAGE a slow decline in
numbers of J2315 was observed over a period of 18 hours, until finally after 19 and
20 hours incubation, less than ten viable bacteria permillilitre were detected. The
decline in bacterial numbers was much more pronounced for J2421. After nine hours
less than ten cfu permillilitre were detected. There was a slight recovery after ten
hours incubation, followed by an immediate decline.
J2315 and J2421 were originally isolated from different environments and have
different antibiotic susceptibilities. J2315 is a multi-resistant clinical isolate whereas
J2421 an environmental isolate is more sensitive to antibiotics. The difference in the
rate of decline of these strains may indicate that strains isolated from the
environment are more susceptible to AGE. Garlic plants produce the thiosulphinates
present in AGE when they are damaged, as a defence mechanism to protect them
from attack by micro-organisms. It would be of benefit to Allium species if plant
pathogenic B. cepacia were highly susceptible to allicin and /or other thiosulphinates.
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However, the environmental strain, J2421 required 6% AGE to be completely killed,
double the concentration required to kill the clinical isolate J2315. The slower rate
of killing observed with J2315 may exist solely because of the lower concentration of
AGE used in that experiment. At concentrations of 6% AGE faster killing of J2315
may be observed.
When the log phase kill curves are compared with kill curves involving stationary
phase cultures of B. cepacia it becomes apparent that J2315 has a slower rate of
growth than the other strains studied, regardless of the stage of growth of bacteria
used as the inoculum. When stationary phase cultures were challenged with AGE, a
slow pattern of killing was displayed over a period of 16 - 20 hours for all the
isolates. From the growth curve controls run alongside these killing experiments, it
could be seen that cells from overnight cultures take approximately 15 hours to reach
their stationary phase; the exception was J2315 which did not reach stationary phase
within the 20 hour period studied. It can be seen from the growth curves in figures
4.1 and 4.2, in which log phase bacteria were used, that J2421 reached its stationary
phase around nine to ten hours but once more J2315 did not reach stationary phase in
the entire 20 hour period. Although J2315 is actually growing at log phase, its
growth rate is much less than that of J2421. It appears that maximum killing of
B. cepacia by AGE occurs as cells reach stationary phase. In conclusion, slower
growing J2315 takes much longer to be killed than the other strains studied. There
also may be a link between growth phase and killing by AGE.
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Previously, Johnson and Vaughan (1969) studied killing of S. typhimurium and
E. coli by dried garlic powder. Inhibition of S. typhimurium by pure allicin
preparation has also been studied (Feldberg et al, 1988). The initial study carried out
by Johnson and Vaughn showed that garlic powder was initially only bacteriostatic
towards S. typhimurium, however bacterial killing was detected after two to six hours
incubation with 10% garlic powder. This pattern was similar to that observed in this
thesis with J2421. Thiosulphinates present in garlic powder other than allicin were
also shown to have antibacterial activity against both resting and growing cells of
S. typhimurium. N-propyl allyl disulfide and di-n-propyl disulfide were active
against resting cells of S. typhimurium. However, these compounds exerted only a
bacteriostatic influence against growing cells which was reversed in two to six hours
(Johnson and Vaughn, 1969). In this thesis, unidentified compounds other than
allicin, present within AGE have also been reported to inhibit B. cepacia. The
possibility exists that thiosulphinates present within compete garlic extracts may act
together to produce a greater bactericidal effect than would be observed for allicin
alone.
The allicin content of the AGE used in this thesis could not be determined by the
spectrophotometric method described by Han and co-workers (1995) as this method
can only provide a measurement of total thiosulphinates present in a given sample.
Therefore, MIC and MBC of pure allicin against strains J2315 and J2421 can not be
compared with the MIC and MBC ofAGE against these strains and, thus, the
potential contribution of other thiosulphinates present within AGE to the anti-cepacia
activity of this extract was not assessed.
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Feldberg and co-workers also studied the effect of garlic compounds upon
S. typhimurium, using a pure preparation of allicin. They proposed that allicin, at
concentrations of between 0.2 and 0.5mM, was merely bacteriostatic and that
inhibition was transient, lasting between 20 and 95 minutes. This inhibition period
lengthened, with increased concentrations of allicin and with greater initial culture
densities. Increasing concentrations of allicin also decreased the rate of growth, and
when growth resumed after the inhibition period, the cell density at which stationary
phase was entered, was lowered and the growth rate decreased.
It may be that if concentrations of allicin had been increased further, a bactericidal
effect would have been observed. As the resumed growth rate was less than the
original growth rate, it can be speculated that the cells do not totally recover form the
effect of allicin inhibition and that some form of irrepairable damage is achieved.
Thus, if greater concentrations of allicin were added greater lasting damage might be
affected, and the cell recovery could be eliminated. It may also be that the
discrepancy in the results of these two studies is due to the unstable nature of the
garlic preparations used. Feldberg and co-workers used a relatively pure allicin
preparation, whereas Johnson and Vaughn used a garlic powder, which contains
many thiosulphinates including allicin that may contribute to the antibacterial effect.
Synergy or an additive effect might also occur between the allicin and other
antibacterial compounds known to be present in garlic.
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4.7.3 Synergy studies
In this thesis, synergy testing carried out by the checkerboard technique described by
Garrod and Waterworth (1962) revealed that combinations ofAGE and conventional
antibiotics were mostly antagonistic. Synergy was observed only with combinations
of ciprofloxacin or ceftazidime with AGE and for only two B. cepacia strains. No
additive combinations were observed. These results contrast with previous studies.
Didry and co-workers tested combinations of garlic extract with ampicillin,
doxycyclin, colistin, tobramycin, cefoxitin and thiamphenicol against eight bacterial
strains selected to include both anaerobic and aerobic bacterial species. These did
not include B. cepacia. No antagonism was observed. However, in approximately
50% of the combinations tested, synergy was observed, the most successful
combinations involving aminoglycoside antibiotics and garlic extract (Didry et al,
1987; 1992). A separate study showed synergy in the combined action of
streptomycin and allicin against tubercule bacilli (Gupta and Vaswanathan, 1955).
The high incidence of antagonism in combinations ofAGE with conventional
antibiotics against B. cepacia may exist due to the presence of compounds in AGE
not present in the garlic extract used by Didry and co-workers. In this thesis, no
combination ofAGE and an aminoglycoside was tested as B. cepacia is known to be
inherently resistant to antibiotics of this class (Burns et al, 1989). There are no
previous reports of the four antibiotics tested in this thesis (ceftazidime,
ciprofloxacin, chloramphenicol and meropenem) being tested in combination with
garlic against B. cepacia or other bacterial species. Thus, the high incidence of
antagonism observed may be explained by the particular antibiotics used and the
115
strains tested. Overall the results obtained in this thesis appear to preclude the use of
garlic extracts in combination with some conventional antibiotics commonly used for
the treatment ofB. cepacia infections.
4.7.4 HPLC
Thiosulphinates other than allicin were originally discovered and separated from
garlic extracts by paper or thin layer chromatography (Barone and Tansey, 1977).
These methods have been superseded as they lack the resolution, sensitivity and
quantitation attainable by modern methods. Han et al (1995) defined a method useful
for the quantification of total thiosulphinates present in a sample. This
spectrophotometric method uses DTNB or DTDP to measure the decrease in cysteine
concentration when allicin reacts with this cysteine to form S-allylmercaptocysteine.
However, as other thiosulphinates also react with cysteine this method is not suitable
for measuring allicin alone. Gas chromatography, a more advanced technique is also
unsuitable as a means of separating allicin because of the high injection port and
column temperatures are required. However, indirect analysis based on measuring
the quantity of allicin degradation products present in a sample can be used (Lawson
et al, 1991c). Analysis using normal phase HPLC of diethyl ether garlic extracts and
garlic products was first reported in 1985 (Miething, 1985). This technique also
proved unsatisfactory, as allicin is unstable in ether and in other solvents required.
Reverse phase HPLC utilising 60% methanol / 40% water as the eluent, did not
present these problems and its first successful use was reported by Jansen et al in
1987. Subsequent studies have used Cig and Si reverse phase HPLC to identify and
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quantitate all eight of the thiosulphinates present in a variety of garlic preparations
(Lawson and Hughes, 1989; Lawson et al, 1991a;c). HPLC analysis has the
advantage that it can be performed at room temperature, however the technique does
require the use of an external standard. At present, HPLC is regarded as the best
method available for the separation of thiosulphinates present in garlic preparations.
In this thesis, reverse phase HPLC was employed using a Beckman (5pm pore size
Ultrasphere ODS; internal dimensions - 150 by 10 mm) column. Detection was at
240nm and separation was performed using an acetonitrile / water gradient. The
results were compared with an allicin standard. Seven compounds were collected
from the separation and tested for antimicrobial activity. Only four of the
compounds collected showed notable activity against B. cepacia and these may act
together within AGE to inhibit B. cepacia. As the allicin standard was shown to
contain only one compound it is unlikely that any decomposition of allicin took place
during analysis. Thus, the trace produced can be used to tentatively identify the
allicin fraction present in AGE separated under identical conditions. Separation of
AGE revealed that compound seven is most likely to be allicin as it is eluted from the
column at the same time and with the same concentration of acetonitrile. Thus,
allicin is present in AGE along with other anti-cepacia compounds.
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4.7.5 Electron Microscopy
Scanning and transmission electron microscopy of B. cepacia revealed distortion of
the bacterial cell structure after incubation with AGE. These morphological changes
were observed after two hours incubation with AGE. The distortion of the cell
membrane is similar to that observed by scanning electron microscopy of C. albicans
treated with AGE (Ghannoum, 1988). In this study, cell leakage studies confirmed
that the integrity of the yeast cell envelope was affected. AGE decreased the total
lipid concentration and altered the fatty acid composition of C. albicans. Damage to
the lipids in the yeast cell envelope would explain the distortion observed. Another
study showed that AGE causes limited inhibition ofprotein and nucleic acid
synthesis in C. albicans, whereas lipid synthesis ceased (Adetumbi et al, 1986).
The outer membrane of B. cepacia is made up of similar fatty acids to those found in
the membrane of C. albicans. B. cepacia produces an unusual range of polar lipids
which include two forms of both phosphatidylethanolamine and ornithine amide
lipid, along with phosphatidylglycerol, bis(phosphatidyl)glycerol and an
uncharacterised glycolipid (Yabuuchi et al, 1992; Taylor et al, 1998). The most
common fatty acids present in strains of B. cepacia are palmitic acid (16:0), oleic
acid (18:1) and C17 and CI9 cyclopropane acids (Taylor et al, 1998; Cox and
Wilkinson, 1989).
If concentrations ofpalmitic and oleic acids are increased in B. cepacia when
incubated in the presence ofAGE, as is observed in C. albicans, the change in
composition of fatty acids and lipids present within the outer membrane could lead to
disruption of the outer membrane. Thus, at low concentrations garlic may inhibit
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protein synthesis of bacteria, but at higher concentration is may also interfere with
the production of fatty acids and lipids leading to the disruption of the outer
membrane. This may be the irrepairable lesion eluded to previously in this thesis.
Resistance of B. cepacia to many conventional antibiotics is mediated by decreased
outer membrane permeability (Burns and Clark, 1992). Small porin channels in the
outer membrane of B. cepacia retard the diffusion of hydrophilic antibiotics to their
targets making the organism resistant to p-lactam antibiotics (Parr et al, 1987;
Arnoff, 1988) and chloramphenicol (Burns et al, 1989).
The unusual profde of polar lipids and fatty acids in B. cepacia may also confer
unusual properties on the cell envelope thus contributing to antibiotic resistance (Cox
and Wilkinson, 1989). Compounds present in AGE may have difficulty crossing the
outer membrane of B. cepacia. Thus, it could be speculated that the outer membrane
needs to be compromised in some way before inhibitory concentrations of the
antibacterial compounds present within AGE can enter the cell.
AGE could exert its bactericidal action against B. cepacia in one of two ways. By
some as yet unknown mechanism, AGE could damage the lipids of the cell
membrane without entering the cell. After the membrane is weakened,
thiosulphinates could enter the cell more easily, causing further damage to cellular
lipids and disruption ofRNA synthesis. Alternatively, small quantities of
thiosulphinates may be able to enter B. cepacia through the pores present within the
cell membrane and attack the sulfhydryl enzymes responsible for lipid synthesis, thus
causing disruption of the cell membrane. As before, once the cell membrane is
disrupted, larger quantities ofAGE would be able to enter the cell causing greater
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interference with lipid and RNA synthesis and also to any other cellular reaction
catalysed by sulfhydryl enzymes, ultimately leading to cell death.
Garlic extracts have been shown to have a beneficial effect upon lipids present in the
bloodstream ofman. There may be similarities between the inhibition of lipids
present within micro-organisms and the inhibition of lipids present within the human
bloodstream. Ingestion of garlic has been shown to decrease levels of lipoproteins
which circulate in the blood in the form of low density lipoprotein (LDL) and
cholesterol. The formation of anti-atherogenic high density lipoprotein (HDL) is
increased at the expense of LDL. Allicin is the compound thought to be responsible
for this therapeutic effect as garlic preparations which do not contain allicin have
been shown to be ineffective at lowering LDL and cholesterol concentrations (Reuter
et al, 1995). Allicin may also lower cholesterol concentrations by the inhibition of
cholesterol biosynthesis. At low concentrations allicin and ajoene have been shown
to inhibit sterol biosynthesis in human HepG2 cells at the level of P-hydroxy-P-
methyl-glutaryl-coA reductase and to inhibit the later stages of cholesterol
biosynthesis at higher concentrations (Reuter et al, 1995). Both allicin and ajoene are
converted to allyl-mercaptan immediately in blood, thus never reach the liver to
affect cholesterol biosynthesis. However, allyl-mercaptan is capable of enhancing
palmitate-induced inhibition of cholesterol synthesis (Gebhart, 1995).
It appears that allicin or allyl-mercaptan affects lipid production in both mammalian
and yeast cells and may also affect the lipids present in the outer membrane of cells
of B. cepacia. Lipid production may be affected by inhibition of sulfhydryl enzymes
crucial for lipid synthesis or by some as yet unknown mechanism. The mechanism
of inhibition could be shared in both micro-organisms and humans.
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Further investigation would be necessary to ascertain if inhibition of production or
damage to the lipids of the outer membrane of B. cepacia is causing the distortion
seem in the electron microscopy photographs, and ultimately the destruction of cell
structure.
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CHAPTER 5 OIL EXTRACTS OF PLANTS
5.1 Screening of 21 plant essential oils for antimicrobial activity.
In a preliminary study, two strains ofB. cepacia from different genomovars, were
tested for susceptibility to 21 essential oils. The minimum inhibitory concentration
(MIC) and minimum bactericidal concentration (MBC) for each isolate was
determined for an inoculum of approximately lxlO5 cfu/ml. A control for each
isolate was prepared containing no essential oil. The control cultures grew to
concentrations of approximately lxlO9 cfu/ml over an 18 hour incubation period.
Table 5.1 Activity of 21 plant oils against two strains of B. cepacia
C1052 J2315
MIC % MBC % MIC % MBC%
Aniseed l >i 0.5 >i
Bay 0.05 0.1 0.05 0.1
Blackberry >1 >i >1 >i
Cinnamon 0.05 0.1 0.1 0.1
Clove 1 i 1 l
Cranberry >1 >i >1 >i
Eucalyptus 0.25 0.25 0.5 >i
Fennel 0.1 0.1 0.05 0.05
Garlic 0.25 0.5 0.1 0.5
Lemon >1 >1 >1 >1
Lime >1 >1 >1 >1
Mint 1 1 1 >1
Onion >1 >1 1 >1
Orange >1 >1 >1 >1
Peppermint >1 >1 >1 >1
Rosemary 0.25 0.5 0.5 1
Raspberry >1 >1 >1 >1
Spearmint 1 1 1 1
Strawberry >1 >1 >1 >1
Tea Tree 0.25 0.25 0.25 0.25
Thyme 0.05 0.05 0.05 0.05
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Eight of the oils tested showed no activity against the two strains of B. cepacia at
concentrations of 1% or less. Thirteen oils had some activity against the strains and
the six most active oils, bay, cinnamon, fennel, garlic, tea tree and thyme were
selected for further study.
5.2 Susceptibility testing
Nineteen strains of the B. cepacia panel were tested for susceptibility to the six most
active plant essential oils chosen from the screening studies. Approximately
lxl05cfu/ml of each bacterial strain, contained in nutrient broth were challenged with
concentrations ofplant oil between 0.01% and 1%. The suspensions were mixed
thoroughly for 30 seconds before incubation in an orbital incubator to ensure
dispersion of the oil throughout the broth. The MICs and MBCs are listed in tables
5.2 and 5.3 below. Cultures ofP. aeruginosa (NCTC 10662), E. coli (J2408) and
S. aureus (J2407) were included in the study as controls.
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Table 5.2 MIC (%) of six plant essential oils against strains of B. cepacia and
controls
Thyme Cinnamon Bay Fennel Garlic Tea Tree
A507 0.01 0.10 0.15 0.025 0.25 0.25
C1052 0.01 0.10 0.05 0.05 0.25 0.25
C1511 0.01 0.10 0.10 0.05 0.10 0.25
C1576 0.01 0.05 0.15 0.15 0.05 0.25
C1632 0.01 0.05 0.05 0.01
C1773 0.01 0.05 0.05 0.05 0.05 0.10
C1962 0.01 0.05 0.05 0.10 0.25 0.25
C1963 0.01 0.05 0.05 0.05 0.05 0.10
C1964 0.01 0.05 0.05 0.05 0.05 0.10
J415 0.01 0.10 0.05 0.10 0.25 0.25
J419 0.01 0.05 0.05 0.05 0.10 0.10
J673 0.01 0.05 0.10 0.05 0.10 0.10
J2315 0.01 0.15 0.05 0.10 0.10 0.10
J2421 0.01 0.05 0.05 0.05 1.00 0.25
J2502 0.01 0.05 0.10 0.05 0.10 0.10
J2503 0.01 0.05 0.05 0.05 0.25 0.10
J2524 0.01 0.05 0.05 0.05 0.25 0.10
J2537 0.01 0.15 0.15 0.025 0.50 0.25
J2552 0.01 0.05 0.05 0.05 0.05 0.10
CONTROLS
J2407 0.05 0.05 0.05 0.10 0.25 0.25
J2408 0.05 0.05 0.10 0.10 1.00 0.05
NCTC10662 1.00 1.00 0.50 >1.00 1.00 1.00
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Table 5.3 MBC (%) of six plant essential oils against strains of B. cepacia and
controls
Thyme Cinnamon Bay Fennel Garlic Tea Tree
A507 0.025 0.200 0.200 0.050 0.500 0.250
C1052 0.010 0.100 0.050 0.100 0.500 0.250
C1511 0.025 0.250 0.150 0.150 0.250 0.250
C1576 0.010 0.150 0.250 0.150 0.500 0.250
C1632 0.010 0.050 0.050 0.010
C1773 0.010 0.050 0.050 0.050 0.100 0.100
C1962 0.025 0.150 0.150 0.100 >1.000 0.250
C1963 0.010 0.050 0.050 0.050 0.250 0.250
C1964 0.010 0.050 0.100 0.050 0.500 0.250
J415 0.025 0.100 0.150 0.250 0.500 0.250
J419 0.025 0.100 0.050 0.100 0.250 0.100
J673 0.010 0.050 0.100 0.100 0.500 0.250
J2315 0.010 0.250 0.250 0.100 0.500 0.250
J2421 0.010 0.050 0.050 0.050 >1.000 0.250
J2502 0.010 0.050 0.100 0.050 0.250 0.100
J2503 0.025 0.050 0.050 0.150 0.500 >1.000
J2524 0.010 0.050 0.050 0.100 0.250 0.100
J2537 0.025 0.500 0.150 0.025 1.000 0.250
J2552 0.010 0.050 0.050 0.100 0.250 0.250
CONTROLS
J2407 0.500 0.100 0.050 >1.000 1.000 0.250
J2408 0.050 0.050 0.100 0.100 1.000 0.050
NCTC10662 1.000 >1.000 1.000 >1.000 1.000 1.000
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A summary of the results is displayed in Table 5.4. Thyme oil was found to be the
most antimicrobial oil. Fennel, cinnamon and bay oils have similar activity against
the strains tested. Garlic and tea tree oils are moderately less active than the other
oils tested. In general, none of the control organisms tested were as susceptible as
the B. cepacia strains to the range of oils. S. aureus (J2407), however, was quite
susceptible to bay oil and E. coli (J2408) appeared relatively sensitive to thyme and
cinnamon oils. P. aeruginosa (NCTC 10662) was the most resistant of the strains
tested. A 1% concentration of thyme, bay, garlic of tea tree oils was required to
inhibit the growth of this strain.
Table 5.4 Summary of susceptibility testing for B. cepacia strains
MIC 90 MIC range MBC range
Thyme 0.01% All 0.01% 0.01% - 0.025%
Fennel 0.1% 0.01%-0.15% 0.01%-0.15%
Cinnamon 0.1% 0.05%-0.15% 0.05% - 0.5%
Bay 0.15% 0.05%-0.15% 0.05% - 0.25%
Tea tree 0.25% 0.1% - 0.25% 0.1% ->1%
Garlic 0.25% 0.05% - 1% 0.1% ->1%
5.3 HPLC analysis of thyme oil
HPLC was used to confirm that thymol was present in the thyme essential oil used in
this thesis. Thymol absorbs light at a wavelength of 275nm, therefore this
wavelength was chosen to separate thyme oil by HPLC. Thyme oil and thymol were
analysed on a continuous linear gradient of acetonitrile in 0.1% (vol/vol)
trifluoroacetic acid designed to give a clear separation of the compounds present.
Separation of thyme oil yielded four peaks. The largest of which, peak 3
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corresponds to the peak produced when thymol is analysed under identical
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Fig 5.1 Separation of thyme oil by HPLC at 275nm
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Fig 5.2 Separation of thymol by HPLC at 275nm
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It can be seen from figures 5.1 and 5.2 above that thymol is likely to present in the
thyme essential oil studied in this thesis. Carvacrol and thymol analysed at the same
absorbance and under identical condition produced almost identical HPLC traces.
Thus, either compound, or more likely a combination of both compounds seems to be
present in the thyme oil analysed in this thesis. Results are shown in the appendix.
5.4 Susceptibility ofB. cepacia to thymol
Since thymol is a major constituent of thyme oil, the MIC and MBC of a pure
preparation of thymol were determined for the panel of 20 B. cepacia strains.
Thymol does not dissolve well in water alone therefore 5% ethanol was used to aid
dispersion. A concentration of ethanol greater than the maximum amount present in
any sample was tested for antimicrobial activity. Thus it was found that 5% ethanol
alone did not have an antibacterial effect. Each strain of B. cepacia was tested for
susceptibility to concentrations of thymol between 100 and 500pg/ml.
Table 5.5 Susceptibility of strains ofB. cepacia to thymol (pg/ml)
MIC MBC MIC MBC
CI 052 200 200 J673 300 300
C1511 300 400 J2315 200 300
C1576 300 300 J 2421 200 300
CI 632 300 300 J2502 200 200
CI 773 200 300 J2503 300 300
CI 962 200 300 J2524 300 300
CI 963 200 200 J2537 300 300
CI 964 200 300 J2552 300 300
J415 300 300 J2742 300 300
J419 200 300 A507 200 200
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Thymol at a concentration of 500pg/ml did not inhibit the growth ofP. aeruginosa
NCTC 10662. Concentrations of between 200 and 400pg/ml were sufficient to
inhibit the growth of the B. cepacia strains tested.
5.5 Killing curves
The declines of both logarithmic and stationary phase populations of B. cepacia
challenged with thyme oil or thymol were studied. The period required for the
minimum bactericidal concentration of each substance to eradicate 105 cfu/ml of
cultures of a clinical or environmental strain of B. cepacia, either in stationary or
logarithmic phase of growth, is shown below. Each experiment was carried out three
times and on each occasion sampling was carried out in triplicate. The standard error
of the mean was calculated and error bars are shown. Figures 5.3 and 5.4 show the
activity of thyme oil against stationary phase cultures of the two B. cepacia strains.
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Fig 5.3 Time related killing of stationary phase cultures of B. cepacia J2315 in the
presence of thyme oil.
Fig 5.4 Time related killing of stationary phase cultures of B. cepacia J2421 in the
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Figures 5.5 and 5.6 show the activity of thyme oil on log phase cultures of two
strains of B. cepacia. Compared with the killing curves observed for stationary
phase cultures, it can be seen that log phase cultures are killed slightly more swiftly.
Approximately twenty minutes contact with oil was necessary to eradicate stationary
phase cultures whereas log phase cultures were 'sterilised' in ten minutes.
At MBC (300pg/ml), thymol did not kill the two strains of B. cepacia tested to the
same extent as thyme oil. At 300pg/ml however, thymol decreased bacterial cfus
within 90 minutes by 40% (data not shown). In order to mimic the rate of
antimicrobial activity of thyme oil against B. cepacia, 1000pg/ml of thymol was
required for J2315 and 800pg/ml for J2421. The results of these experiments are
shown in figures 5.7, 5.8, 5.9 and 5.10. Once again, the experiments were carried out
on three occasions and on each occasion sampling was carried out in triplicate.
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Fig 5.7 Time related killing of stationary phase cultures of B. cepacia J2315 in the
presence of thymol.
Fig 5.8 Time related killing of stationary phase cultures of B. cepacia J2421 in the
presence of thymol.
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5.6 Killing curves in the absence of a carbon source
To determine if cells must be actively growing for thyme oil to have a bactericidal
effect, killing curves were carried out in PBS instead of nutrient broth i.e. in the
absence of a carbon source.
Figures 5.11 and 5.12 show that there was no noticeable difference in the decline of
these strains upon challenge with thyme oil in PBS or nutrient broth. Therefore, it
can be assumed that the cells do not need to be actively growing for thyme oil to
produce a bactericidal effect.
Figure 5.11 Time related killing in the absence of a carbon source of a log phase
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Fig 5.12 Time related killing in the absence of a carbon source of a log phase
culture of B. cepacia J2421 in the presence of thyme oil.
5.7 Dose response curves
The bactericidal activity of thyme oil and thymol were measured at a range of
concentrations for two strains of B. cepacia in nutrient broth. Bacterial numbers
were shown to decrease steadily with increasing concentrations of thyme oil or
thymol until all detectable cells were eradicated.
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Fig 5.13 Survival of B. cepacia J2315 (initial concentration 4.4 x 10 cfu/ml)
and J2421 (initial concentration 7.52 x 106 cfu/ml) after exposure to thyme oil for 5h
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Fig 5.14 Survival of B. cepacia J2315 (initial concentration 7.32 x 105 cfu/ml)
and J2421 (initial concentration 1.06 x 105 cfu/ml) after exposure to thymol for 5h
and 4h respectively in iso-sensitest broth at 37°C.
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Transmission electron microscopy revealed significant changes after only three
minutes incubation of cells of strain J2315 with thyme oil. No intact bacteria could
be observed after this short incubation period.
Scanning electron microscopy
Scanning electron microscopy revealed only limited numbers of cells of strain J2315
survived two minutes incubation with thyme oil. Figure 5.16 and figure 5.17 both
show damaged bacterial cells, some with blebs ofmaterial on their surface. Cells of
J2315 incubated in thyme oil also appear shorter than the control cells of this strain
shown in figure 5.15.
Fig. 5.15 Control cells of B. cepacia J2315.
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Fig. 5.16 B. cepacia J2315 after two minutes incubation with thyme oil
1 0 jim20.0 kU 4.78E3 6102/98 SE
Fig 5.17 B. cepacia J2315 after two minutes incubation with thyme oil
^
f
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5.9 Discussion: Oil extracts of plants
5.9.1 Screen of 21 essential oils
Of the essential oils tested in this study, only 50% showed inhibitory activity against
B. cepacia at concentrations of 1% or less. None of the seven fruit essential oils, nor
onion oil, showed any activity. Peppermint oil also had no anti cepacia activity at the
concentrations tested, however oils ofmint and spearmint were inhibitory at
concentrations of 1%. The other ten oils tested did show inhibitory activity against
B. cepacia. These oils were mainly isolated from herbs, and many contain the same
or similar chemicals. Bay, cinnamon and clove oils contain mainly the phenol
eugenol. Fennel and aniseed oils contain mostly trans-anethole. Additional
compounds, present within these oils may contribute to their antimicrobial activity as
bay, cinnamon and fennel oils are much more inhibitory to the growth of the
B. cepacia strains tested than oils from clove and aniseed. However, a greater
number of strains need to be tested before firm conclusions are drawn. Rosemary
and eucalyptus oils comprise mainly 1,8-cineole, a cyclic ether, and both oils showed
a similar level of antibacterial activity against the two B. cepacia strains tested.
Garlic, tea tree and thyme oils are composed of compounds unique amongst the oils
tested. Garlic oil is composed of a number of sulphur containing compounds and tea
tree oil contains mainly terpinen-4-ol, a terpene alcohol. Thyme oil, the most active
of all the oils tested against B. cepacia contains the phenols, thymol and carvacrol.
Oils of bay, cinnamon, fennel, garlic, tea-tree and thyme were selected for further
investigation as they exhibited the greatest activity against the strains of B. cepacia
tested in the preliminary screen.
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5.9.2 Activity of selected oils against the B. cepacia panel
Thyme oil was the most inhibitory of the oils tested against B. cepacia with the batch
tested having a MIC of 0.01% for all strains tested. The MBCs ranged from 0.01%
to 0.025%. Many studies of the antibacterial and antifungal activity of thyme oil and
its main active constituents thymol and carvacrol, have been reported previously.
Thyme oil has powerful antibacterial and antifungal activity against a wide range of
organisms. In a study of fifty plant essential oils against single strains of 25 genera of
bacteria, Deans and Ritchie (1987) found thyme oil to be active against 23 of the
genera tested. Only two genera, represented by Clostridium sporogenes and
Leuconostoc cremoris, were resistant to thyme oil. Only angelic and bay oils were
found to inhibit more bacteria than thyme oil. It is important to note that this study
was carried out using agar diffusion, a technique which does not provide as accurate
results due the difficulties in obtaining uniform distribution because of the
hydrophobicity of essential oils (Janssen et al, 1987). In a more directly comparable
study carried out using methods similar to those used to test conventional antibiotics,
thyme oil was again shown to be highly active, inhibiting eight out of the ten
organisms tested (Hammer et al, 1999). Only P. aeruginosa and S. typhimurium were
resistant to up to 2% v/v concentrations of thyme oil. Thyme oil has also been
shown to have activity against organisms highly resistant to conventional antibiotics,
such as MRSA and vancomycin resistant enterococci using a broth dilution method
(Nelson, 1997). Although most other studies of the antibacterial activity of thyme oil
have unfortunately been carried out using agar or disk diffusion methods, they
provide comparative and qualitative data for the activity of thyme oil against a wide
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variety of organisms. For example, thyme oil was found to be the most active of six
essential oils tested against Gram-positive, Gram-negative, acid fast bacteria and
yeast at concentrations of 1.25mg/ml and less (Farag, 1989). Thyme oil was also the
most active of the oils tested in a study of inhibition of oral bacteria (Meeker, 1988).
Thyme oil, along with bay and cinnamon oils, was again the most active of 23 oils
tested against food-borne pathogens (Smith-Palmer et al, 1998). Other studies have
concentrated on the considerable activity of thyme oil against fungi and yeasts
(Conner and Beauchat, 1984; Llewellin et al, 1981). Dried, alcoholic and aqueous
extracts of thyme have also been shown to possess antimicrobial activity (Beuchat,
1976; Hitokoto et al, 1980; Huhtanen, 1980; Tabak et al, 1996).
Some investigators have reported that thymol alone is active against S. typhimurium,
S. aureus, V. parahaemolyticus (Karpainar and Aktung, 1987), some oral bacteria
(Shapiro et al, 1994) and fungi (Thompson, 1990; Buchannan and Shepherd, 1981).
Carvacrol, the other main antibacterial compound present in thyme oil has been
shown to have activity against B. cereus. It should be noted that studies of the
individual components of essential oils are not directly comparable with studies of
whole oil as interactions between the compounds within the oil may have additive,
synergistic or antagonistic contributions to the antimicrobial effect.
Two of the other oils tested in this thesis also contain high levels of phenols. These
are cinnamon leaf and bay oils which are both mainly composed of eugenol. These
oils were found to be highly active against the B. cepacia panel with a similar range
ofMICs and MBCs. Indeed, the susceptibilities of approximately 60% of the strains
to cinnamon and bay oils were identical. Where differences did exist it, it is possible
that other compounds present within these oils, perhaps with different modes of
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action, may contribute or detract from the antibacterial activity against individual
strains. It is unlikely that the differences are due to a particular oil containing a
higher concentration of eugenol as no oil was consistently more active than the other.
Although this thesis focused on B. cepacia, in general the antibacterial activities of
bay and cinnamon oils observed were consistent with other studies. However,
cinnamon essential oil can be produced from either the leaves or the bark of this
plant and in most studies, the type of cinnamon oil used is not specified (Aureli et al,
1992; Deans and Ritchie, 1987; Maruzzella and Henry, 1958; Yousef and Twail,
1980; Llewellyn et al, 1981). In this thesis, activity of oil of cinnamon leafwas
investigated. Cinnamon bark essential oil contains between 55 and 75%
cinnamaldehyde, which is not present in cinnamon leaf oil. It also contains much
less eugenol than cinnamon leaf oil (Tissarand and Balacs, 1995). Smith-Palmer
and co-workers (1998) have shown bay and cinnamon leaf oils to be active against
E. coli, S. aureus, L. monocytogenes and S. enteritidis at concentrations of 1% or
less. All species tested with the exception ofE. coli were susceptible to different
concentrations of bay and cinnamon oils. Bay oil was found to be active against
Acinetobacter baumanii, Aeromonas sobria, C. albicans, E.faecalis, E. coli,
K. pneumoniae, P. aeruginosa, S. typhimurium, S. marcescens and S. aureus at
concentrations of 1% or less (Hammer et al, 1999). This confirmed the antibacterial
activity of bay oil, previously observed by Nadal et al (1973) and other investigators,
who used agar diffusion techniques. Eugenol was found to inhibit the growth of
Staphylococcus, Micrococcus, Bacillus and Enterobacter isolates at a concentration
of 750pg/ml (Moleyar and Narasimham, 1992). In a separate study, 1 OOpg/ml
eugenol was required to completely inhibit S. typhimurium, S. aureus and
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V. parahaemolyticus (Karapinar and Aktug, 1987). A mixture of cinnamaldehyde
and eugenol was found to be more active than the same concentrations of these
compounds alone against Staphylococcus, Micrococcus, Bacillus and Enterobacter
isolates (Moleyar and Narasimham, 1992).
In this thesis, sweet fennel oil proved to be marginally more active that cinnamon
and bay oils against the B. cepacia panel. This oil is composed mainly of trans-
anethole, Anethole has previously been reported to be antimicrobial against strains of
S. aureus, S. typhimurium and V. parahaemolyticus at concentrations of 500pg/ml
(Karapinar and Aktug, 1987). However, Smith -Palmer et al (1998) found fennel oil
to have no activity against a selection of food poisoning organisms at concentrations
of less than 1%. Other studies have shown fennel to be antimicrobial against a
limited range of bacteria and fungi (Deans and Ritchie, 1987; Yousef and Twail,
1980; Conner and Beauchat, 1984). Fennel oil is surprisingly active against
B. cepacia considering its limited range of activity against other bacteria and fungi,
many of which are considerably more sensitive to conventional antimicrobial agents.
All the studies mentioned above were carried out in agar as opposed to broth which
may account for the poor inhibitory activity observed.
Garlic and tea tree oils were less active against the B. cepacia panel strains than the
other oils tested. Garlic oil is reported to contain mostly diallyl disulphide and other
sulphur containing compounds, discussed extensively in chapter 4. Garlic oil is
unlikely to contain allicin, as this volatile compound would not survive prolonged
storage at room temperature. Therefore, other compounds present within the oil may
be responsible for anti-cepacia activity. Tea tree oil also has activity against the
strains of B. cepacia studied. Although it was not as active as some of the other oils
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tested, the range ofactivity of tea tree oil was similar to that observed in previous
studies against MRSA (Nelson, 1997). Lower concentrations of tea tree oil were
required to inhibit certain oral bacteria, considered more sensitive to conventional
antibiotics (Shapiro et al, 1994).
From the results obtained in this thesis, it can be assumed that eugenol is unlikely to
be as active against B. cepacia strains as a combination of thymol and carvacrol and
may not even be as active as either of these compounds alone. Compounds present
within fennel oil, most probably tran-anathole, also have considerable anti-cepacia
activity. Of all the oils, only garlic and tea tree were unable to completely inhibit all
the B. cepacia strains investigated at concentrations of 1% or less.
Some B. cepacia strains were susceptible to relatively low concentrations of some
oils; those included strains C1773, C1963/C1964, J419, J673, J2502 and J2552. In
contrast, strains A507, CI511, CI576, J2315 and J2537 required higher
concentrations to inhibit growth. Susceptibility or resistance was not associated with
any particular B. cepacia genomovar or with the source of the isolate. However, it
should be noted that not all genomovars were represented in this study. In contrast,
strains which were least sensitive to the oils were those exhibiting most resistance to
conventional antibiotics. Those included strains CI576 and J3215 which were
resistant to all the antibiotics tested and C1511 and J2537 which were sensitive to
only two conventional antibiotics.
Strains of B. cepacia which were most sensitive to the plant oils were also sensitive
to many of the conventional antibiotics studied. CI 773, J419, CI 963 and CI 964 are
clinical B. cepacia isolates sensitive to two or three of the conventional antibiotics.
Two of the strains (J673 and J2502) were sensitive to four conventional antibiotics
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and strain J2552, which exhibited the most sensitivity to conventional antibiotics,
was also relatively sensitive to the plant oils.
Interestingly, strains of B. cepacia which were most sensitive to an AGE were not
those which were most sensitive to garlic oil. Strains C1773, C1962, J2315, J2421
and J2742 were the most sensitive strains to AGE whereas CI576, CI773,
C1963/C1964 and J2552 were the most sensitive to garlic oil. Only strain CI773
was particularly sensitive to both garlic extracts. Strain J2421 was especially
sensitive to AGE, however this strain was the most resistant to garlic oil having a
MIC of 1%. These results support the hypothesis that different compounds are
responsible for the antibacterial activity ofAGE and garlic oil.
Thyme oil was the most active of all the oils tested. The batch of thyme oil analysed,
eradicated all cells of every strain at concentrations of 0.025% and was selected for
further study.
5.9.3 HPLC analysis of thyme oil
Essential oils from a single plant can contain over 100 different chemical
compounds. However, most individual oils contain one or two major compounds
which shape the pharmacology of that particular oil (Tisserand and Balacs, 1995).
HPLC was employed to investigate the batch of thyme oil for the presence of its
major components thymol and carvacrol. Spectrophotometry revealed that thyme oil
absorbed light mainly at 275nm, therefore this wavelength was used when the oil
was examined by HPLC. Thyme oil, separated using a continuous linear gradient of
acetonitrile, yielded four compounds. The largest peak corresponded to the peak
produced when a thymol standard was analyzed under similar conditions. This
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finding suggested that the large peak is the thymol fraction of thyme oil. Carvacrol
produced an almost identical trace to thymol and thyme oil when analysed under
identical conditions. This result was not surprising, as thymol and carvacrol are
isomers. It would be impossible to separate these compounds by RP-HPLC and it
may be that both thymol and carvacrol are contributing to the major peak observed
when thyme oil is analysed under identical conditions.
When the material from the four thyme oil HPLC peaks was examined for activity
against B. cepacia, only the thymol / carvacrol peak exhibited strong antimicrobial
activity (data not shown).
5.9.4 Killing curves
Surprisingly, very few studies of the antimicrobial activity of plant essential oils or
compounds present within essential oils have included time kill experiments. Studies
by Kim and co-workers (Kim et al, 1995a; 1995b) did however, include experiments
where the growth rate ofE. coli, E. coli 0157:H7, Listeria monocytogenes, Vibrio
vulnificus and Salmonella typhimurium was measured in the presence and absence of
eight plant essential oils components, including carvacrol and eugenol. In these
experiments, absorbance at 540nm was used to measure bacterial growth. The use of
'turbidity' measurements to assess bacterial growth would include cells which were
no longer viable. In addition, this technique is relatively insensitive for measuring
small bacterial populations.
Similar experiments, measuring the growth of B. cereus in the presence of different
concentrations of carvacrol, were carried out be Ultee et al (1998). In these studies,
carvacrol at a concentration of 3mmol f1 was shown to cause no increase in
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absorbance at 660nm i.e. no growth. Further experiments were carried out to
ascertain the rate of killing of B. cereus by 2mmol f1 carvacrol. The concentration of
B. cereus was reduced from 107cfu/ml to 104cfu/ml in only 20 minutes. This rate of
killing is similar to that observed in this thesis when B. cepacia was exposed to
thyme oil. Other studies, which have used serial dilutions to obtain counts of viable
bacteria remaining after challenge by essential oil, have included the examination of
the bactericidal activity of thyme oil against Vibrio parahaemolyticus (Beauchat,
1976) and Listeria monocytogenes (Aureli et al, 1992). The growth of
V. parahaemolyticus was challenged with three essential oils, thyme, oregano and
sassafras over a period of seven hours. Viable organisms were reduced from 104 to
almost zero by oregano oil within one hour, however recovery was observed,
beginning after three hours and reaching almost 10 cfu/ml after seven hours. The
effect of thyme oil was similar, yet not as pronounced. Bacterial numbers were
reduced from 104cfu/ml to 102cfu/ml in one hour, after which growth recovered to
the original level of 104cfu/ml after seven hours. Sassafras oil was found to possess
limited bactericidal activity. The rapid reduction of bacterial numbers observed by
these two essential oils, both known to contain high levels of thymol and carvacrol,
is consistent with other studies, and with the results observed in this thesis. In this
thesis, thyme oil appeared to inhibit bacterial growth completely, however due to the
limitations of the serial dilution technique it was not possible to determine bacterial
numbers of less than lO'/ml. Thus recovery may have been possible, although
unlikely, if incubation had been prolonged. Aureli et al (1992) reported a slower rate
of killing when five strains ofListeria monocytogenes were challenged with thyme,
oregano, cinnamon, clove and pimento essential oils. Four hours incubation with
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0.1% thyme and oregano essential oils was required for each of the five strains to be
completely eradicated. Pimento and clove oils were found to have a faster rate of
killing with some strains whereas the same concentration of cinnamon oil could only
inhibit three of the five strains tested within four hours. The concentration of oil
used by Aureli and co-workers was comparable with the minimum bactericidal
concentration of essential oil for B. cepacia found in this thesis. However, longer
incubation and slightly greater concentrations of thyme oil were required to eradicate
L. monocytogenes than were required to eradicate B. cepacia. Thyme oil can vary
dramatically in its composition between batches (Cruz et al, 1993), making reliable
comparison difficult. In addition, the initial bacterial inocula used by Aureli et al
were ten fold larger than those used in this thesis.
5.9.5 Mode of action
In this thesis, bacteria in the log phase of growth were killed more quickly than cells
in stationary phase. Similar results have been noted for inhibition of E. coli by tea
tree oil (Gustafson et al 1998; Cox et al 1998). However, the differences between
inhibition of stationary and exponential phase cultures of E. coli were much more
pronounced than with B. cepacia. In the case of E. coli, exponential phase cells were
eradicated in 30 minutes, but 105cfu/ml of stationary phase cells remained after 120
minutes. When bacteria, such as Escherichia, Salmonella and Vibrio reach
stationary phase they become metabolically less active and more resistant to
antimicrobials. Changes in membrane fatty acid composition and differences in the
structure of the cell membrane synthesised during stationary phase may contribute to
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the increased resistance of stationary phase cells to essential oils (Siegele and Kolter,
1992).
Killing of B. cepacia strains by thyme oil and thymol was swift, taking place within
30 minutes of addition of the antimicrobial. Further experiments carried out in PBS
instead of ISB gave similar results with no detectable viable bacteria remaining after
ten minutes. These results suggest that cells ofB. cepacia do not need to be actively
growing to be inhibited be thyme oil or thymol; thus, it is unlikely that these
substances are inhibiting processes such as DNA, RNA or protein synthesis.
To produce the same rate of killing as thyme oil, concentrations of thymol of
lOOOpg/ml and 800pg/ml were required for J2315 and J2421 respectively. These
concentrations appear high, as the MBC of thymol for both these strains was only
300pg/ml. It may be that other compounds present in thyme oil, such as carvacrol, a
compound with known antimicrobial properties and an isomer of thymol, contribute
to the rapid bactericidal effect.
The mechanism by which thymol and carvacrol exert their antimicrobial activity has
been considered by other investigators. By studying compounds that inhibit the
bactericidal action of thymol, Juven and co-workers formed a hypothesis for the
mode of action of thymol based on the known mode of action of other phenols. They
proposed that after crossing the bacterial cell wall, thymol interacts with periplasmic
enzymes, and upon penetrating the cytoplasmic membrane interacts with membrane
proteins by hydrophobic and hydrogen bonding, causing a back flow of protons
across the cell membrane. This activity subsequently would affect cellular functions
powered by the proton motive force (Juven et al, 1994). As a sudden decrease in
bacterial viable counts was observed when a critical concentration of thymol was
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reached, they proposed that the phenolic compounds sensitise the membrane and
when active membrane sites are saturated there follows a sudden collapse of the
cytoplasmic membrane and subsequent leakage of intracellular constituents.
Carvacrol and eugenol are likely to have similar activity against bacterial cells.
Ultee and co-workers found the activity of carvacrol to be dependent upon
concentration, exposure time, pH and temperature, in a manner similar to other
phenols. Considering these results and the hydrophobic nature of carvacrol, they
proposed that the cellular target would be the cell membrane (Ultee et al, 1998).
Other researchers have proposed that phenols present within plant essential oils may
damage yeast cells by inhibiting enzyme pathways such as those involved in energy
production and in the synthesis of structural components (Conner and Beauchat,
1984). However, no evidence was provided to support this hypothesis. In this thesis,
it seems unlikely that interference with bacterial enzymes is the major cause of
bacterial killing due to the short time period required for B. cepacia killing and
because the bacterial cells do not need to be actively growing for killing to take
place.
Transmission electron microscopy revealed cell debris and no intact cells only three
minutes after addition of the minimum bactericidal concentration of thymol to
105cfu/ml of the ET12 strain of B. cepacia. Such rapid destruction of cells is
evidence to support the hypothesis that the phenolic compounds present within
thyme oil attack the bacterial cell membrane causing leakage of intracellular
components. Electron microscopy has also been employed by other researchers to
elucidate the mode of action several oils against E. coli. Cox and co-workers (1998)
observed that incubation of E. coli in the presence of tea tree oil caused loss of
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cellular material, the coagulation of cytoplasmic constituents and the formation of
blebs ofmaterial on the cells surface. Non-viable cells were observed to have intact
cell membranes. Scanning electron microscopy employed in this thesis revealed cell
debris and blebs ofmaterial on the surface of the limited numbers of intact bacterial
cells remaining after two minutes incubation with thyme oil. In another study,
Pattnaik and co-workers (1995) showed that E. coli cells did not lyse in the presence
of oils of eucalyptus, lemongrass, peppermint and palmarosa oils. However,
elongated, filamentous forms of E. coli were observed after cells were incubated in
the presence of peppermint and palmarosa, but not eucalyptus or lemongrass oils,
perhaps due to an effect on cell division or cell wall formation. In contrast, scanning
electron microscopy employed in this thesis showed intact bacterial cells remaining
after two minutes incubation in thyme oil to be shorter in appearance than control
cells of B. cepacia.
Accumulated results suggest that different oils attack different bacteria in different
ways, however damage to the cell membrane is a common observation.
In this thesis, time course experiments carried out on strains of B. cepacia in the
presence of thyme oil or thymol showed rapid reduction in bacterial numbers, both in
the presence and absence of a carbon source. Interestingly, the speed of killing of
log phase B. cepacia cells was only slightly faster than that of stationary phase
cultures. This rapid killing regardless of bacterial growth phase, supports the
hypothesis that disruption of the B. cepacia membrane is responsible for cell death.
The greatest time period from addition of thyme oil to killing of all B. cepacia cells
was 30 minutes. The few cells remaining ten minutes after addition, may have
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already been damaged by the phenols present within the oil, but recovered when
removed from the antimicrobial agent and spread onto nutrient agar.
In conclusion, it seems reasonable to speculate that thyme oil, a mixture of the
phenols thymol and carvacrol, kills cells of B. cepacia by disrupting the integrity of
the cell membrane. Enzymes present within the cell membrane or the phospholipids
themselves may also be damaged. Further investigations are required to clarify the
precise mechanism(s) responsible for membrane disruption.
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CHAPTER 6 ENDOGENOUS ANTIMICROBIAL PEPTIDES
6.1 Activity of hBD-1 against P. aeruginosa and B. cepacia.
To investigate activity of hBD-1 against B. cepacia, 5xl04 cfu of an overnight
cultures of non-mucoid P. aeruginosa (J1385) and three strains of B. cepacia, (the
ET12 epidemic strain J2315, the environmental isolate J2421 and the proposed
biological control strain J2742) were challenged with 50pg/ml of hBD-1 in the
presence ofNaCl concentrations between 0 and 150mM. Experiments were carried
out in lOmM phosphate buffer containing 0.1% D-Glucose to investigate whether
hBD-1 activity is salt sensitive. Duplicate reactions were prepared containing buffer
alone or synthetic peptide rehydrated in buffer across the same range ofNaCl
concentrations. Each reaction was sampled in duplicate. The results are recorded in
figures 6.1, 6.3, 6.4 and 6.5 below. SEM error bars are shown.
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Figure 6.2 Percentage survival ofP. aeruginosa when challenged with hBD-1 at a
range of salt concentrations.
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Figure 6.2 confirms that inhibitory activity of the hBD-1 peptide against
P. aeruginosa is salt sensitive. Activity of the peptide was greatest in the absence of
salt or at low salt concentrations up to 60mM. One hundred percent killing of
P. aeruginosa was observed when cells were exposed to hBD-1 when no salt was
present. Only 17% of the bacterial cells survived incubation with hBD-1 in 60mM
NaCl for 20 minutes relative to the control. At higher salt concentrations however,
activity of the peptide was considerably reduced. Approximately 40% of bacterial
cells survived challenge with the peptide at salt concentrations of 90mM and above.
Thus, the hBD-1 peptide was confirmed as having salt-sensitive antimicrobial
activity against a non-mucoid clinical strain of P. aeruginosa.
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Figure 6.3 shows that hBD-1 does not inhibit the growth of the ET12 strain of
B. cepacia. In fact at low salt concentrations the presence of the peptide may even
enhance the growth of this strain. Due to the multivorous nature of this organism it
is even possible that B. cepacia is capable of using the antimicrobial agent as a
carbon source in a similar fashion to that previously reported for penicillin (Beckman
and Lessie, 1979).
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Figure 6.5 Activity of hBD-1 against the proposed environmental control strain of
B. cepacia (J2742).
0 _ _
0 30 60 90 120 150
NaCI mM
Both environmental strains of B. cepacia were also found to be resistant to the
antimicrobial activity of hBD-1. Even at low salt concentrations, there was no
difference between the numbers of viable bacterial cells remaining in reactions
containing the peptide and the controls. Thus, none of the strains of B. cepacia
tested showed susceptibility to hBD-1.
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6.2 Antimicrobial activity of elafin
To determine whether the proteinase inhibitor elafin, had antimicrobial activity
similar to the activity recently recognised in the other member of the ALP family,
SLPI (Hiemstra et al, 1996), preliminary experiments were carried out in which
5xl04 cfu/ml of S. aureus, P.aeruginosa and B. cepacia were challenged with
recombinant adeno-elafin. Experiments were conducted in the absence of salt as the
activity of this molecule is thought to be salt sensitive. Results shown represent the
average of four separate experiments and are expressed as a percentage of controls
which contained only salt-free phosphate buffer.
Figure 6.6 Survival of B. cepacia (J2315), P. aeruginosa (PAOl) and S. aureus
(CI705) upon challenge with recombinant elafin.
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The results in figure 6.6 show that recombinant elafin has antimicrobial activity
against P. aeruginosa and S. aureus, but not B. cepacia. It was noted that survival of
both P. aeruginosa and S. aureus was reduced after two hours incubation in the salt-
free buffer even in the absence of elafin (data not shown). This may have been due
to the absence of salt from this buffer or because only a single carbon source
(D-glucose) was available. In contrast, B. cepacia appears to thrive in the presence
of elafin and salt-free buffer. Again it is possible that B. cepacia is capable of using
elafin as a carbon source.
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6.3 Discussion: Endogenous antimicrobial peptides
6.3.1 Antimicrobial activity of hBD-1
Synthetic hBD-1, a mature peptide of 36 amino acids in length was shown to have
salt sensitive antimicrobial activity against P. aeruginosa, but to have no inhibitory
activity against B. cepacia. The murine homologue of hBD-1, mBD-1 also had no
antimicrobial activity against B. cepacia (J2315) regardless of salt concentration
(data not shown). Activity of the two known human p-defensins (hBD-1 and hBD-2)
is considered to be salt sensitive (Goldman et al, 1997; Bals et al, 1998a). A sharp
decrease in the antimicrobial activity of synthetic hBD-1 against P. aeruginosa was
observed when salt concentrations increased form 50mM to 125mM (Goldman et al,
1997). Interestingly, at high salt concentrations (150mM), 50% of the antimicrobial
activity of the peptide remained. The length of the synthetic peptide analysed in these
studies was not stated. The 36 amino acid mature form of hBD-1 isolated from
human urine has been reported to maintain virtually all its antimicrobial activity
against E. coli in both dilute and normal urine, whereas longer synthetic forms of
hBD-1 which included part of the pro-piece of the peptide exhibited drastically
reduced activity in the presence of salt (Valore et al, 1998). Bals et al (1998a)
reported that the activity of hBD-2 against E. coli was diminished eightfold when salt
concentrations were increased from 20mM to 150mM
The synthetic hBD-1 used in this thesis at a concentration of 0.05mg/ml retained
almost half of its antimicrobial activity against P. aeruginosa at salt concentrations
of 90mM and above, however the peptide was much more active at NaCl
161
concentrations of 60mM or less. In the absence ofNaCl all bacterial cells were
killed by the peptide. Other studies have confirmed the antimicrobial activity of
hBD-1 against strains ofP. aeruginosa at peptide concentrations between 60 and
500pg/ml (Goldman et al, 1997) and against E. coli at concentrations between 0.3
and lOpM (Valore et al, 1998).
In this thesis, despite confirmation that the peptide preparations were exhibiting
activity against P. aeruginosa, no antibacterial activity was observed when
B. cepacia strains were challenged with synthetic hBD-1 and mBD-1. The results
presented in chapter 3, together with evidence from previous studies, indicate that
B. cepacia is also inherently resistant to larger cationic molecules such as polymyxin
and to aminoglycoside antibiotics (Fass and Barnishan 1980).
Polycationic antibiotics such as polymyxin and aminoglycosides interact with
lipopolysaccaride (LPS) present in the outer membrane ofGram-negative bacteria.
9+ 9+
Divalent cations, such as Mg and Ca normally bind to LPS because of the
polyanionic nature of this molecule. The integrity of the bacterial outer membrane is
maintained as the divalent cations link adjacent LPS molecules. Polycationic
antibiotics have greater affinity for LPS and thus competitively displace the native
divalent cations. Once bound, these large molecules cause gaps to form in the outer
membrane through which more of the antibiotic can flow. Polycationic antibiotics
can then reach their final target, the cytoplasmic membrane, where these amphipathic
molecules aggregate to form channels causing leakage of cytoplasmic components,
and thus cell death (Hancock et al, 1984; 1995).
It appears that polycationic antibiotics are unable to permeate the outer membrane of
B. cepacia allowing the organism to remain resistant to this class of antibiotics. A
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link has been proposed between polymyxin resistance and the presence of a high
content of phosphate-linked 4-amino-4-deoxyarabinose in the B. cepacia, Proteus
mirabilis and Chromobacterium violaceum (Vaara, 1992).
A study ofpolymyxin B resistant mutants of S. typhimurium has shown that an
increased level of 4-amino-4-deoxyarabinose bound to the lipid A phosphate of LPS
would dispense with the necessity for divalent cations to form crossbridges between
adjacent phosphate molecules. Instead, positively charged arabinose forms ion pairs
with the negatively charged phosphates present on adjacent LPS molecules to
provide outer membrane stability. Mutants ofP. mirabilis which lack
4-amino-4-deoxyarabinose are sensitive to polymyxin (Kaca et al, 1990).
B. cepacia LPS has been shown to contain high levels of 4-amino-4-deoxyarabinose
which could explain the resistance of this organism to EDTA and cationic antibiotics
(Cox and Wilkinson, 1991). The low content ofKDO and phosphate present in the
LPS of B. cepacia also decreases the overall negative charge of this molecule when
compared to other Gram-negative bacteria and thus further reduces the capacity of
the outer membrane of B. cepacia to bind cations (Cox and Wilkinson, 1991).
Interestingly, these chemical characteristics of B. cepacia might explain the
significant differences which have been described in the inflammatory properties of
LPS from B. cepacia and P. aeruginosa (Shaw et al, 1995).
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6.3.1 Antimicrobial activity of elafin
Elafin is also polycationic and the antimicrobial activity exhibited by this molecule
may also come from an ability to disrupt bacterial membranes. Results from the
preliminary experiments performed in this thesis show P. aeruginosa and S. aureus
to be sensitive to the antimicrobial activity of this peptide, whereas B. cepacia
appears resistant.
Unlike the synthetic peptide hBD-1, the recombinant adeno-elafm used in this thesis
was synthesised within human cells (A549). Although these experiments provide
useful preliminary data they were not well controlled and the possibility exists that
some other compound present within the cell culture system was causing the
antibacterial effect. Synthetic elafin was therefore synthesised and tested to exclude
this possibility. Recently, full-length synthetic elafin has been shown to have
antibacterial activity against P. aeruginosa (PAOl) and S. aureus (CI705) (Simpson
etal, 1999).
As synthetic peptides are very expensive and difficult to produce, the small quantity
that was available was used to study the antimicrobial activity of elafin against only
one strain of each ofP. aeruginosa and S. aureus, in detail. These strains were
chosen as favourable results had been obtained with these organisms in the
preliminary experiments. Due to the resistance of B. cepacia to elafin observed in
the preliminary studies, the susceptibility ofB. cepacia to synthetic elafin was not
studied.
Mean results of between four and eight replicate experiments show that full length
synthetic elafin killed significant numbers ofPAOl at doses of between 1 and 25pM.
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The maximum effect of elafin against PA01 was at 2.5pM, a concentration at which
93% of bacterial cells were killed. Killing of S. aureus by full length elafin increased
with increasing concentrations of elafin and had its maximum effect at the highest
concentration tested (25pM). At this concentration, 48% of the cells of S. aureus
were killed. Experiments carried out using human serum albumin as a control
showed that activity observed was not due to a non-specific peptide effect.
Ifmore synthetic elafin was to become available it would be interesting to determine
that J2315 is resistant to the antimicrobial activity of this peptide. It would also be
useful to study a range of B. cepacia strains to determine if the majority of strains of
B. cepacia are resistant to the activity of this cationic peptide.
Problems were encountered in both the hBD-1 and elafin studies which may be due
to the use of the salt-free phosphate buffer. Salt-free buffer was necessary for study
of these cationic peptides as the activity of hBD-1 is salt sensitive, and perhaps that
of elafin also. The detrimental effect of the buffer on both P. aeruginosa and
S. aureus was more pronounced in the elafin studies, possibly due to the extended
incubation times necessary in these experiments.
Differences may also be due to the different growth phases of the bacteria used in
each experiment. Stationary phase bacterial cells as used in the defensin experiments
may survive better in this buffer than log phase cell utilised in the elafin experiments.
It may also be that the sudden transition from growth in rich media to the simple
phosphate media with D-glucose as a sole carbon source has a detrimental effect
upon bacterial survival. High levels of salt also appear to effect growth of
P.aeruginosa. Physiological saline contains approximately 145mM NaCl, however,
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the highest salt concentration used in the defensin studies had a slightly higher salt
concentration of 150mM. Survival of P. aeruginosa was considerably diminished in
the controls run alongside the defensin experiment carried out in phosphate buffer
containing 150mM NaCl. However, it seems unlikely that this slight increase in salt
concentration alone would so drastically affect the survival of bacterial cells.
Thus, although both hBD-1 and elafin have considerable activity against individual
strains ofP. aeruginosa and S. aureus, neither were found to have antimicrobial
activity against B. cepacia. Further studies are required but one explanation is that




The exploration of novel antimicrobial strategies against B. cepacia has proved
necessary as this organism is inherently resistant to conventional antibiotics and
poses a major threat to the health of immunocompromised patients, in particular
those with CF. In this thesis, two main strategies are investigated, one is the study of
antimicrobial compounds produced by plants and the other, an examination of the
antimicrobial activity of cationic peptides present in human airway secretions.
Examination of antimicrobials isolated from plants focused mainly on two plant
species, garlic and thyme. Garlic contains the effective although unstable
antimicrobial compound, allicin, which showed inhibitory activity against a range of
B. cepacia isolates including strains such as the highly resistant and epidemic lineage
ET12. Unfortunately, not only is allicin unstable, but it is also difficult to
manufacture by chemical synthesis. Other compounds present in AGE were also
revealed to possess antimicrobial activity against the ET12 strain of B. cepacia. In
future, it may be useful to study the effect of ingestion of correctly dried garlic
powder preparations on the antimicrobial activity of human serum. If antimicrobial
activity associated with garlic consumption was observed in human serum it would
be interesting to study potential beneficial effects in B. cepacia colonised CF
patients. Allicin and some of the other compounds produced when garlic is cut or
crushed are unlikely to survive the acidic conditions present in the stomach as
alliinase is completely and irreversibly inhibited at a pH of 3.6 or lower. Thus, to
allow allicin to be absorbed into the bloodstreem, garlic powder preparations would
require encapsulation as protection against low pH conditions of the stomach.
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However, as allicin is thought to react in blood to form allylmercaptan, encapsulation
may be unnecessary.
Thyme, in particular thyme oil, contains the antimicrobial compounds, thymol and
carvacrol which are much more stable than allicin. However, antimicrobial use of
these compounds presents other problems. As phenols, they have toxic properties if
ingested or applied to mucus membranes including the lungs. However, relatively
small concentrations of thyme oil were required for bactericidal activity against
strains of B. cepacia, and these levels might be tolerated by the body without toxic
effects. Even lower concentrations of thyme oil or its antimicrobial phenolic
components, would be required if synergy occurred between these compounds and
conventional antibiotics. It would therefore be fruitful to examine combinations of
thyme oil and a variety of conventional antibiotics for synergistic antimicrobial
activity against B. cepacia.
The endogenous antimicrobial peptides hBD-1 and elafin, like other previously
studied cationic antibiotics, exhibit no inhibitory activity against B. cepacia. If the
hypothesis is correct that high levels of salt in CF lung secretions deactivate
antimicrobial peptides which would otherwise protect from bacterial infection, it
would still not explain why B. cepacia is capable of causing human lung infection.
The predilection of B. cepacia to colonise and infect the CF lungs must result from a
defect in another aspect of lung defence. Further studies of the activity of synthetic
human elafin against B. cepacia would be beneficial exclude the possibility that this
compound has anti-cepacia activity.
There is an urgent need for the development of effective anti-5. cepacia agents as the
organisms present 'resistance' deprives patients of effective therapy. Although the
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administration ofplant extracts may seem an unconventional approach to treatment,
it may be a useful strategy to focus further research on the most potent plant extracts,
namely those from thyme oil. Priority might be given to investigate potential
synergistic activity between these compounds and conventional antibiotics.
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Allyl methyl trisulphide Diallyl disulphide
CHi











Due to unforeseen circumstances, the HPLC analysis of carvacrol was carried out on
alternative equipment. The alternative equipment comprised a Waters 600s
controller (Milford, MASS, USA), Waters 626 pump and a Waters 486 detector, all
controlled by Waters Millennium software. Separation was again performed on a
continuous linear gradient of acetonitrile and detection was at 275nm. Thyme oil,
thymol and carvacrol were all analysed with this alternative equipment so results
could be compared.
Results show that each of the three samples produced an almost identical trace and
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Abstract. Defensin are 3-4 kDa antimicrobial peptides of which
three distinct families have been identified; ct-defensin. j3-
defensins, and insect defensins. Recent investigations have shown
that fi-defensins are present in the human airways and may be
relevant to the pathogenesis of cystic fibrosis (CF) lung disease.
We report here the further characterization of a recently identified
mouse 3-defensin gene. Defbl. sometimes referred to as mBD-l.
which is homologous to the human airway beta defensin hBD-l.
We report that Defbl is expressed in a variety of tissues including
the airways and. similar to hBD-l. is not upregulated by lipopoiy-
saccharide l LPS). Defbl was found to consist of two small exons
separated by a 16-kb intron and cytogenetic, and physical mapping
linked it to the alpha defensin gene cluster on mouse Chromosome
(Chr) 8. Functional studies demonstrate that, like hBD-l. Defbl
demonstrates a salt-sensitive antimicrobial activity against Psett-
dornonas aeruginosa. Of relevance to CF lung disease is the fact
that neither the hBD-l nor the mBD-l peptides are active against
Burkholderia c epacia.
Defensins are a large family of peptides of which two groups exist
in mammals; alpha defensins and beta defensins. which are dis¬
tinguishable by the spacing and connectivity of the conserved cys¬
teine residues within the mature peptides. It is thought that de¬
fensins function in the eradication of pathogens from the host
system by inserting themselves into the bacterial membrane under
the influence of membrane potential, forming channels which lead
to leakage of cytoplasmic molecules and cell death (reviewed by
Hancock 1997). Two bovine beta defensins, tracheal antimicrobial
peptide (TAP; Diamond et al. 1991) and lingual antimicrobial
peptide (LAP. Schonwetter et al. 1995), have been identified
which are expressed from airway epithelial cells, and both were
shown to have bactericidal activity against a broad array of organ¬
isms. These molecules were the only known airway epithelial de¬
fensins until recently when a human beta defensin molecule (hBD-
I) was identified that was expressed in the airways (Goldman et al.
1997; McCray and Bentley 1997). Smith et al. (1996) demon¬
strated that the airway surface fluid (ASF) covering the apical
surface of primary cultures of airway epithelial cells isolated from
normal individuals had antimicrobial activity, but this activity was
markedly reduced in ASF from epithelial cells from cystic fibrosis
(CF) individuals. It had previously been reported that ASF had
elevated concentrations of CI" and Na+ in CF compared with nor¬
mal (Joris et al. 1993; Gilljam et al. 1989), and Smith and asso¬
ciates (1996) demonstrated in vitro that when the salt concentra¬
tion of normal ASF was increased to the CF level, the antimicro¬
bial activity of the fluid was decreased. This led to the speculation
that the molecule responsible for the antimicrobial activity in ASF
Correspondence to: J R. Dorin
that was defective in CF might be a salt-sensitive defensin. An
hBD-1 synthetic peptide was shown to have broad spectrum bac¬
tericidal activity which was markedly reduced in salt concentra¬
tions similar to those reported for CF ASF, and it was, therefore,
proposed that the reduced ability of hBD-1 to kill bacteria in a CF
environment was of relevance to the pathogenesis of CF lung
disease. Although these recent findings are very encouraging and
give some form of explanation for the early onset of bacterial
colonization in the CF lung, they have so far been studied only in
in vitro systems. Further functional studies of hBD-l with regard
to its possible involvement in the onset of CF lung disease and the
relevance of this defensin molecule in other infectious disorders
may be facilitated by the use of a transgenic mouse model. Re¬
cently Huttner and colleagues (1997) described a mouse homolog
of hBD-l. We confirm and extend these results to show the re¬
sponse of Defb! to LPS challenge and demonstrate the antimicro¬
bial activity of synthetic mBD-l peptide.
Materials and methods
Expression ofDefbl. Total RNA was isolated from a variety of tissues
from C57/BI6 mice using RNa/ol as described by the manufacturer. cDNA
synthesis was accomplished using a 1st strand cDNA synthesis kit (Boeh-
ringer Mannheim) and the resultant cDNAs used as a template in a PCR
reaction with primers det'i (CCAGCTGCCCATCTAATACC) and det'2
IAATCCATCGCTCGTCCTTTA) and the following conditions: denatur-
ation at 94°C for 3 min; 35 cycles of 94°C for 30 s. 56°C for 30 s and 72°C
for 1 min. The amplified products (112 bp) were then analyzed on a 4'/r
NuSIEVE agarose gel (FMC BioProducts) by electrophoresis. Reactions
were verified for RNA amplification by including controls without reverse
transcriptase.
LPS administration and semi-quantitative RT-PCR. 40 pg of LPS
(E. coli 055:B5. Sigma) was administered to mice by intratracheal delivery,
and the mice were sacrificed at various time points after instillation. Total
RNA was isolated from the lungs and trachea, and RT-PCR for Defbl was
performed as described above except with the primer def5' (CACTCTG-
GACCCTGGCTGCC) instead of def 1 which gave an amplified product of
277 bp. Amplification of Hprt from exon 3 to exon 8 was carried out in
parallel to monitor the amount of input RNA with the forward CTGTA-
GATTTTATCAGACTGAAGAG and reverse GTCAAGGGCATATC-
CAACAACAAA primers and the following conditions: denaturation 94°C
for 3 min: 30 cycles of93°C for 30 s, 55°C for I min, and 75°C for 1.5 min.
The amplified products were analyzed on a 1% agarose gel by electropho¬
resis.
Screening of the genomic libraries. A mouse BAC library from the
cell line CJ7 derived from a mouse I29SV strain (Research Genetics Inc)
was screened for Defbl by PCR using the primers defl and def2 and
conditions mentioned previously. Two plate pools, 421 and 524. which
gave the expected PCR product, were then screened by hybridization w ith
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Fig. 1. Comparison of the human and mouse beta
det'ensin peptide sequence. Vertical line, direct
match: two dots, close similarity: one dot. some
similarity. The peptide sequences used to produce
the synthetic peptides are highlighted in bold. The
positions of the oligos used for PCR and
hybridization are also shown.
the entire cDNA sequence of Defbl as a probe. A mouse lambda GET
library was also screened by hybridization, and positive clones were con¬
verted to plasmid as described (Nehls et at. 1994).
Characterization ofgenomic clones. Restriction enzyme analysis was
performed on the BAC and lambda clones with a variety of 6-bp cutters.
Probes corresponding to the 5' end of the cDNA (CACTCTGGACCCTG-
GCTGCC) and the T end of the cDNA (ATTTCTCTGTTTAGAAGAGC)
were used to map genomic fragments.
Co-localization of mouse alpha and beta defensins. BACs t8 and
120 were screened for the presence of alpha defensins with the probes
TCCAGGCTGATCCTATCC and TGDTATGCTATTGTAGAT. which
are derived from the consensus regions, codon 17-23 and codon 62-68.
which are found in all 16 mouse alpha defensins (Huttner et al. 1994).
Locus mapping. The BAC clones 18 and 120 and pDet'l were used as
probes either in isolation or in combination for one- or two-color chromo¬
some mapping. Fluorescence in situ hybridization (FISH) was performed
according to previously published protocols (Fantes et al. 1995) with E14
IV mouse embryonic cells for the chromosome spreads. A chromosome-
specific paint was used to confirm the identity of mouse Chr 8, and Dapi
staining was used to reveal chromosomal banding patterns, which allowed
the localization of the hybridization signal to a specific chromosomal re¬
gion.
Peptide synthesis. hBD-l was synthesized from Fmoc-Lys(Boc) loaded
Wang resin (0.25 mmol). and mBD-l was synthesized from Fmoc-Ser
loaded Wang resin (0.48 mmol). I mmol of the amino acids was single
coupled via HOCt/DIC with the exception of His. which was coupled with
3 mmol of HOCt. The hBD-1 peptide was cleaved from the resin by stirring
in EDT (0.25 ml), thioanisole (0.5 ml). H.O (0.5 ml) and phenol (0.75 g)
for 2 min, then adding TFA (9.5 ml) and stirring for 4 h at room tempera¬
ture. The resin was removed by filtration into ether from which the peptide
was precipitated, washed with ether, and appiied to a Vvdac CIS column
(flow rate 5 ml/min. 5 ml loop. 10-5097 B over 28 min). m-BD-1 was
cleaved from the resin by stirring in EDT (0.25 ml) and H,0 (0.5 ml) for
2 min before adding TFA 19.5 ml). The mixture was stirred at room
temperature under nitrogen for 2 h before being filtered into ether from
which the cleaved peptide was precipitated, washed in ether, and taken into
aqueous acetonitrile and lyophilized. The peptide was then applied to a
Vydac C18 column (flow rate 8 ml/min. 5 ml loop, 10-90% B. 40 min).
The purified peptides were analyzed by RP HPLC (Vydac C18. 5 min
loop). R, = 17 min, which, in both cases, resulted in a single peak, and
MALDI TOF MS analysis showed the correct molecular weight for hBD-1
and mBD-l.
Functional analysis of synthetic mBD-l and hBD-1. The synthetic
peptides were tested against two strains of P. aeruginosa, lab strain PAOl
and CF clinical isolate J1385, and B. cepacia CF clinical isolate J2315.
These clinical isolates were carefully chosen because of their pedigrees
(Govanetal. 1993, 1996). Fresh, overnight cultures of bacteria were grown
in nutrient broth and then suspended in phosphate-buffered saline at ~ 1 x
109 colony forming units per ml. These samples were then split, resus-
pended and diluted in 10 m.vt phosphate buffer containing 0.1% D-glucose
and a range of concentrations of NaCl (buffer pH 7.60 at 0 mM NaCl. pH
7.40 at 30 mM NaCl, pH 7.33 at 60 m.M NaCl, pH 7.27 at 90 mM NaCl. pH
7.23 at 120 mM NaCl. and pH 7.20 at 150 mM NaCl). Two sets of duplicate
500-p.! reactions were prepared containing either buffer alone or synthetic
peptide rehydrated in buffer, across the same range of NaCl concentrations,
to which ~5 x 104 bacteria in the appropriate salt concentration were added.
These reactions were incubated for 20 min at 37°C. after which duplicate
sets of serial dilutions were prepared from each sample, in buffer of the
appropriate salt concentration, plated out on Pseudomonas Isolation agar
(DIFCO) and incubated overnight at 37°C or on Cepacia Medium (Mast
Diagnostics) and incubated at 37"C for 48 h and colony counts performed.
The antimicrobial activity of the peptide was compared against buffer
alone, to control tor the effects on the bacteria of varying the NaCl envi¬
ronment.
Statistical analysis. The data generated were regarded as having a Pois-
son distribution: thus, a square root transformation was appropriate to
homogenize the variance between groups. Analysis of the significance of
differences between peptide and control samples was performed and illus¬
trated graphically, plotting the NaCl concentrations against means under
square root transformation, derived from the mean square error, with group
standard errors. The means of the colony forming unit counts were used to
calculate the proportion of bacteria surviving in the peptide-treated samples
as a percentage of the counts from the buffer-only samples, to control for.
the effects of changes in NaCl concentration alone. These percentages w ere
expressed as ""percentage killing": standard errors were estimated and
displayed graphically.
Results
Identification ofmurine sequences homologous to hBD-l. Seven
near identical eDNA sequences from mouse heart, kidney, embry¬
onic carcinoma, and macrophage cDNA libraries were retrieved
from an EST database following a BLAST search using the hBD-l
sequence (GenBank #AA 104376. AA0655I0, AA071757.
AA105324. AA107538, AA107977, AA108061). The peptide
translation of these sequences was found to be 53% similar to
hBD-l (Fig. I).
Genomic characterization ofthe Defbl gene. Two genomic clones
of Defbl. 18 from plate 421 and 120 from plate 524, were isolated
following the BAC library screen. Two clones were isolated from
the lambda GET library which were subsequently converted into
plasmids and shown to be identical; only one was used in subse¬
quent analysis and was termed pDefl. Southern blot hybridization
results indicated that both the 18 and 120 BAC clones contained the
entire Defbl gene sequence, which was found to extend over ap¬
proximately 22 kb (Fig. 2), although they were not identical as
they were flanked by differing lengths of genomic sequence 5' and
3' to the gene. Defbl was found to consist of two exons separated
by an intron of approximately 16 kb (data not shown). pDefl was
found to contain only exon two and approximately 5 kb of intronic
sequence.
Chromosomal location of Defbl by FISH. By use of FISH, both
the BACs and pDefl were localized to band A4 of mouse Chr 8
(Fig. 3A-C). When the BACs were hybridized together, on inter¬
phase cells it was possible to see a region of overlap between the
G.M. Morrison et al.: niBD-l is a functional homolos of hBD-l
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Fig. 3. (A) Chromosomal location of Defbl gene using BAC 120 as a probe. (B) Identification of Chr
8 using a chromosome specific paint. (C) Enlarged image of mouse Chr 8 indicating the proximal
position of Defbl and a diagrammatic representation of mouse Chr 8 showing a summary of FISH
mapping results with each dot representing an individual FISH image. (D) Southern blot hybridiza¬
tion of BAC 120 DNA digested with a range of restriction enzymes and using a probe specific for a
mouse alpha defensin consensus region.
BACs and also areas to either side to which only one BAC hy¬
bridized (data not shown).
Identification of alpha defensin sequence on BAC 120. Southern
blot analysis of 18 and 120 with two distinct probes based on the
alpha defensin consensus regions gave a positive signal only in
BAC 120 (Fig. 3D). It was concluded that BAC 120 extended into
the region of Chr 8 where the alpha defensin gene family is lo¬
cated. and therefore the a and [3 family of genes in the mouse are
separated by less than 80 kb. This is of interest because the human
a and (i defensin genes have also been shown to be located in close
proximity to each other on a conserved syntenic region of human
Chr 8.
Expression of Defbl. Expression of Defbl by RT-PCR was de¬
tected in the following tissues: kidney, lung, heart, gut, and puri¬
fied alveolar macrophages (data not shown). We examined the
response to LPS and did not see any evidence for gross upregu-





Fig. 4. RT-PCR of Hprt and Defbl from tracheal RNA following LPS
instillation. The hours shown represent the time after LPS instillation when
the mice were sacrificed with a plus (+RT) and minus (-RT) reverse
transcriptase reaction shown for every sample.
lation of Defbl at any time point tested following administration
directly to the mouse lung (Fig. 4).
Synthetic ttiBD-l demonstrates a salt-sensitive antimicrobial ac¬
tivity. Using the synthetic hBD-l peptide, we demonstrated a sta¬
tistically significant killing effect against both strains of P. aeru¬
ginosa at a peptide concentration of 50 pug/ml (Fig. 5A-B. PAOI
data not shown). This effect was shown to be extremely salt sen¬
sitive. dropping from 100% to 50% as the NaCI concentration rose
from 0 m\t to 90 m.\t. then leveling off at higher concentrations. In
parallel studies using the synthetic mBD-l peptide we observed a
similar, statistically significant killing effect, against both strains
of P. aeruginosa, at a peptide concentration of 500 pig/ml (but not
significant at 50 pg/ml or I00 p.g/ml) (Fig. 5C 1). PAOI data not
shown). This antimicrobial effect displayed the same pattern of salt
sensitivity, but was somewhat less effective than the synthetic
hBD-l peptide under optimal conditions, killing only 85% of the
bacteria at 0 mM NaCI concentration. Thus, both synthetic peptides
showed a rapid decline in activity between the low salt levels,
thought to be physiologically normal in human airway surface
fluid, and the raised NaCI environment thought to exist in the
human CF lung, at which marked inhibition was observed.
We used the same assay to examine the effect of the peptides
on 8. cepacia, in these studies we observed no significant killing
effect at any NaCI concentration with either peptide, under the
conditions observed in our previous studies to be optimal for kill¬
ing of P. aeruginosa (Fig. 5E-F). Surprisingly, at 0 uim NaCI. 8.
cepacia appeared to thrive in the presence of synthetic hBD-l
when compared with buffer, and it may be of interest that previous
studies have shown that B. cepacia can use other antibacterial
substances to its advantage such as penicillin G as its sole source
of carbon and energy (Beckman and Lessie 1979).
Discussion
Defensins have been shown to be a widespread and ancient means
of host defense existing as two distinct families in mammals. Re¬
cently, Liu and coworkers (1997) concluded that the a and (3
defensins are derived from a common ancestral gene because of
the close proximity of the hBD-l to the human alpha gene cluster.
Both alpha and beta defensin gene members have been mapped to
human Chr 8p23.1-23.2 (Liu et al. 1997). The mouse alpha defen-
sin genes lie in a cluster on the proximal region of mouse Chr 8.
and Huttner and associates (1997) mapped Defbl locus to the same
region of mouse Chr 8 by analysis of DNA from two sets of
multiloeus crosses. We confirm the map position of Defbl to
mouse Chr 8 region A4 and physically show that the alpha defen¬
sin eene cluster lies within 80 kb. The close proximity of these two
gene families and similarity of the beta genes between species
(53% at the amino acid level) compared with the low level of
similarity between alpha and beta genes within a species strongly
suggests that gene duplication of a common ancestral defensin
gene occurred before human mouse species divergence.
A heightened salt concentration of CF ASF has been impli¬
cated in the decreased ability of hBD-l to destroy bacteria (Smith
et al. 1996) and therefore it was of interest to find out whether the
mBD-l peptide had the same antimicrobial activity. CF is charac¬
terized by its progression from repeated childhood infections with
it relatively restricted range of organisms including Staphylococcus
aureus and Haemophilus influenzae to chronic colonization with
P. aeruginosa and the additional impact of B. cepacia infection.
We have demonstrated that the synthetic mBD-1 peptide displays
salt-sensitive antibacterial activity against P. aeruginosa similar to
that of hBD-1. We have also demonstrated an absence of antibac¬
terial activity when using the synthetic peptides against B. cepacia.
Our observations support previous suggestions that this organism
may be resistant to cationic peptides, and we conclude that the
predisposition of CF patients to pulmonary infection with B. ce¬
pacia results from impairment of some other component of lung
defense.
The similarity of the results obtained with the human and
mouse peptide suggests that a comparable lung defense mecha¬
nism is present in the mouse, which may be impaired by abnor¬
malities in the ionic composition of the airway surface fluid, al¬
though. to date, no measurements of the ionic composition of the
ASF in normal and CF mice are available. Our results show that
sy nthetic mBD-1 is required at a much higher concentration than
synthetic hBD-1 to achieve antibacterial activity. This may reflect
differences in the success of peptide synthesis or. alternatively, it
is possible that these molecules possess slightly different profiles
in vivo, in terms of the extent of their effects, the pathogens against
which they act. and their dependence upon the synergistic effects
of other components of the defense mechanism or their relative
importance within it.
The discovery of a second human beta defensin (hBD-2) ex¬
pressed in the airways and upregulated by exposure to LPS
(Harder et al. 1997a) and also located in the same chromosomal
region as hBD-l (Harder et al. 1997b) suggests it is possible that
additional airway defensins are also present in the mouse. Recent
studies demonstrating a salt-sensitive synergistic antibacterial re¬
lationship between the A.SF components, lysozyme and lactoferrin
(Singh and Welsh 1997). suggest a complex array of interacting
antimicrobial factors contributing to an innate lung defense sys¬
tem. However, it is obvious that CF lung disease is more complex
in its etiology than simply a perturbation of the antimicrobial com¬
ponents of the airway surface fluid. Indeed, the partial inhibition of
such broad-spectrum antibacterial agents would not be expected to
result in the very specific profile of infections evident in CF. The
pathogenesis of CF lung disease will no doubt be the end product
of multiple abnormalities downstream from the mutation of CFTR.
In summary, we have demonstrated the existence of a mouse
beta defensin, Defbl, which is expressed in the airways, but is not
upregulated by LPS exposure and, like hBD-l. displays salt-
sensitive antibacterial activity against the major CF-associated
pathogen P. aeruginosa, but not against B. cepacia. These obser¬
vations justify the use of the mouse as a model system to study the
contribution of defensins to host innate defense and their relevance
to CF lung disease and other infectious disorders.
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Fig. 5. Functional analysis of
synthetic hBD-l and mBD-i. P.
aeruginosa J1385 was treated
with hBD-1 at 0.05 mg/ml
(A-B). mBD-l at 0.5 mg/ml
(C-D), or 0.1 mg/ml (D) or
buffer alone. B. cepacia J2315
was treated with hBD-l at 0.05
mg/ml (E). mBD-l at 0.5 mg/m!
(F) or buffer alone. NaCl
concentrations were plotted
against colony forming unit
count means under square root
transformation to allow
statistical analysis (A and C)
and against the percentage ot
bacteria killed in the
peptide-treated sample, in
comparison with control, using
means of colony forming unit
counts (B, D. E and F). At each
point n = 4. standard error bars
have been applied to all points.
Two asterisks indicate
significance at the 19c level, one
asterisk indicates significance at
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Abstract F.Ia fin (elastase-specific inhibitor) is a low molecular
weight inhibitor of neutrophil elastase which is secreted in the
lung. Using synthetic peptides corresponding to full-length elafin
(HsN-'AVT '^Q-OH), the NHj-terminal domain (HiN-
'.VV T '"K-OH) and the COOH-terminal domain (HsN-
PGS 9;,Q-OH), we demonstrate that elafin's anti-elastase
activity resides exclusively in the COOH-terminus. Several
characteristics of elafin suggest potential anti-microbial activity.
The anti-microbial activity of elafin. and of its two structural
domains, was tested against the respiratory pathogensP.vewrfo-
tnonas aeruginosa and Staphylococcus aureus. F.lafin killed both
bacteria efficiently, with 93% killing of P. aeruginosa by 2.5 jn.VI
elafin and 48% killing of S. aureus by 25 u.M elafin. For both
organisms, full-length elafin was required to optimise bacterial
killing. These findings represent the first demonstration of co¬
existent anti-proteoly tic and anti-microbial functions for elafin.
c" 1999 Federation of European Biochemical Societies.
Key words: Eiafin; Human neutrophil elastase;
Anti-microbial activity; Pseudomonas aeruginosa:
Staphylococcus aureus
I. Introduction
As part of the immediate defence against bacterial patho¬
gens. the lung is equipped with a number of endogenous anti¬
microbial peptides, including defensins. secretory leucocyte
protease inhibitor (SLPI). Ivsozyme and laetoferrin [1 6|. In
addition, bacteria stimulate the recruitment and activation of
neutrophils, resulting in engulfment of organisms and ulti¬
mately their destruction by oxidants or proteolytic enzymes
such as human neutrophil elastase (HNE) (7], Natural inhib¬
itors of HNE in the lung are thought to play a critical role in
neutralising HNE liberated extraeellularly. thus circumventing
proteolytic damage to the host [8J.
Eiatin (also known as elafin-specific inhibitor (ESI) or skin
anti-leucoprotease (SKALP)) is a low molecular weight (9.9
kDa) inhibitor of HNE and proteinase 3. which is secreted in
the respiratory tract [9.10]. Along with ct|-protease inhibitor
(ott-PI) [8] and SLPI [11], elafin comprises an integral part of
the "anti-elastase shield' in the lung [12].
Several features suggest an additional anti-microbial func¬
tion for elafin. In particular, elafin is highly cationic. it is
Corresponding author. Fax: (44) (131) 650 4384.
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Abbreviations: HNE. human neutrophil elastase: cxi-PI. op-protease
inhibitor: SLPI. secretory leucocyte protease inhibitor: EISA, human
serum albumin: TSB. trvptone soya broth: I.PS. lipopolysaecharide:
CF. cystic fibrosis
expressed selectively in the lung, the skin and at mucosal
surfaces and SLPI (which has 42% sequence homology with
elafin) has anti-microbial activity [5.13-47],
In this study, we describe an investigation of the anti-micro¬
bial activity of elafin against Pseadomonas aeruginosa and
Staphylococcus aureus, two important pulmonary pathogens
with a particular propensity to antibiotic resistance [IX 25).
2. Materials and methods
J.I. Proteins
Elafin peptides were produced synthetically in accordance with the
derivation of amino acids from the established gene sequence [15] and
were supplied by Albaehem (Edinburgh. UK I. using standardised
protocols described elsewhere [24). Three peptides were provided.
namely full-length elafin (FLN-AVT "Q-OHl. the \H--terminu-
domuin (FUN-'AVT "K-OFI) and the COOH-terminus domain
(H;N--,|PGS '"Q-OH). The terminal amino acid of the NIL do¬
main and the first amino acid of the COOH domain were determined
by analysis of the established crystal structure of a 57 amino acid
fragment of elafin |H;N-WAQE '''Q-OH) [17]. in conjunction with
the established sequence of human SLPI. which has 42 sequence
homology with elafin [13-15.25], The molecular weights of elafin moi¬
eties. determined by mass spectrometry (Albaehem. Edinburgh. UKi
were 9925 Da for full-length elafin. 5172 Da for the NfL-terminal
domain and 4776 Da for the COOH-terminal domain.
Human serum albumin (HSA) was purchased from Sigma Chem¬
icals (St. Louis. MO. I SA). Recombinant human SLPI was pur¬
chased from R and D Systems (Minneapolis. MN. USA). Lyophilised
preparations of elafin. SLPI and HSA were all reconstituted in 0.01 M
K IIPOj/K.H-P04. pH 7.4 (phosphate buffer).
2. J. Bacteria
PAOI. a clinical strain and well-characterised type strain of P.
aeruginosa, and CI705. a clinical strain of S. aureus, were available
in-house [20.24].
J.I. USE activity assay
The HNE activity assay has been described in detail elsewhere [26].
Briefly, serial dilutions of test inhibitor were added to 300 ng of
purified HNE (Elastin Products. Owensville. MO. USA). All dilutions
were performed in Tris 50 mM. Triton 0.1%. sodium chloride 0.5 M.
pH 8.0. The samples were incubated for 15 min at 37°C before addi¬
tion of the chromogenic substrate .V-methoxysuccinyl-Ala-Ala-Pro-
Val-p-nitroanilide (Sigma). In positive controls, buffer replaced test
inhibitor. The change in absorbance. measured spectrophotometri-
calty at 405 nm (MR5000 Plate Reader. Dynatech. Dynex. Billing-
hurst. UK), was expressed as a function of time. The inhibitory ca¬
pacity of test inhibitors was derived by extrapolation to the ordinate
of curves obtained by plotting the HNE activity against the concen¬
tration of inhibitor added, as described elsewhere [27],
J. 4. A ssay of microbial activity
Bacteria were grown initially as colonies on Columbia agar (Uni-
path. Basingstoke. UK) and. then, in 10 ml tryptone soya broth (TSBi
(Unipath) overnight at 37°C in an orbital shaker (Gallenkamp. Fisher
Scientific. Loughborough. UK) at 200 rev/min. 100 pi of the bacterial
culture was resuspended in 10 ml fresh TSB and incubated for 3 h at
37°C with rotation, corresponding to a point compatible with loga¬
rithmic growth for both PAOI and C1705. The resulting suspension
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was eentrifuged at 4500 rpm tor 20 min at room temperature (Bio-
t'uge. Heraeus Instruments. Kendro. Bishops Stortfortl. UK). the
supernatant discarded and replaced with 10 ml phosphate butler
and then resuspended. This process was repeated once. The quantity
of viable bacteria was calculated from pre-constructed growth curves
and dilutions made in phosphate buffer to give an estimated count of
5x 104 viable colonies per ml.
In experiments using purified elaftn. HSA or SLPI. 30 ul aliquots of
the bacterial suspension were added to 90 ul aliquots of test sub¬
stance. each diluted in phosphate buffer to give final concentrations
of 1. 2.5. 10 or 25 tiM of the test substance. In positive controls. 90 ul
of phosphate buffer replaced the test solution and in negative controls.
30 ill of phosphate buffer replaced the bacterial suspension.
The test bacterial suspension mix was incubated for 2 h at 37°C'.
Appropriate dilutions were made in phosphate buffer and 100 ul
aliquots plated out on Columbia agar. Colonies were counted after
incubation of the plates for 16 h at 37°C.
2. J. Statistics
Data pertaining to V. aureus were normally distributed and com¬
parisons between test substances and controls were performed using
the paired /-test. Data pertaining to P. aeruginosa were not normally
distributed and comparisons between test substances and controls
were performed using the Wileoxon signed rank test. Statistical sig¬
nificance was regarded as P <0.05.
3. Results
3.1. Anti-ela.srci.se activity of elafin moieties
All three peptides (full-length elafin. the N'Hh-terminal do¬
main and the COOH-terminal domain) were tested for anti-
HNE activity (Fig. I). No anti-HNE activity was detected in
the NHi-terminal domain. In contrast, the COOH-terminal
domain and the full-length molecule were found to have an









concentration of test peptide (uM)
Fig. I. Anti-elastase activity of full-length elafin, NHi-terminal do¬
main elafin and COOH-terminal domain elafin. Known quantities
of test inhibitor were added to 300 ng HNE. All dilutions were per¬
formed in Tris 50 mM. Triton 0.1%. sodium chloride 0.5 M. pH
8.0. Chromogenic substrate (iV-methoxysuccinyl-Ala-Ala-Pro-Val-p-
nitroanilide) was added and the change in absorbance at 405 rim
was measured as a function of time. The molecular weights of full-
length elafin. NH^-terminal domain elafin. COOH-terminal domain
elafin and HNE are 9.9, 5.2, 4.8 and 30 kDa. respectively. Results























Fig. 2. Anti-microbial effect of elafin moieties against P. aeruginosa
(PAOl) and S. aureus (CI705). expressed as a percentage of the col¬
ony count in phosphate buffer alone (control). In (a), results repre¬
sent medians (« = 8 for concentrations of 2.5-25 pM: n = 4 at l pM).
In (b), results represent means (« = 5). * = P<0.05. ** = P< 0.01.
*** = P<0.001.
tase activity resides exclusively in the COOH-terminal do¬
main.
3.2. Anti-microbial activity of elafin
Full-length elafin resulted in a significant killing of PAOl at
all doses tested (1-25 pM) (Fig. 2). The maximum effect was
observed at 2.5 uM, at which 93% of PAOl was killed, rela¬
tive to PAOl grown in phosphate buffer alone. At 1 and
2.5 pM, the contributions of the NH2-terminus and COOH-
tcrminus were approximately additive, but at higher doses, the
predominant anti-microbial effect resided in the NHi-terminal
domain. The anti-microbial effect of full-length elafin against
I. / cf J! I /.BS / v 4:2 IW'/ A"1'
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In a separate set of experiments. the activity oi' SI PI
against PAOI and CITt 15 was tested over the Jose range I
10 uM and compared with that of full-length elatin (Table 11.
The anti-tnicrobial activity of elatin against PAOI conformed
to the characteristic pattern shown in Fig. 2. with a maximal
effect at 2.5 u.VI. The anti-tnicrobial activity of elatin was
greater than that of SLPI at all doses tested. To test for
potential synergy, equimolar concentrations of SLPI and ela¬
tin (0.5 uM elafin added to 0.5 Li NT SLPI) were compared with
either 1 uM elatin or I itM SLPI alone. No evidence of a
svnergistic effect was found (S6"• killing of PAOI using the
elafin/SLPI combination. 88% using elatin alone. NO", using
SLPI alone). The anti-microbial activity of elatin and St.PI








Fig. A Anti-microbial effect of full-length elatin against P. aerugino-
sa (PAOI) and S. aureus (CI 705). expressed as a percentage of the
colony count in HSA. In (a), results represent medians t/t = N for
concentrations of 2.5-25 u.M: n —4 at I uM). In (b). results repre¬
sent means (r/ = 5). Comparisons were made between equimolar con¬
centrations of test peptide and HSA. * = 6" <0.05. ** = />< 0.01.
*** = />< 0.001. For reasons of visual clarity, only data for full-
length elafin arc shown, however, dose-response curves for NH - -ter¬
minal domain elafin and COOH-terminal domain elatin also closely
paralleled those shown in Fig. 2.
S. aureus (CI705) was dose-dependent and was significant
over a dose range of 2.5 25 pM (Fig. 2). At 25 uM. 48"'..
killing of CI705 was achieved. The NHL-terminus showed a
significant anti-microbial activity only at 25 pM and the
COOH-terminus only at 10 pM. To ensure that the effects
observed were not attributable to a non-speeitie peptide effect,
the effects of full-length elafin. the NFC-terminal domain and
the COOH-terminal domain against PAOI and CI705 were
also compared with a control protein (HSA) (Fig. 3). For full-
length elafin. the maximal activity was described at 2.5 pM
against PAOI (81% killing) and at 25 pM against CI705 (63%
killing) (Fig. 3). closely in keeping with the findings when the
effect of full-length elafin was compared with that of phos¬
phate buffer alone (Fig. 2). The dose-response curves gener¬
ated for both NFF-terminul domain elafin and COOH-termi-
nal domain elafin against PAOI and CI705 also closely
paralleled those obtained when survival was expressed relative
to POj butter instead of FfSA (data not shown).
4. Discussion
Elafin (ESI/SKALP) was originally characterised and se¬
quenced from human bronchial secretions and from human
psoriatic skin, on the basis of its anti-elastase activity [9.14).
The identification of anti-microbial activity against Gram-neg¬
ative and Gram-positive respiratory pathogens at concentra¬
tions potentially achievable in epithelial lining fluid [28] (espe¬
cially after genetic augmentation [26]) suggests more complex
functions for elafin in the context of inflammation. This ob¬
servation is in keeping with the identification of additional
functions for other major anti-elastases such as SLPI. which
htts intrinsic anti-bacterial and anti-viral activity [5.16.29] and
which can influence the function of lipopolysaccharide (LPS)
[30] and prostaglandins [31 J.
Indeed, elafin can be added to the growing list of endoge¬
nous lung peptides which harbour an anti-microbial function,
including defensins. SLPI. lactoferrin and lysozyme fl 6|.
These molecules share certain general characteristics, for ex¬
ample. a low molecular weight and net positive charge. How¬
ever. each has unique structural features, which may play a
role in determining the anti-microbial function. The gene se¬
quence and derived amino acid sequence of elafin have al¬
lowed identification of various structural determinants [13).
The NFF-terminal domain, as defined in this study, has a
net positive charge of +5. as well as repeated structural motifs
potentially acting as substrate for transglutaminase which
may allow elafin to bind to the interstitium covalently
[13.15.32], The COOFl-terminal domain, as defined in this
study, has a net positive charge of +2 and has four disulfide
bonds which confer structural stability [13.32]. Previous stud¬
ies using elafin fragments of either 57 amino acids (FFN-
Table 1
Anti-microbial effect of full-length elatin and SLPI against P. aeru¬
ginosa (PAOI) and S. aureus (CI705)
















Results are expressed as percentage killing relative to that in P04
butter alone (taken as 0%) and represent medians from three sepa¬
rate experiments.
When expressed relative to HSA. the results obtained were similar
and followed the same trend (data not shown).





"'AQE "Q)-OH) or 4s amino acids ifLN-'Slk Q-
OH) have demonstrated high affinity anti-elastusc activity
tK, in the n\! range), but were unable to provide information
concerning the NT-L-termmal end of the molecule [9.14.33],
These findings, in conjunction with crystallographic studies
[17], suggested that elafin's anti-elastase activity resides exclu¬
sively in the COOH-terminal domain. L'sing discrete function¬
al domains of elatin and studving full-length elafin for the first
time, we have been able to provide direct confirmatory evi¬
dence to support this hypothesis by demonstrating that the
COOH-terminal domain of elafin and the full-length molecule
bind HNE with an equal efficiency (Fig. 11.
Furthermore, the use of discrete functional domains of ela¬
fin has allowed us to infer which regions of the molecule may
be responsible for anti-microbial effects. In the case of P
aeruginosa, our data suggest that inherent anti-microbial ac¬
tivity exists in both structural domains and imply that their
interaction may be necessary to augment anti-microbial activ¬
ity at low concentrations. The inverse dose-response relation¬
ship noted may reflect the ability of P. aeruginosa to use high¬
er concentrations of peptide as nutrients, promoting growth
and competing with the killing effect of elafin. Indeed. P.
aeruginosa is known to grow in increasing concentrations of
organic nitrogen [34]. This may explain why elafin's anti-mi¬
crobial effect was slightly less pronounced when albumin was
used as control (see Fig. 3).
The anti-microbial effects of several low molecular weight
peptides have been ascribed to their eationic nature. Cationic
peptides are capable of binding P. aeruginosa LPS. altering
the outer membrane stability and increasing susceptibility to
other bactericidal compounds [35]. While the charge may have
contributed to the killing observed here, it is unlikely to ex¬
plain the entire anti-microbial effect of elafin (especially at low
doses, where the less cationic COOH-terminal domain was
more effective).
The anti-microbial activity against P. aeruginosa was inde¬
pendent of the anti-elastase activity of elafin. as the majority
of anti-microbial activity resided in the N EE-terminal domain,
while anti-elastase activity resided exclusively in the COOH-
terminal domain. Interestingly, a quite different, dose-depend¬
ent pattern of anti-microbial activity was seen against S. au¬
reus. The N EE-terminal domain alone contributed only
slightly and at high concentrations. As with P. aeruginosa.
this suggests that a simple charge effect is unlikely to explain
elafin's anti-microbial effect. The observation that full-length
elafin was more effective than the additive effects of the two
structural domains may again imply a critical interaction
between these. In a similar study using structural domains
derived from SLPI. Hiemstra et al. [5] also found that the
full-length molecule was more active against Escherichia coli
and S. aureus than was either terminal fragment.
In our hands. SLPI was found to have anti-microbial ac¬
tivity against P. aeruginosa and S. aureus as has been de¬
scribed elsewhere [5.16]. The anti-microbial effects of SLPI
were less pronounced in our study, but this may reflect the
use of different clinical strains. Our data suggest that in equi-
molar concentrations, elafin is at least as effective as SLPI
against PAOI.
The anti-microbial activity of elafin adds to the emerging
picture of its primary role in the lung defence. Elafin is ideally
placed to promote the early eradication of invading pathogens
and to protect the host against proteolytic destruction in the
of neutrophil recruitment. Indeed, the co-existence
unti-microbiul and anti-elastase activity in the ciatin molecuL
could have therapeutic implications. P. aeruginosa and ,V au
reu\ can each cause severe pneumonia [18.21] and frequently
eo-colonise patients with cystic fibrosis (C'F) [19], The signiri
cant morbidity and mortality associated with these organisms,
coupled w ith their propensity to dev elop resistance to com en
tional antibiotics [22.23], demands the development of nove
anti-microbial strategies. In CF. HNE is thought to contribute
to the airway pathology by degrading substrate in the inter¬
stitial!). enhancing inflammatory cell ehemotaxis. stimulating
mucous hypersecretion and promoting the adherence of
aeruginosa [36-38], Furthermore. PAOI is known to promote
significant release of elastasc from hamster neutrophils in vivo
[39], Effective augmentation of anti-microbiai anti-elastascs
for patients known to be at risk of developing infection
with P. aeruginosa and/or S. aureus may thus be theoretically
desirable. Our findings suggest that elafin gene augmentation
could be particularly beneficial in CF. Elafin levels are known
to be reduced in C'F [40]. high levels of elafin can be effected
using adenoviral gene therapy in rats in vivo [26], elafin's
transglutamination sites may confer a longer biological half-
life in vivo [15.32] and elafin appears particularly active
against the non-mucoid clinical isolate PAOI. Strategically,
eradication of P. aeruginosa whilst still in the non-mueoid
form may be especially important in preventing or delaying
progression to chronic infection with mucoid variants, which
are seldom eradicated and are associated with a significantly
worse prognosis in CF [2()|.
VVe recently showed that genetic augmentation of claim
using adenov iral gene therapy protects human alveolar epithe¬
lial (A549) cells against HNE and activated neutrophils [41],
We have extended these findings to show that elafin's anti¬
microbial activity against PAOI can be augmented in super¬
natant derived from A549 cells transfccted with adenovirus
encoding elafin (unpublished data). This suggests that genetic
augmentation of endogenous anti-microbials may be effective
against pulmonary pathogens, as has also been demonstrated
using '/-interferon [42.43).
In summary, these findings demonstrate for the first time
that elafin has an intrinsic anti-microbial activity against im¬
portant Gram-negative and Gram-positive respiratory patho¬
gens and that this activity is independent of the molecule's
anti-elastase activity.
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